BRM and BRG1 targeting compounds and associated methods of use

Bifunctional compounds targeting SMARCA2 and SMARCA4 through ubiquitination modulation address the limited efficacy of existing inhibitors by effectively inhibiting these essential subunits, offering a targeted therapeutic strategy for cancers with SWI/SNF mutations.

WO2026236343A1PCT designated stage Publication Date: 2026-11-12PRELUDE THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026875
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current therapeutic compounds that inhibit SMARCA2 and SMARCA4, essential subunits of the SWI/SNF chromatin remodelers, exhibit limited efficacy in inhibiting cancer cell proliferation, particularly in SMARCA4 mutated cancer cells, highlighting a discrepancy between gene expression downregulation and small molecule-based inhibition approaches.

Method used

Development of bifunctional compounds comprising a target protein binding moiety and an E3 ubiquitin ligase binding moiety, specifically designed to modulate targeted ubiquitination of SMARCA2 and SMARCA4, thereby inhibiting their function and promoting their degradation.

Benefits of technology

The bifunctional compounds effectively inhibit SMARCA2 and SMARCA4, leading to suppressed cancer cell proliferation and providing a targeted approach for treating cancers with mutations in SWI/SNF subunits.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026875_12112026_PF_FP_ABST
    Figure US2026026875_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The disclosure is directed to compounds of Formula (IA) Pharmaceutical compositions comprising compounds of Formula (IA), as well as methods of their use and preparation, are also described.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] 105807.001161 - PCT Application

[0002] BRM AND BRG1 TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

[0003] CROSS REFERENCE TO RELATED APPLCIATIONS

[0004] [1] This application claims the benefit of U. S. Provisional Application No. 63 / 800,528, filed May 6, 2025, the entirety of which is incorporated by reference herein.

[0005] TECHNICAL FIELD

[0006] [2] The description provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use. The bifunctional compounds are useful as modulators of targeted ubiquitination, especially with respect to S witch / Sucrose Non-Fermentable (SWI / SNF)-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin, Subfamily A, Member 2 (SMARCA2, i.e., BRAHMA or BRM) and Member 4 (SMARCA4, i.e., BRG1), both of which are degraded and / or otherwise inhibited by bifunctional compounds according to the present disclosure.

[0007] BACKGROUND

[0008] [3] The human S Witch / Sucrose Non-Fermentable (SWI / SNF) complexes are ATP-dependent chromatin remodelers. These large complexes play important roles in essential cellular processes, such as transcription, DNA repair and replication by regulating DNA accessibility.

[0009] [4] Mutations in the genes encoding up to 20 canonical SWI / SNF subunits are observed in nearly 20% of all human cancers with the highest frequency of mutations observed in rhabdoid tumors, female cancers (including ovarian, uterine, cervical and endometrial), lung adenocarcinoma, gastric adenocarcinoma, melanoma, esophageal, and renal clear cell carcinoma.

[0010] [5] SMARCA2 (BRM) and SMARCA4 (BRG1) are the subunits containing catalytic ATPase domains and they are essential for the function of SWI / SNF in perturbation of histone-DNA contacts, thereby providing access points to transcription factors and cognate DNA elements that facilitate gene activation and repression.

[0011] [6] Previous studies have demonstrated the strong synthetic lethality using gene expression manipulation such as RNAi; downregulating SMARCA2 gene expression in SMARCA4 mutated cancer cells results in suppression of cancer cell proliferation. However, SMARCA2 / 4 bromodomain inhibitors (e.g., PFI-3) exhibit little to no effect on cell proliferation inhibition [Vangamudi et al. Cancer Res 2015], Thus, a phenotypic discrepancy exists between gene expression downregulation and small molecule-based inhibition approaches.

[0012] [7] Therapeutic compounds that inhibit SMARCA2 and SMARCA4 are needed.

[0013] 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0014] SUMMARY

[0015] [8] The present disclosure is directed to compounds of Formula (I):

[0016] PTM - ULM(I)

[0017] or a pharmaceutically acceptable salt or solvate thereof,

[0018] wherein PTM is a moiety of Formula IA:

[0019]

[0020] wherein

[0021] R1is a covalent bond, or chemical moiety that links PTM and ULM;

[0022] * is a point of attachment to ULM;

[0023] Rhis H, D, Ci-6 alkyl, C3-6 cycloalkyl, C1-3 haloalkyl, or C1-4 alkoxy;

[0024] Rdlis H, D, halo, cyano, C1-6 alkyl, C3-6 cycloalkyl, C1-3 haloalkyl, or C1-4 alkoxy; ULM is

[0025]

[0026] wherein

[0027] each X2 is independently N or CR15, provided that one X2 is a C atom having the attachment point to R1; and

[0028] -2 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0029] each R15is independently H, D, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -C1-8 alkoxy, Ce-io aryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C5-12 heteroaryl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl;

[0030] wherein in R15, any alkyl group, alkenyl group, alkoxy group, aryl group, cycloalkyl group, cycloalkenyl group, heteroaryl group, heterocycloalkyl group and heterocycloalkenyl group is optionally substituted by one or more Rfgroups;

[0031] each Rfis independently D, oxo, halogen, Ci-Cs alkoxy, Ci-Cs alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, -OH, -CN, -NO2, -C2-C6 alkenyl, -C2-C6 alkynyl, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Rb, -C(O)ORb, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)RcRd, -P(O)(ORb)(ORb), -B(ORc)(ORd), -S(O)2Rb, -C(O)NRbORb, -S(O)2ORb, -OS(O)2ORb, or -OPO(ORb)(ORb); wherein said Ci-C8alkoxy, Ci-C8alkyl, Ci-C8alkoxy, Ci-Cs alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, -OH, -CN, -NO2, -C2-C6 alkenyl, -C2-C6 alkynyl, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, is optionally substituted by 1-6 groups selected from D, halogen, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Rb, -C(O)ORb, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)RcRd, -P(O)(ORb)(ORb), -B(ORc)(ORd), -S(O)2Rb, -C(O)NRbORb, -S(O)2ORb, -OS(O)2ORb, or -OPO(ORb)(ORb);

[0032] each Rais independently H, D, -C(O)Rb, -C(O)ORC, -C(O)NRcRd, -C(=NRb)NRbRc, -C(=NORb)NRbRc, -C(=NCN)NRbRc, -P(ORC)2, -P(O)RcRb, -P(O)RcRd, -P(O)ORcORb, -S(O)Rb, -S(O)NRcRd, -S(O)2Rb, -S(O)2NRcRd, SiRb3, -Ci-Cioalkyl, -C2-C10 alkenyl, -C2-C10 alkynyl, -C1-8 alkoxy, Ce-io aryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C5-12 heteroaryl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl;

[0033] each Rb, is independently H, D, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -C1-8 alkoxy, Ce-io aryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C5-12 heteroaryl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl;

[0034] each Rcor Rdis independently H, D, -C1-C10 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -C1-8 alkoxy, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl;

[0035] or Rcand Rd, together with the atom to which they are both attached, form a monocyclic or multi cyclic heterocycloalkyl, or a monocyclic or multi cyclic heterocycloalkenyl group;

[0036] wherein any alkyl group, alkenyl group, alkoxy group, aryl group, cycloalkyl group, cycloalkenyl group, heteroaryl group, heterocycloalkyl group, or heterocycloalkenyl group ofRa, Rb, Rcand Rdis optionally substituted by one or more Rlegroups; and

[0037] - 3 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0038] wherein each Rleis independently D, -halo, -Ci-Csalkyl, -O-Ci-Csalkyl, -Ci-Cehaloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-Csalkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-11 membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-Csalkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-Csalkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -CO2H, -CN, -CF3, -CHF2, -CH2F, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(CI-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-Csalkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHC0NH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2.

[0039] [9] Stereoisomers of the compounds of Formula (I), and the pharmaceutical salts and stereoisomers thereof, are also contemplated, described, and encompassed herein. Methods of using compounds of Formula (I) are described, as well as pharmaceutical compositions including the compounds of Formula (I).

[0040] DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

[0041]

[0010] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. The terminology used in the description is for describing particular embodiments only and is not intended to be limiting of the disclosure.

[0042]

[0011] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise (such as in the case of a group containing a number of carbon atoms in which case each carbon atom number falling within the range is provided), between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges is also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either both of those included limits are also included in the disclosure.

[0043]

[0012] The following terms are used to describe the present disclosure. In instances where a term is not specifically defined herein, that term is given an art -recognized meaning by those of ordinary skill applying that term in context to its use in describing the present disclosure.

[0044] - 4 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0045]

[0013] The articles “a” and “an” as used herein and in the appended claims are used herein to refer to one or to more than one (e.g., to at least one) of the grammatical object of the article unless the context clearly indicates otherwise. By way of example, “an element” means one element or more than one element.

[0046]

[0014] The terms “co-administration” and “co-administering” or “combination therapy” refer to both concurrent administration (administration of two or more therapeutic agents at the same time) and time varied administration (administration of one or more therapeutic agents at a time different from that of the administration of an additional therapeutic agent or agents), as long as the therapeutic agents are present in the patient to some extent, preferably at effective amounts, at the same time. In certain preferred aspects, one or more of the present compounds described herein, are co-administered in combination with at least one additional bioactive agent, especially including an anticancer agent. In particularly preferred aspects, the co-administration of compounds results in synergistic activity and / or therapy, including anticancer activity.

[0047]

[0015] The term “compound”, as used herein, unless otherwise indicated, refers to any specific chemical compound disclosed herein and includes tautomers, regioisomers, geometric isomers, and where applicable, stereoisomers, including optical isomers (enantiomers) and other stereoisomers (diastereomers) thereof, as well as pharmaceutically acceptable salts and derivatives, including prodrug and / or deuterated forms thereof where applicable, in context. Deuterated small molecules contemplated are those in which one or more of the hydrogen atoms contained in the drug molecule have been replaced by deuterium.

[0048]

[0016] Within its use in context, the term compound generally refers to a single compound, but also may include other compounds such as stereoisomers, regioisomers and / or optical isomers (including racemic mixtures) as well as specific enantiomers or enantiomerically enriched mixtures of disclosed compounds. The term also refers, in context to prodrug forms of compounds which have been modified to facilitate the administration and delivery of compounds to a site of activity. It is noted that in describing the present compounds, numerous substituents and variables associated with same, among others, are described. It is understood by those of ordinary skill that molecules which are described herein are stable compounds as generally described hereunder.

[0049]

[0017] The term “ubiquitin ligase” refers to a family of proteins that facilitate the transfer of ubiquitin to a specific substrate protein, targeting the substrate protein for degradation. For example, an E3 ubiquitin ligase protein that alone or in combination with an E2 ubiquitin-conjugating enzyme causes the attachment of ubiquitin to a lysine on a target protein, and subsequently targets the specific protein substrates for degradation by the proteasome. Thus, E3 ubiquitin ligase alone or in complex with an E2 ubiquitin conjugating enzyme is responsible for - 5 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0050] the transfer of ubiquitin to targeted proteins. In general, the ubiquitin ligase is involved in polyubiquitination such that a second ubiquitin is attached to the first; a third is attached to the second, and so forth. Polyubiquitination marks proteins for degradation by the proteasome.

[0051] However, there are some ubiquitination events that are limited to mono-ubiquitination, in which only a single ubiquitin is added by the ubiquitin ligase to a substrate molecule. Mono-ubiquitinated proteins are not targeted to the proteasome for degradation but may instead be altered in their cellular location or function, for example, via binding other proteins that have domains capable of binding ubiquitin. Further complicating matters, different lysines on ubiquitin can be targeted by an E3 to make chains. The most common lysine is Lys48 on the ubiquitin chain. This is the lysine used to make polyubiquitin, which is recognized by the proteasome.

[0052]

[0018] As used herein, the term “alkyl”, by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon radical having up to twelve carbon atoms. In some embodiments, the number of carbon atoms is designated (i.e., Ci-Cs means one to eight carbons). Examples of alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, iso-butyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. Alkyl groups may be optionally substituted as provided herein. In some embodiments, the alkyl group is a Ci-Ce alkyl; in some embodiments, it is a C1-C4 alkyl.

[0053]

[0019] When a range of carbon atoms is used herein, for example, Ci-Ce, all ranges, as well as individual numbers of carbon atoms are encompassed. For example, “C1-C3” includes C1-C3, Ci-C2, C2-C3, Ci, C2, and C3.

[0054]

[0020] The term “optionally substituted”, as used in combination with a substituent defined herein, means that the substituent may, but is not required to be, substituted with one or more suitable functional groups or other substituents as provided herein. For example, a substituent may be optionally substituted with one or more of: halo, cyano, C1-6 alkyl, C3-6 cycloalkyl, C2-6 alkenyl, C2-ealkynyl, halo(Ci-6)alkyl, C1-6 alkoxy, halo(C 1-6 alkoxy), C 1-6 alkylthio, C1-6 alkylamino, NH2, NH(CI-6 alkyl), N(CI-6 alkyl)2, NH(Ci-ealkoxy), N(CI-6 alkoxy )2, — C(O)NHCi-6alkyl, — C(O)N(Ci-6alkyl)2, — C(O)NH2, — C(O)Ci-6alkyl, — C(O)2Ci-6alkyl, — NHCO(CI-6alkyl), — N(CI-6 alkyl)CO(Ci-6 alkyl), — S(O)C 1-6 alkyl, — S(O)2Ci-6 alkyl, oxo, 6-12 membered aryl, benzyl, pyridinyl, pyrazolyl, thiazolyl, isothiazolyl, or other 5 to 12 membered heteroaryl groups. In some embodiments, each of the above optional substituents are themselves optionally substituted by one or two groups.

[0055]

[0021] The term “cycloalkyl” as used herein refers to a 3-12 membered cyclic alkyl group, and includes bridged (e.g., adamantine) and spirocycles (e.g., spiro[3.5]nonane). Cycloalkyl groups may be fully saturated or partially unsaturated. The term “cycloalkyl” also includes multiple - 6 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0056] condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a single cycloalkyl ring (as defined above) can be condensed with one or more groups selected from heterocycles, carbocycles, aryls, or heteroaryls to form the multiple condensed ring system. Such multiple condensed ring systems may be optionally substituted with one or more (e.g., 1, 2, 3 or 4) oxo groups on the carbocycle or heterocycle portions of the multiple condensed ring. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another. It is also to be understood that the point of attachment of a multiple condensed ring system (as defined above for a cycloalkyl) can be at any position of the cycloalkylic ring.

[0057] Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, cyclohexyl, cycloheptyl, cyclooctyl, indenyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, bicyclo[4.1.0]heptanyl, spiro[3.3]heptanyl, and spiro[3.4]octanyl. In some embodiments, the cycloalkyl group is a 3-7 membered cycloalkyl.

[0058]

[0022] The term “alkenyl” as used herein refers to C2-C12 alkyl group that contains at least one carbon-carbon double bond. In some embodiments, the alkenyl group is optionally substituted. In some embodiments, the alkenyl group is a C2-C6 alkenyl.

[0059]

[0023] The term “cycloalkenyl” when used alone or as part of a substituent group refers to monocyclic or multi cyclic, partially saturated ring structure having from 3 to 10 carbon atoms (“C3-C10”), preferably from 3 to 6 carbon atoms (“C3-C6”). Cycloalkenyl groups of the disclosure include monocyclic groups, as well as multicyclic groups such as bicyclic and tricyclic groups. In those embodiments having at least one multicyclic cycloalkenyl group, the cyclic groups can share one common atom ( / .<?., spirocyclic). In other embodiments having at least one multicyclic cycloalkenyl group, the cyclic groups share two common atoms (e.g., fused or bridged). The term -C3-C6 cycloalkenyl refers to a cycloalkenyl group having between three and six carbon atoms. The cycloalkenyl group may be attached at any carbon atom of the partially saturated ring such that the result is a stable structure. Cycloalkenyl groups include groups in which the partially saturated ring is fused to an aryl group. Examples of cycloalkenyl groups include, for example, cyclopropenyl (C3), cyclobutenyl (C4), cyclopropenylmethyl (C4), cyclopentenyl (C5), cyclohexenyl (Ce), 1 -methylcyclopropenyl (C4), 2-methylcyclopentenyl (C4), adamantenyl (C10), spiro[3.3]heptenyl, bicyclo[3.3.0]octenyl, indanyl, and the like. Cycloalkenyl groups of the disclosure are optionally substituted. Unless otherwise specified, in those embodiments wherein the cycloalkenyl group is substituted, the cycloalkenyl group can be substituted with 1, 2, or 3 substituents independently selected from -OH, -CN, amino, halo, Ci-Cealkyl, Ci-Cealkoxy, Ci-C6haloalkyl, and Ci-C6haloalkoxy, -C(O)NH(Ci-C6alkyl), -C(O)N(Ci-C6alkyl)2, -OC(O)NH(Ci- - 7 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0060] C6alkyl), -OC(O)N(Ci-C6alkyl)2, -S(O)2NH(Ci-C6alkyl), and -S(O)2N(Ci-C6alkyl)2. In other embodiments, the cycloalkenyl group is optionally substituted by 1-6 R groups selected from H, D, halogen, -OH, -CN, -ORa, -SRa, -NRaRd, or NRcRd.

[0061]

[0024] The term “alkynyl” as used herein refers to C2-C12 alkyl group that contains at least one carbon-carbon triple bond. In some embodiments, the alkenyl group is optionally substituted. In some embodiments, the alkynyl group is a C2-C6 alkynyl.

[0062]

[0025] The terms “alkoxy,” “alkylamino” and “alkylthio”, are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom (“oxy”), an amino group (“amino”) or thio group. The term “alkylamino” includes mono- dialkylamino groups, the alkyl portions can be the same or different.

[0063]

[0026] The terms “halo” or “halogen”, by itself or as part of another substituent, means a fluorine, chlorine, bromine, or iodine atom.

[0064]

[0027] The term “heteroalkyl” refers to an alkyl group in which one or more carbon atom has been replaced by a heteroatom selected from S, O, P and N. Exemplary heteroalkyls include alkyl ethers, secondary and tertiary alkyl amines, alkyl amides, alkyl sulfides, and the like. The group may be a terminal group or a bridging group. As used herein reference to the normal chain when used in the context of a bridging group refers to the direct chain of atoms linking the two terminal positions of the bridging group.

[0065]

[0028] The term “aryl” as used herein refers to a single, all carbon aromatic ring or a multiple condensed all carbon ring system wherein at least one of the rings is aromatic. For example, in certain embodiments, an aryl group has 6 to 12 carbon atoms. Aryl includes a phenyl radical. Aryl also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) having about 9 to 12 carbon atoms in which at least one ring is aromatic and wherein the other rings may be aromatic or not aromatic. Such multiple condensed ring systems are optionally substituted with one or more (e.g., 1, 2 or 3) oxo groups on any carbocycle portion of the multiple condensed ring system. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the point of attachment of a multiple condensed ring system, as defined above, can be at any position of the aromatic ring. Non-limiting examples of aryl groups include, but are not limited to, phenyl, indenyl, naphthyl, 1, 2, 3, 4-tetrahydro-naphthyl, and the like.

[0066]

[0029] The term “heteroaryl” as used herein refers to a single aromatic ring that has at least one atom other than carbon in the ring, wherein the atoms are selected from the group consisting of oxygen, nitrogen and sulfur; “heteroaryl” also includes multiple condensed ring systems that have at least one such aromatic ring, which multiple condensed ring systems are further

[0067] - 8 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0068] described below. Thus, “heteroaryl” includes single aromatic rings of from about 1 to 6 carbon atoms and about 1-4 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur. The sulfur and nitrogen atoms may also be present in an oxidized form provided the ring is aromatic. Exemplary heteroaryl ring systems include but are not limited to pyridyl, pyrimidinyl, oxazolyl or furyl. “Heteroaryl” also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a heteroaryl group, as defined above, is condensed with one or more rings selected from heteroaryls (to form for example a naphthyridinyl such as 1,8-naphthyridinyl), heterocycles, (to form for example a 1, 2, 3, 4-tetrahydronaphthyridinyl such as l,2,3,4-tetrahydro-l,8-naphthyridinyl), carbocycles (to form for example 5,6,7,8-tetrahydroquinolyl) and aryls (to form for example indazolyl) to form the multiple condensed ring system. Thus, a heteroaryl (a single aromatic ring or multiple condensed ring system) has about 1-20 carbon atoms and about 1-6 heteroatoms within the heteroaryl ring. A heteroaryl (a single aromatic ring or multiple condensed ring system) can also have about 5 to 12 or about 5 to 10 members within the heteroaryl ring. Multiple condensed ring systems may be optionally substituted with one or more (e.g., 1, 2, 3 or 4) oxo groups on the carbocycle or heterocycle portions of the condensed ring. The rings of a multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another. It is also to be understood that the point of attachment of a multiple condensed ring system (as defined above for a heteroaryl) can be at any position of the heteroaryl ring. It is also to be understood that the point of attachment for a heteroaryl or heteroaryl multiple condensed ring system can be at any suitable atom of the heteroaryl ring including a carbon atom and a heteroatom (e.g., a nitrogen). Exemplary heteroaryls include but are not limited to pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, 5,6,7,8-tetrahydroisoquinolinyl benzofuranyl, benzimidazolyl, thianaphthenyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl-4(3H)-one, triazolyl, 4,5,6,7-tetrahydro-lH-indazole and 3b,4,4a,5-tetrahydro-lH-cyclopropa[3,4]cyclo-penta[l,2-c]pyrazole. In one embodiment the term “heteroaryl” refers to a single aromatic ring containing at least one heteroatom. For example, the term includes 5-membered and 6-membered monocyclic aromatic rings that include one or more heteroatoms. Non-limiting examples of heteroaryl include but are not limited to pyridyl, furyl, thiazole, pyrimidine, oxazole, and thiadiazole.

[0069]

[0030] The term “heterocyclyl” or “heterocycle” as used herein refers to a single saturated or partially unsaturated ring that has at least one atom other than carbon in the ring, wherein the - 9 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0070] atom is selected from the group consisting of oxygen, nitrogen and sulfur; the term also includes multiple condensed ring systems that have at least one such saturated or partially unsaturated ring, which multiple condensed ring systems are further described below. Thus, the term includes single saturated or partially unsaturated rings (e.g., 3, 4, 5, 6 or 7-membered rings) from about 1 to 6 carbon atoms and from about 1 to 3 heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring. The ring may be substituted with one or more (e.g., 1, 2 or 3) oxo groups and the sulfur and nitrogen atoms may also be present in their oxidized forms. Exemplary heterocycles include but are not limited to azetidinyl, tetrahydrofuranyl and piperidinyl. The term “heterocycle” also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a single heterocycle ring (as defined above) can be condensed with one or more groups selected from heterocycles (to form for example a 1,8-decahydronapthyridinyl), carbocycles (to form for example a decahydroquinolyl) and aryls to form the multiple condensed ring system. Thus, a heterocycle (a single saturated or single partially unsaturated ring or multiple condensed ring system) has about 2-20 carbon atoms and 1-6 heteroatoms within the heterocycle ring. Such multiple condensed ring systems may be optionally substituted with one or more (e.g., 1, 2, 3 or 4) oxo groups on the carbocycle or heterocycle portions of the multiple condensed ring. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another. Accordingly, a heterocycle (a single saturated or single partially unsaturated ring or multiple condensed ring system) has about 3-20 atoms including about 1-6 heteroatoms within the heterocycle ring system. It is also to be understood that the point of attachment of a multiple condensed ring system (as defined above for a heterocylyl) can be at any position of the heterocyclic ring. It is also to be understood that the point of attachment for a heterocycle or heterocycle multiple condensed ring system can be at any suitable atom of the heterocyclic ring including a carbon atom and a heteroatom (e.g., a nitrogen). In one embodiment the term heterocycle includes a C2-20 heterocycle. In one embodiment the term heterocycle includes a C2-7 heterocycle. In one embodiment the term heterocycle includes a C2-5 heterocycle. In one embodiment the term heterocycle includes a C2-4 heterocycle. Exemplary heterocycles include, but are not limited to aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, homopiperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, tetrahydrofuranyl, dihydrooxazolyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1, 2,3,4-tetrahydroquinolyl, benzoxazinyl, dihydrooxazolyl, chromanyl, 1,2-dihydropyridinyl, 2,3-dihydrobenzofuranyl, 1,3-benzodioxolyl, 1,4-benzodioxanyl, spiro[cyclopropane-l,l'-isoindolinyl]-3'-one, isoindolinyl-l-one, 2-oxa-6-azaspiro[3.3]heptanyl, imidazolidin-2-one N- - 10 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0071] methylpiperidine, imidazolidine, pyrazolidine, butyrolactam, valerolactam, imidazolidinone, hydantoin, di oxolane, phthalimide, 1,4-di oxane, thiomorpholine, thiomorpholine-S-oxide, thiomorpholine-S, S-oxide, pyran, 3 -pyrroline, thiopyran, pyrone, tetrhydrothiophene, quinuclidine, tropane, 2-azaspiro[3.3]heptane, 2,7-diazaspiro[3.5]nonane, (lR,5S)-3-azabicyclo[3.2.1]octane, (ls,4s)-2-azabicyclo[2.2.2] octane, (lR, R)-2-oxa-5-azabicyclo[2.2.2]octane and pyrrolidin-2-one. In one embodiment the term “heterocycle” refers to a monocyclic, saturated or partially unsaturated, 3-8 membered ring having at least one heteroatom. For example, the term includes a monocyclic, saturated or partially unsaturated, 4, 5, 6, or 7 membered ring having at least one heteroatom. Non-limiting examples of heterocycle include aziridine, azetidine, pyrrolidine, piperidine, piperidine, piperazine, oxirane, morpholine, and thiomorpholine. The term “9- or 10-membered heterobicycle” as used herein refers to a partially unsaturated or aromatic fused bicyclic ring system having at least one heteroatom. For example, the term 9- or 10-membered heterobicycle includes a bicyclic ring system having a benzo ring fused to a 5-membered or 6-membered saturated, partially unsaturated, or aromatic ring that contains one or more heteroatoms.

[0072]

[0031] The term “heterocycloalkyl” when used alone or as part of a substituent group refers to any three to twelve membered monocyclic or multicyclic, saturated ring structure containing at least one heteroatom selected from the group consisting of O, N and S. Heterocycloalkyl groups of the disclosure include monocyclic groups, as well as multicyclic groups such as bicyclic and tricyclic groups. In those embodiments having at least one multicyclic heterocycloalkyl group, the cyclic groups can share one common atom ( / .<?., spirocyclic). In other embodiments having at least one multicyclic heterocycloalkyl group, the cyclic groups share two common atoms (e.g., fused or bridged). The term -C3-C6 heterocycloalkyl refers to a heterocycloalkyl group having between three and six carbon ring atoms. The heterocycloalkyl group may be attached at any heteroatom or carbon atom of the group such that the result is a stable structure. Examples of heterocycloalkyl groups include, but are not limited to, azepanyl, aziridinyl, azetidinyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, pyrazolidinyl, piperazinyl, piperidinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, oxazepanyl, oxiranyl, oxetanyl, quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperazinyl, azepanyl, diazepanyl, oxepanyl, dioxepanyl, azocanyl diazocanyl, oxocanyl, dioxocanyl, azaspiro[2.2]pentanyl, oxaazaspiro[3.3]heptanyl,

[0073] oxaspiro[3.3]heptanyl, dioxaspiro[3.3]heptanyl, 3-azabicyclo[3.1.0]hexanyl,

[0074]

[0075] , and the like. Heteroycloalkyl groups of the disclosure are optionally substituted. Unless otherwise specified, in those embodiments wherein the heterocycloalkyl group is substituted, the

[0076] - 11 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0077] heterocycloalkyl group can be substituted with 1, 2, or 3 substituents independently selected from -OH, -CN, amino, halo, Ci-Cealkyl, Ci-Cealkoxy, Ci-Cehaloalkyl, and Ci-Cehaloalkoxy, -C(O)NH(Ci-C6alkyl), -C(O)N(Ci-C6alkyl)2, -OC(O)NH(Ci-C6alkyl), -OC(O)N(Ci-C6alkyl)2, -S(O)2NH(Ci-Cealkyl), and -S(O)2N(Ci-C6alkyl)2. In other embodiments, the heterocycloalkyl group is optionally substituted by 1-6 R groups selected from H, D, halogen, -OH, -CN, -ORa, -SRa, -NRaRd, or NRcRd.

[0078]

[0032] The term “heterocycloalkenyl” when used alone or as part of a substituent group refers to any three to twelve membered monocyclic or multicyclic, partially saturated ring structure containing at least one heteroatom selected from the group consisting of O, N and S.

[0079] Heterocycloalkenyl groups of the disclosure include monocyclic groups, as well as multicyclic groups such as bicyclic and tricyclic groups. In those embodiments having at least one multicyclic heterocycloalky enyl group, the cyclic groups can share one common atom ( / .<?., spirocyclic). In other embodiments having at least one multicyclic heterocycloalkenyl group, the cyclic groups share two common atoms (e.g., fused or bridged). The term -C3-C6 heterocycloalkenyl refers to a heterocycloalkenyl group having between three and six carbon atoms. The heterocycloalkenyl group may be attached at any heteroatom or carbon atom of the partially saturated ring such that the result is a stable structure. Heterocycloalkenyl groups include groups in which the partially saturated ring is fused to an aryl group, such as, for example

[0080] isoindoline,

[0081]

[0082] , or in which the partially saturated ring is fused to a heteroaryl group,

[0083] such as, for example, 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine,

[0084]

[0085] . Heteroycloalkenyl groups of the disclosure are optionally substituted. Unless otherwise specified, in those embodiments wherein the heterocycloalkenyl group is substituted, the heterocycloalkenyl group can be substituted with 1, 2, or 3 substituents independently selected from -OH, -CN, amino, halo, Ci-Cealkyl, Ci-Cealkoxy, Ci-Cehaloalkyl, and Ci-Cehaloalkoxy, -C(O)NH(Ci-C6alkyl), -C(O)N(Ci-C6alkyl)2, -OC(O)NH(Ci-C6alkyl), -OC(O)N(Ci-C6alkyl)2, -S(O)2NH(Ci-C6alkyl), and -S(O)2N(Ci-C6alkyl)2. In other embodiments, the heterocycloalkenyl group is optionally substituted by 1-6 R groups selected from H, D, halogen, -OH, -CN, -ORa, -SRa, -NRaRd, or NRcRd.

[0086]

[0033] As used herein, the term “heteroatom” is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si). The nitrogen and sulfur can be in an oxidized form when feasible.

[0087]

[0034] As used herein, the term “chiral” refers to molecules which have the property of non-superimposability of the mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner.

[0088] - 12 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0089]

[0035] As used herein, the term “stereoisomers” refers to compounds which have identical chemical constitution but differ with regard to the arrangement of the atoms or groups in space, e.g., enantiomers, diastereomers, tautomers.

[0090]

[0036] The term “patient” or “subject” is used throughout the specification to describe an animal, preferably a human or a domesticated animal, to whom treatment, including prophylactic treatment, with the compositions according to the present disclosure is provided. For treatment of those infections, conditions or disease states which are specific for a specific animal such as a human patient, the term patient refers to that specific animal, including a domesticated animal such as a dog or cat or a farm animal such as a horse, cow, sheep, etc. In general, in the present disclosure, the term patient refers to a human patient unless otherwise stated or implied from the context of the use of the term.

[0091]

[0037] The term “effective” is used to describe an amount of a compound, composition or component which, when used within the context of its intended use, effects an intended result. The term effective subsumes all other effective amount or effective concentration terms, which are otherwise described or used in the present application.

[0092]

[0038] “Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U. S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, e.g., in humans.

[0093]

[0039] “Pharmaceutically acceptable salt” refers to a salt of a compound of the disclosure that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyljbenzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2 -hydroxy ethane-sulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-l-carboxylic acid, glucoheptonic acid, 3 -phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or - 13 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0094] coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like. Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.

[0095]

[0040] A “pharmaceutically acceptable excipient” refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith.

[0096] Examples of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.

[0097]

[0041] A “solvate” refers to a physical association of a compound of Formula I with one or more solvent molecules.

[0098]

[0042] “Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (e.g., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treating” or “treatment” refers to delaying the onset of the disease or disorder.

[0099]

[0043] In one aspect, the disclosure is directed to a compound of Formula (I):

[0100] PTM - ULM(I)

[0101] or a pharmaceutically acceptable salt or solvate thereof,

[0102] wherein PTM is a moiety of Formula IA:

[0103]

[0104] wherein

[0105] R1is a covalent bond, or chemical moiety that links PTM and ULM;

[0106] * is a point of attachment to ULM;

[0107] Rhis H, D, Ci-6 alkyl, C3-6 cycloalkyl, C1-3 haloalkyl, or C1-4 alkoxy;

[0108] - 14 - 105807.001161(4928-3254-4676.1105807.001161 - PCT Application

[0109] Rdlis H, D, halo, cyano, Ci-6 alkyl, C3-6 cycloalkyl, C1-3 haloalkyl, or Ci-4alkoxyl;

[0110] ULM is

[0111]

[0112] wherein

[0113] each X2 is independently N or CR15, provided that one X2 is a C atom having the attachment point to R1; and

[0114] each R15is independently H, D, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, Ci-s alkoxy, Ce-io aryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C5-12 heteroaryl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl;

[0115] wherein in R15, any alkyl group, alkenyl group, alkoxy group, aryl group, cycloalkyl group, cycloalkenyl group, heteroaryl group, heterocycloalkyl group, or heterocycloalkenyl group is optionally substituted by one or more Rfgroups;

[0116] each Rfis independently D, oxo, halogen, Ci-Cs alkoxy, Ci-Cs alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, -OH, -CN, -NO2, -C2-C6 alkenyl, -C2-C6 alkynyl, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Rb, -C(O)ORb, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)RcRd, -P(O)(ORb)(ORb), -B(ORc)(ORd), -S(O)2Rb, -C(O)NRbORb, -S(O)2ORb, -OS(O)2ORb, or -OPO(ORb)(ORb); wherein said Ci-C8alkoxy, Ci-C8alkyl, Ci-C8alkoxy, Ci-Cs alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, -OH, -CN, -NO2, -C2-C6 alkenyl, -C2-C6 alkynyl, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, is optionally substituted by 1-6 groups selected from D, halogen, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Rb, -C(O)ORb, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -

[0117] - 15 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0118] S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)RcRd, -P(O)(ORb)(ORb), -B(ORc)(ORd), -S(O)2Rb, -C(O)NRbORb, -S(O)2ORb, -OS(O)2ORb, or -OPO(ORb)(ORb);

[0119] each Rais independently H, D, -C(O)Rb, -C(O)ORC, -C(O)NRcRd, -C(=NRb)NRbRc, -C(=NORb)NRbRc, -C(=NCN)NRbRc, -P(ORC)2, -P(O)RcRb, -P(O)RcRd, -P(O)ORcORb, -S(O)Rb, -S(O)NRcRd, -S(O)2Rb, -S(O)2NRcRd, SiRb3, -Ci-Cioalkyl, -C2-C10 alkenyl, -C2-C10 alkynyl, -Ci-8alkoxy, Ce-io aryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C5-12 heteroaryl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl;

[0120] each Rb, is independently H, D, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, Ce-io aryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C5-12 heteroaryl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl;

[0121] each Rcor Rdis independently H, D, -C1-C10 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -C1-8 alkoxy, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl;

[0122] or Rcand Rd, together with the atom to which they are both attached, form a monocyclic or multi cyclic heterocycloalkyl, or a monocyclic or multi cyclic heterocycloalkenyl group;

[0123] wherein any alkyl group, alkenyl group, alkoxy group, aryl group, cycloalkyl group, cycloalkenyl group, heteroaryl group, heterocycloalkyl group, or heterocycloalkenyl group ofRa, Rb, Rcand Rdare optionally substituted by one or more Rlegroups; and

[0124] wherein each Rleis independently D, -halo, -Ci-Csalkyl, -O-Ci-Csalkyl, -Ci-Cehaloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-Csalkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-11 membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-Csalkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-Csalkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -CO2H, -CN, -CF3, -CHF2, -CH2F, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(CI-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-Csalkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2.

[0125]

[0044] In some embodiments, Rhin Formula (IA) is H, D, C1-6 alkyl, C3-6 cycloalkyl, C1-3 haloalkyl, or C1-4 alkoxy. In some embodiments, Rhin Formula (IA) is H. In some embodiments, Rhin Formula (IA) is D. In other embodiments, Rhin Formula (IA) is C1-6 alkyl.

[0126] - 16 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0127] In other embodiments, Rhin Formula (IA) is C3-6 cycloalkyl. In yet other embodiments, Rhin Formula (IA) is C1-3 haloalkyl. In yet other embodiments, Rhin Formula (IA) is C1-4 alkoxy.

[0128]

[0045] In some embodiments, Rhin Formula (IA) is C1-6 alkyl, such as, for example, Ci alkyl, C2, alkyl, C3 alkyl, methyl, ethyl, propyl, isopropyl, and the like. In some embodiments, Rhin Formula (IA) is methyl. In other embodiments, Rhin Formula (IA) is ethyl. In other embodiments, Rhin Formula (IA) is CH2F.

[0129]

[0046] In some embodiments, Rdlin Formula (IA) is H, D, halo, cyano, C1-6 alkyl, C3-6 cycloalkyl, C1-3 haloalkyl, or Ci-4alkoxyl. In some embodiments, Rdlin Formula (IA) is H. In some embodiments, Rdlin Formula (IA) is D. In other embodiments, Rdlin Formula (IA) is halo. In other embodiments, Rdlin Formula (IA) is cyano. In other embodiments, Rdlin Formula (IA) is C1-6 alkyl. In other embodiments, Rdlin Formula (IA) is C3-6 cycloalkyl. In yet other embodiments, Rdlin Formula (IA) is C1-3 haloalkyl. In yet other embodiments, Rdlin Formula (IA) is Ci-4alkoxyl.

[0130]

[0047] According to the disclosure, ULM in Formula I or Formula IA is

[0131]

[0132] wherein

[0133] each X2 is independently N or CR15, provided that one X2 is a C atom having the attachment point to R1; and

[0134] each R15is independently H, D, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, Ci-s alkoxy, Ce-io aryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C5-12 heteroaryl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl.

[0135] - 17 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0136]

[0048] In some embodiments, wherein in R15, any alkyl group, alkenyl group, alkoxy group, aryl group, cycloalkyl group, cycloalkenyl group, heteroaryl group, heterocycloalkyl group, or heterocycloalkenyl group is optionally substituted by one or more Rfgroups.

[0137]

[0049] In some embodiments, each Rfis independently D, oxo, halogen, Ci-Cs alkoxy, Ci-Cs alkyl, Ci-6 haloalkyl, Ci-6 haloalkoxy, -OH, -CN, -NO2, -C2-C6 alkenyl, -C2-C6 alkynyl, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Rb, -C(O)ORb, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)RcRd, -P(O)(ORb)(ORb), -B(ORc)(ORd), -S(O)2Rb, -C(O)NRbORb, -S(O)2ORb, -OS(O)2ORb, or -OPO(ORb)(ORb); wherein said Ci-C8alkoxy, Ci-Cs alkyl, Ci-Cs alkoxy, Ci-Cs alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, -OH, -CN, -NO2, -C2-C6 alkenyl, -C2-C6 alkynyl, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, is optionally substituted by 1-6 groups selected from D, halogen, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Rb, -C(O)ORb, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)RcRd, -P(O)(ORb)(ORb), -B(ORc)(ORd), -S(O)2Rb, -C(O)NRbORb, -S(O)2ORb, -OS(O)2ORb, or -OPO(ORb)(ORb).

[0138]

[0050] In some embodiments, each Rais independently H, D, -C(O)Rb, -C(O)ORC, -C(O)NRcRd, -C(=NRb)NRbRc, -C(=NORb)NRbRc, -C(=NCN)NRbRc, -P(ORC)2, -P(O)RcRb, -P(O)RcRd, -P(O)ORcORb, -S(O)Rb, -S(O)NRcRd, -S(O)2Rb, -S(O)2NRcRd, SiRb3, -Ci-Cioalkyl, -C2-C10 alkenyl, -C2-C10 alkynyl, -C1-8 alkoxy, Ce-io aryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C5-12 heteroaryl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl.

[0139]

[0051] In some embodiments, each Rb, is independently H, D, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-Ce alkynyl, C1-8 alkoxy, Ce-io aryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C5-12 heteroaryl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl.

[0140]

[0052] In some embodiments, each Rcor Rdis independently H, D, -C1-C10 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, -C1-8 alkoxy, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl.

[0141]

[0053] In some embodiments, Rcand Rd, together with the atom to which they are both attached, form a monocyclic or multicyclic heterocycloalkyl, or a monocyclic or multicyclic heterocycloalkenyl group.

[0142]

[0054] In some embodiments, any alkyl group, alkenyl group, alkoxy group, aryl group, cycloalkyl group, cycloalkenyl group, heteroaryl group, heterocycloalkyl group, or heterocycloalkenyl group of Ra, Rb, Rcand Rdis optionally substituted by one or more Rlegroups;

[0143] wherein each Rleis independently D, -halo, -Ci-Csalkyl, -O-Ci-Csalkyl, -Ci-Cehaloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-Csalkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11

[0144] - 18 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0145] membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-11 membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-Csalkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -CO2H, -CN, -CF3, -CHF2, -CH2F, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(CI-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-Csalkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2.

[0146]

[0055] In some embodiments,

[0147]

[0148] wherein each X2 is independently N or CR15.

[0149]

[0150]

[0057] In some embodiments,

[0151]

[0152] wherein each X2 is independently N or CR15.

[0153] - 19 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0154]

[0058] In some embodiments,

[0155]

[0156] N or CR15.

[0157]

[0059] In some embodiments,

[0158]

[0159] wherein each X2 is independently N or CR15.

[0160]

[0060] In other embodiments,

[0161]

[0162] wherein each X2 is independently N or CR15.

[0163]

[0061] In other embodiments,

[0164]

[0165] wherein each X2 is independently N or CR15.

[0166]

[0062] In other embodiments,

[0167]

[0168] wherein each X2 is independently N or CR15.

[0169]

[0063] In some embodiments, each X2 of ULM is independently N or CR15. In some embodiments, at least one X2 of ULM is N. In some embodiments, at least one X2 of ULM is - 20 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0170] CR15. In some embodiments, each X2 of ULM is CR15provided that one X2 is a C atom having the attachment point to R1.

[0171]

[0064] According to the disclosure, each R15is independently H, D, halogen, oxo, -OH, -CN, -NO2, -Ci-Cealkyl, -Ci-Cehaloalkyl, -C2-Cealkenyl, -C2-Cealkynyl, C1-8 alkoxy, Co-Cialk-aryl, Co-Cialk-heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Ra, -C(O)ORa, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)(ORb)(ORb), -B(ORd)(ORc) or -S(O)2Rb.

[0172]

[0065] In some embodiments, each R15is H. In some embodiments, at least one R15is H. In some embodiments, each R15is D. In some embodiments, at least one R15is D. In other embodiments, each R15is Ci-Cealkyl. In other embodiments, at least one R15is Ci-Cealkyl. In other embodiments, each R15is methyl. In yet other embodiments, at least one R15is methyl. In other embodiments, each R15is ethyl. In yet other embodiments, at least one R15is ethyl.

[0173]

[0066] In some embodiments, each R15is independently selected from halogen, oxo, -OH, -CN, -NO2, -Ci-Cehaloalkyl, -C2-Cealkenyl, -C2-Cealkynyl, C1-8 alkoxy, Co-Cialk-aryl, Co-Cialk-heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Ra, -C(O)ORa, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)(ORb)(ORb), -B(ORd)(ORc) or -S(O)2Rb.

[0174]

[0067] In some embodiments, in R15, any alkyl group, alkenyl group, alkoxy group, aryl group, cycloalkyl group, cycloalkenyl group, heteroaryl group, heterocycloalkyl group, or heterocycloalkenyl group is optionally substituted by one or more Rfgroups.

[0175]

[0068] In some embodiments, each Rfis independently D, oxo, halogen, Ci-Cs alkoxy, Ci-Cs alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, -OH, -CN, -NO2, -C2-C6 alkenyl, -C2-C6 alkynyl, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Rb, -C(O)ORb, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)RcRd, -P(O)(ORb)(ORb), -B(ORc)(ORd), -S(O)2Rb, -C(O)NRbORb, -S(O)2ORb, -OS(O)2ORb, or -OPO(ORb)(ORb); wherein said Ci-C8alkoxy, Ci-Cs alkyl, Ci-Cs alkoxy, Ci-Cs alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, -OH, -CN, -NO2, -C2-C6 alkenyl, -C2-C6 alkynyl, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, is optionally substituted by 1-6 groups selected from D, halogen, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Rb, -C(O)ORb, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)RcRd, -P(O)(ORb)(ORb), -B(ORc)(ORd), -S(O)2Rb, -C(O)NRbORb, -S(O)2ORb, -OS(O)2ORb, or -OPO(ORb)(ORb).

[0176]

[0069] In some embodiments, Rfis H. In some embodiments, Rfis D. In some embodiments, Rfis oxo. In some embodiments, Rfis halogen. In some embodiments, Rfis Ci-Cs alkoxy. In some embodiments, Rfis Ci-Cs alkyl. In some embodiments, Rfis haloalkyl. In some embodiments, Rf- 21 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0177] is -OH. In some embodiments, Rfis -CN. In some embodiments, Rfis -NO2. In some embodiments, Rfis -C2-C6 alkenyl. In some embodiments, Rfis -C2-C6 alkynyl. In some embodiments, Rfis Ce-Cio aryl. In some embodiments, Rfis C5-C12 heteroaryl. In some embodiments, Rfis C3-C8 cycloalkyl. In other embodiments, Rfis C3-C8 cycloalkenyl. In other embodiments, Rfis C3-C8 heterocycloalkyl. In other embodiments, Rfis C3-C8 heterocycloalkenyl. In other embodiments, Rfis -ORa. In other embodiments, Rfis -SRa. In other embodiments, Rfis -NRcRd. In other embodiments, Rfis -NRaRc. In other embodiments, Rfis -C(O)Rb. In other embodiments, Rfis -OC(O)Rb. In other embodiments, Rfis -C(O)ORb. In other embodiments, Rfis -C(O)NRcRd. In yet other embodiments, Rfis -S(O)Rb. In yet other embodiments, Rfis -S(O)2NRcRd. In yet other embodiments, Rfis -S(O)(=NRb)Rb. In yet other embodiments, Rfis -SF5. In yet other embodiments, Rfis -P(O)RbRb. In yet other embodiments, Rfis -P(O)(ORb)(ORb). In yet other embodiments, Rfis -B(ORc)(ORd). In yet other embodiments, Rfis -S(O)2Rb. In yet other embodiments, Rfis -C(O)NRbORb. In yet other embodiments, Rfis -S(O)2ORb. In yet other embodiments, Rfis -OS(O)2ORb. In yet other embodiments, Rfis -OPO(ORb)(ORb).

[0178]

[0070] In some embodiments, in Rf, any Ci-Cs alkoxy, Ci-Cs alkyl, Ci-Cs alkoxy, Ci-Cs alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, -OH, -CN, -NO2, -C2-C6 alkenyl, -C2-C6 alkynyl, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, is optionally substituted by 1-6 groups selected from D, halogen, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Rb, -C(O)ORb, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)RcRd, -P(O)(ORb)(ORb), -B(ORc)(ORd), -S(O)2Rb, -C(O)NRbORb, -S(O)2ORb, -OS(O)2ORb, or -OPO(ORb)(ORb).

[0179]

[0071] In some embodiments, each Rais independently H, D, -C(O)Rb, -C(O)ORC, -C(O)NRcRd, -C(=NRb)NRbRc, -C(=NORb)NRbRc, -C(=NCN)NRbRc, -P(ORC)2, -P(O)RcRb, -P(O)ORcORb, -S(O)Rb, -S(O)NRcRd, -S(O)2Rb, -S(O)2NRcRd, SiRb3, -Ci-Cioalkyl, -C2-C10 alkenyl, -C2-C10 alkynyl, -C1-8 alkoxy, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl.

[0180]

[0072] In some embodiments, Rais H. In some embodiments, Rais D. In some embodiments, Rais -C(O)Rb. In some embodiments, Rais -C(O)ORC. In some embodiments, Rais -C(O)NRcRd. In some embodiments, Rais -C(=NRb)NRbRc. In some embodiments, Rais C(=NORb)NRbRc. In some embodiments, Rais -C(=NCN)NRbRc.

[0181]

[0073] In other embodiments, Rais -P(ORC)2, -P(O)RcRb, -P(O)ORcORb, -S(O)Rb, -S(O)NRcRd, -S(O)2Rb, -S(O)2NRcRd, SiRb3, and the like. In yet other embodiments, Raof ring Z in Formula la is -Ci-Cioalkyl, -C2-C10 alkenyl, -C2-C10 alkynyl, -C1-8 alkoxy, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, heterocycloalkenyl, and the like.

[0182] - 22 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0183]

[0074] In some embodiments, each Rbis independently H, D, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-Ce alkynyl, -C1-8 alkoxy, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl.

[0184]

[0075] In some embodiments, Rbis H. In some embodiments, Rbis D. In some embodiments, Rbis -Ci-Ce alkyl. In some embodiments, Rbis -C2-C6 alkenyl. In some embodiments, Rbis -C2-C6 alkynyl. In some embodiments, Rbis -C1-8 alkoxy. In other embodiments, Rbis aryl. In other embodiments, Rbis cycloalkyl. In other embodiments, Rbis cycloalkenyl. In other embodiments, Rbis heteroaryl. In other embodiments, Rbis heterocycloalkyl. In other embodiments, Rbis heterocycloalkenyl.

[0185]

[0076] In some embodiments, each Rcor Rdis independently H, D, -C1-C10 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, Ci-Cs alkoxy, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl.

[0186]

[0077] In some embodiments, Rcor Rdis H. In some embodiments, Rcor Rdis D. In some embodiments, Rcor Rdis -C1-C10 alkyl. In some embodiments, Rcor Rdis -C2-C6 alkenyl. In some embodiments, Rcor Rdis -C2-C6 alkynyl. In some embodiments, Rcor Rdis -C1-8 alkoxy. In other embodiments, Rcor Rdis Ce-io aryl. In other embodiments, Rcor Rdis C3-8 cycloalkyl. In other embodiments, Rcor RdC3-8 cycloalkenyl. In other embodiments, Rcor Rdis C5-12 heteroaryl. In other embodiments, Rcor Rdis C3-8 heterocycloalkyl. In other embodiments, Rcor Rdis C3-8 heterocycloalkenyl.

[0187]

[0078] In yet other embodiments, Rcand Rd, together with the atom to which they are both attached, form a monocyclic or multicyclic heterocycloalkyl, or a monocyclic or multicyclic heterocycloalkenyl group. In yet other embodiments, Rcand Rdform a monocyclic heterocycloalkyl. In yet other embodiments, Rcand Rdform a multicyclic heterocycloalkyl. In yet other embodiments, Rcand Rdform a monocyclic heterocycloalkenyl group. In yet other embodiments, Rcand Rdform a multicyclic heterocycloalkenyl group.

[0188]

[0079] In yet other embodiments, any alkyl group, alkenyl group, alkoxy group, aryl group, cycloalkyl group, cycloalkenyl group, heteroaryl group, heterocycloalkyl group, or heterocycloalkenyl group of Ra, Rb, Rcand Rdis optionally substituted by one or more Rlegroups;

[0189] wherein each Rleis independently D, -halo, -Ci-Csalkyl, -O-Ci-Csalkyl, -Ci-Cehaloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-Csalkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-11 membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-Csalkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci- - 23 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0190] Csalkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -CO2H, -CN, -CF3, -CHF2, -CH2F, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(CI-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-Csalkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2.

[0191]

[0080] In some aspects, R1in Formula IA is a covalent bond, or chemical moiety that links PTM and ULM.

[0192]

[0081] In some embodiments, R1in Formula IA is a covalent bond.

[0193]

[0082] In other embodiments, R1in Formula IA is a chemical moiety that links PTM and ULM.

[0194]

[0083] Chemical moieties that are used to link PTM and ULM moieties are known in the art. These moieties are sometimes referred to as “linkers” in the art. In some embodiments, R1in Formula IA is a chemical moiety that is used to link a PTM and ULM that is known in the art.

[0195]

[0084] In some embodiments, R1in Formula IA is a chemical moiety that is used to link a PTM and ULM as described in U. S. Patent Application Publication No. 2019 / 0300521, the entirety of which is incorporated by reference herein.

[0196]

[0085] In other embodiments, R1in Formula IA is a chemical moiety that is used to link a PTM and ULM as described in U. S. Patent Application Publication No. 2019 / 0255066, the entirety of which is incorporated by reference herein.

[0197]

[0086] In other embodiments, R1in Formula IA is a chemical moiety that is used to link a PTM and ULM as described in WO 2019 / 084030, the entirety of which is incorporated by reference herein.

[0198]

[0087] In other embodiments, R1in Formula IA is a chemical moiety that is used to link a PTM and ULM as described in WO 2019 / 084026, the entirety of which is incorporated by reference herein.

[0199]

[0088] In some embodiments, R1in Formula IA is a chemical structural unit represented by the formula:

[0200] ■(A)q-,

[0201] wherein:

[0202] q is an integer from 1 to 14;

[0203] each A is independently selected from the group consisting of a bond, CRlaRlb, O, S, SO,

[0204]

[0205] - 24 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0206] NRlcC(=NCN)NRldNRlcC(=NCN), NRlcC(=CNO2)NRld, 3-11 membered cycloalkyl, optionally substituted with 1-6 Rlaand / or Rlbgroups, 3-11 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups, aryl optionally substituted with 1-6 Rlaand / or Rlbgroups, heteroaryl optionally substituted with 1-6 Rlaand / or Rlbgroups,

[0207] and Rla, Rlb, Rlc, and Rldare each independently, -H, D, -halo, -Ci-Csalkyl, -Ci-Cehaloalkyl, -O-Ci-Csalkyl, -S-Ci-Csalkyl, -NHCi-Csalkyl, -N(Ci-Csalkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-11 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-11 membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-Csalkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -CO2H, -CN, -CF3, -CHF2, -CH2F, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-Csalkyl, -SON(Ci-C8alkyl)2, -CONHCi-C8alkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2.

[0208]

[0089] In these embodiments, q represents the number of connected A groups. For example, when q = 1, -(A)q- is -Ai-; when q = 2, -(A)q- is -A1-A2-; when q = 3, -(A)q- is -A1-A2-A3-; when q = 4, -(A)q- is -A1-A2-A3-A4-; when q = 5, -(A)q- is -AI-A2-A3-A4-AS-; when q = 6, -(A)q- is -AI-A2-A3-A4-AS-A6-; when q = 7, -(A)q- is -AI-A2-A3-A4-AS-A6-A7-; when q = 8, -(A)q- is -Ai-A2-A3-A4-AS-A6-A7-AS-; when q = 9, -(A)q- is -AI-A2-A3-A4-A5-A6-A7-A8-A9-; when q = 10, -(A)q- is -AI-A2-A3-A4-A5-A6-A7-AS-A9-AIO-; when q = 11, -(A)q- is -AI-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-; when q = 12, -(A)q- is -Ai-A2-A3-A4-A5-A6-A7-As-A9-Aio-An-Ai2-; when q = 13, -(A)q- is -Ai-A2-A3-A4-A5-A6-A7-A8-A9-Aio-An-Ai2-Ai3-; and when q = 14, -(A)q- is -A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-AB-A14-.

[0209]

[0090] In some embodiments, q = 5 and R1is a chemical moiety represented by the formula: -Ai-A2-A3-A4-A5-, wherein each of Ai, A3and A5 is independently selected from the group consisting

[0210]

[0211] - 25 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0212] 4P(0)Rla(CRlaRlb)o-4, -(CRlaRlb)o-4P(0)ORla(CRlaRlb)o-4, (CRlaRlb)i-4, optionally substituted 3-11 membered cycloalkyl, 3-11 membered heterocyclyl, aryl, and heteroaryl; wherein each of A2 and A4 is independently selected from the group consisting of is independently selected from the group consisting of a bond, (CRlaRlb)i-4, optionally substituted 3-11 membered cycloalkyl, 3-11 membered heterocyclyl, aryl, and heteroaryl; wherein Rlaand Rlbare each independently selected from the group consisting of -H, D, -halo, -Ci-Csalkyl, -O-Ci-Csalkyl, -Ci-Cehaloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-Csalkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -CO2H, -CN, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(CI-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-Csalkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2; and Rlcand Rldare each independently selected from the group consisting of H, D, optionally substituted C1-4 alkyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, aryl, or heteroaryl.

[0213]

[0091] In other embodiments, q = 4 and R1is a chemical moiety represented by the formula:-Ai-A2-A3-A4-, wherein each of A1-4 is independently selected from the group consisting of O, S, SO,

[0214]

[0215] substituted 3-11 membered cycloalkyl, 3-11 membered heterocyclyl, aryl, and heteroaryl; wherein Rlaand Rlbare each independently selected from the group consisting of -H, D, -halo, -Ci-C8alkyl, -O-Ci-C8alkyl, -Ci-C6haloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-C8alkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2C1-Csalkyl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-Csalkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -CO2H, -CN, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci- - 26 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0216] C8alkyl)2, -SONHCi-Csalkyl, -SON(Ci-C8alkyl)2, -CONHCi-Csalkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-Csalkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2; and Rlcand Rldare each independently selected from the group consisting of H, D, optionally substituted C1-4 alkyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, aryl, or heteroaryl.

[0217]

[0092] In other embodiments, q = 3 and R1is a chemical moiety represented by the formula:-Ai-A2-A3-, wherein each of A1-3 is independently selected from the group consisting of O, S, SO,

[0218]

[0219] substituted 3-11 membered cycloalkyl, 3-11 membered heterocyclyl, aryl, and heteroaryl; wherein Rlaand Rlbare each independently selected from the group consisting of -H, D, -halo, -Ci-C8alkyl, -O-Ci-C8alkyl, -Ci-C6haloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-C8alkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2C1-Csalkyl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-Csalkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -CO2H, -CN, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-Csalkyl, -SON(Ci-C8alkyl)2, -CONHCi-Csalkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2; and Rlcand Rldare each independently selected from the group consisting of H, D, optionally substituted C1-4 alkyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, aryl, or heteroaryl.

[0220]

[0093] In yet other embodiments, q = 2 and R1is a chemical moiety represented by the formula:-A1-A2-, wherein each of A1-2 is independently selected from the group consisting of O, S, SO,

[0221]

[0222] substituted 3-11 membered cycloalkyl, 3-11 membered heterocyclyl, aryl, and heteroaryl;

[0223] wherein Rlaand Rlbare each independently selected from the group consisting of -H, D, -halo, -Ci-C8alkyl, -O-Ci-C8alkyl, -Ci-C6haloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci- - 27 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0224] C8alkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-11 membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -CO2H, -CN, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-C8alkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-Csalkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2; and Rlcand Rldare each independently selected from the group consisting of H, D, optionally substituted C1-4 alkyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, aryl, or heteroaryl.

[0225]

[0094] In yet other embodiments, q = 1 and R1is a chemical moiety represented by the formula: -Ai, wherein Ai is selected from the group consisting of O, S, SO, SO2, NRlc, SO2NRlc, SONRlc, SO(=NRlc), SO(=NRlc)NRld, CONRlc, NRlcCONRld, NRlcC(O)O, NRlcSO2NRld, CO, CRla=CRlb, C=C, SiRlaRlb, P(O)Rla, P(O)ORla, (CRlaRlb)i-4, -(CRlaRlb)i-4O(CRlaRlb)i-4, -(CRlaRlb)i-4S(CRlaRlb)i-4, -(CRlaRlb)i-4NR(CRlaRlb)i-4, optionally substituted 3-11 membered cycloalkyl, 3-11 membered heterocyclyl, aryl, and heteroaryl; wherein Rlaand Rlbare each independently selected from the group consisting of -H, D, -halo, -Ci-C8alkyl, -O-Ci-C8alkyl, -Ci-Cehaloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-C8alkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-11 membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-Csalkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -CO2H, -CN, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-C8alkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2; and Rlcand Rldare each independently selected from the group consisting of H, D, optionally substituted C1-4 alkyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, aryl, or heteroaryl.

[0226] - 28 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0227]

[0095] In some embodiments, R1is a covalent bond, 3-11 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups, 3-11 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups, -(CRlaRlb)i-5, -(CRla=CRlb)-, -(CRlaRlb)i-5-A- wherein A is O, S, orNRlc, -(CRlaRlb)i-5-A-(CRlaRlb)i-5- wherein A is O, S, orNRlc, -(CRlaRlb)i-5-A-(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(CRla=CRlb)-(CRlaRlb)i-5-, -(CRlaRlb)i-5-( CRla=CRlb)-(CRlaRlb)i-5-A- wherein A is O, S, orNRlc, -(CRlaRlb)i-5-(C=C)-(CRlaRlb)i-5-, -(CRlaRlb)i-5-(C=C)-(CRlaRlb)i-5-A- wherein A is O, S, orNRlc, -(C=C)-(CRlaRlb)i-5-A-(CRlaRlb)i-5- wherein A is O, S, or NRlc, -(C=C)-(CRlaRlb)i-5, -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-, -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-, -(3-11 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-5-, -(3-11 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups) -(CRlaRlb)i-5-, -(CRlaRlb)i-5-(3-11 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-A-, -(CRlaRlb)i-5-(3-ll membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-A-, -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-5, -(CRlaRlb)i-5-(3-ll membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s, -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s-A- wherein A is O, S, orNRlc, -(CRlaRlb)i-5-(3-ll membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-11 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s-A- wherein A is O, S, orNRlc, -(CRlaRlb)i-5-A-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s-A-wherein each A is independently O, S, orNRlc, -(CRlaRlb)i-5-A-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-5-A- wherein each A is independently O, S, or NRlc, -(CRlaRlb)i-5-A-(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(CRlaRlb)i-5-A-(CRlaRlb)i-5-A-(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(CO) wherein A is O, S, or NRlc, -(CRlaRlb)i-5-( CRla=CRlb)-(CRlaRlb)i-5-A-(CO)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(C=C)-(CRlaRlb)i-5-A-(CO)- wherein A is O, S,

[0228] - 29 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0229] or NRlc, -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-5-A-(CO)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(CO)-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-ll membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-5-A-(CO)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(CO)-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-A-(CO)- wherein each A is independently O, S, orNRlc, -(3-11 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-CO-(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-ll membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-5-A-(CO)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s-A-(CO)-wherein A is O, S, or NRlc, -(3-11 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s-, or -(3-11 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-5-

[0096] In some embodiments, R1is -CRla=CRlb-, such as, for example, -CH=CH-.

[0230]

[0097] In some embodiments, R1is -(CRlaRlb)i-5, for example -(CH2)I-5-, -CH2-, -CH2CH2CH2-and the like.

[0231]

[0098] In some embodiments, R1is -(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, such as for example, -(CH2)I-5-O-, -(CH2)I-5-S-, -(CH2)I-5-NH-, or

[0232] -(CH2)O-2-(C(CH3)2)-(CH2)O-2-0-.

[0233]

[0099] In other embodiments, R1is -(CRlaRlb)i-5-A-(CRlaRlb)i-5- wherein A is O, S, or NRlc, such as, for example, -(CH2)I-5-O-(CH2)I-5-, -(CH2)I-5-S-(CH2)I-5-, -(CH2)I-5-NH-(CH2)I-5-.

[0234]

[0100] In some embodiments, R1is -(C=C)-(CRlaRlb)i-5, such as, for example, -(C=C)-(CH2)2-, and the like.

[0235]

[0101] In some embodiments, R1is -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-, such as, for example, -Cfk-cyclobutyl-.

[0236]

[0102] In some embodiments, R1is -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s, such as, for example, -Clb-cyclobutyl-CH2- and the like.

[0237]

[0103] In some embodiments, R1is -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s, such as, for example, -Cfk-azetidinyl-CH2-.

[0238]

[0104] In some embodiments, R1is -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-, such as, for example, -Cfb-azetidinyl-.

[0239] - 30 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0240]

[0105] In some embodiments, R1is -(3-11 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups) -(CRlaRlb)i-5-, such as, for example, -azetidinyl-CH2-, -pyrolidnyl-CFfc-, -piperidinyl-CH2-, and the like.

[0241]

[0106] In some embodiments, R1is -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s-A- wherein A is O, S, or NRlc, such as, for example, -CH2-cyclopropyl-CH2-O-, and the like.

[0242]

[0107] In some embodiments, R1is -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s-A- wherein A is O, S, or NRlc, such as, for example, -CH2-piperidinyl-CH2CH2-O-, and the like.

[0243]

[0108] In some embodiments, R1is -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-A- wherein A is O, S, or NRlc, such as, for example, -CH2-azetidinyl-O-, and the like.

[0244]

[0109] In some embodiments, R1is -(CRlaRlb)i-5-A-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)- wherein A is O, S, or NRlc, such as, for example, -CH2-O-azetidinyl-, -CH2-NH-azetidinyl-, and the like.

[0245] [HO] In other embodiments, R1is -(CRlaRlb)i-5-A-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)- wherein A is O, S, or NRlc, such as -CH2-O-cyclobutylene-, -CH2-NH-cyclobutylene-, and the like.

[0246]

[0111] In some embodiments, R1is -(CRlaRlb)i-5-A-(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, such as, for example, -CH2-O-CH2CH2-O-.

[0247]

[0112] In some embodiments, Y in Formula I is

[0248]

[0249] wherein

[0250] ** is a point of attachment to the ULM;

[0251] * is a point of attachment to the oxygen atom of PTM;

[0252] Li, L2, and L3 are each independently a bond, CRlaRlb, O, S, SO, SO2, NRlc, SO2NRlc,

[0253]

[0254] ring Ai and ring A2 are each independently absent, a 3-15 membered cycloalkyl, optionally substituted with 1-6 Rlaor Rlbgroups, 3-15 membered heterocyclyl optionally substituted with 1-6 Rlaor Rlbgroups, aryl optionally substituted with 1-6 Rlaor Rlbgroups, or heteroaryl optionally substituted with 1-6 Rlaor Rlbgroups,

[0255] - 31 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0256] wherein Rla, Rlb, Rlc, and Rldare each independently, -H, D, -halo, -Ci-Csalkyl, -O-Ci-Csalkyl, -Ci-Cehaloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-C8alkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-11 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-11 membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, -SO2-aryl, -SO2-heteroaryl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -C(O)OCi-C8alkyl, -CO2H, -CN, -CF3, -CHF2, -CH2F, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-Csalkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2.

[0257]

[0113] In some embodiments, Y in Formula I is

[0258]

[0259] ** is a point of attachment to the ULM;

[0260] * is a point of attachment to the oxygen atom of PTM;

[0261] Li is a bond, (C(R10)2)P, CO or C(O)O;

[0262] L2is a bond, (C(R10)2)P, CO or C(O)O;

[0263] L3is a bond, (C(R10)2)P, CO or C(O)O;

[0264] each p is independently 1, 2, 3, or 4;

[0265] each R10is independently H, D, or C1-C4 alkyl;

[0266] ring Ai is a 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, an aryl group, or a heteroaryl group; and

[0267] ring A2 is absent, a 4-15 membered cycloalkyl group, a 4-15-membered heterocycloalkyl group, an aryl group, or a heteroaryl group. In some embodiments, ring Ai and ring A2 are each optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

[0268]

[0114] As used herein, when Li, L2, or L3is a bond, it is to be understood that the two groups between which the L intervenes are directly connected by a covalent bond. For example, when Li is a bond, it is taken to mean that PTM is directly bound to ring Ai by a covalent bond.

[0269] Similarly, when L2 is a bond, it is taken to mean that ring Ai is directly bound to ring A2 by a covalent bond, and when L3is a bond, it is taken to mean that ring A2 is directly bound to ULM by a covalent bond.

[0270] - 32 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0271]

[0115] According to the disclosure, Li is a bond, (C(R10)2)P, CO or C(O)O. In some embodiments, Li is a bond. In some embodiments, Li is (C(R10)2)P. In other embodiments, Li is CO. In other embodiments, Li is C(O)O.

[0272]

[0116] According to the disclosure, L2 is a bond, (C(R10)2)P, CO or C(O)O. In some embodiments, L2 is a bond. In some embodiments, L2 is (C(R10)2)P. In other embodiments, L2 is CO. In other embodiments, L2 is C(O)O.

[0273]

[0117] According to the disclosure, L3 is a bond, (C(R10)2)P, CO or C(O)O. In some embodiments, L3 is a bond. In some embodiments, L3 is (C(R10)2)P. In other embodiments, L3 is CO. In other embodiments, L3 is C(O)O.

[0274]

[0118] According to the disclosure, each p is independently 1, 2, 3, or 4. In some embodiments, each p is 1. In some embodiments, at least one p is 1. In some embodiments, each p is 2. In some embodiments, at least one p is 2. In other embodiments, each p is 3. In other embodiments, at least one p is 3. In other embodiments, each p is 4. In other embodiments, at least one p is 4.

[0275]

[0119] According to the disclosure, each R10is independently H, D, or C1-C4 alkyl. In some embodiments, each R10is H. In some embodiments, at least one R10is H. In some embodiments, each R10is D. In some embodiments, at least one R10is D. In other embodiments, each R10is C1-C4 alkyl. In other embodiments, at least one R10is C1-C4 alkyl. In other embodiments, each R10is methyl or ethyl. In other embodiments, at least one R10is methyl or ethyl.

[0276] According to the disclosure, ring Ai is a 3-7 membered cycloalkyl group, a 4-10 membered heterocycloalkyl group, an aryl group, or a heteroaryl group. In some embodiments, ring Ai is a 3-15 membered cycloalkyl group. In some embodiments, ring Ai is a 4-15 membered heterocycloalkyl group. In other embodiments, ring Ai is an aryl group. In other embodiments, ring Ai is a heteroaryl group. In some embodiments, ring Ai is optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

[0277]

[0120] In some embodiments, ring Ai is a heteroaryl group. In some embodiments, ring Ai is a pyridyl group. In some embodiments, ring Ai is a methyl substituted pyridyl group. In other embodiments, ring Ai is a dimethyl substituted pyridyl group.

[0278]

[0121] In some embodiments, ring Ai is an aryl group. In some embodiments, ring Ai is a phenyl group.

[0279]

[0122] In some embodiments, ring Ai is a 4-10-membered heterocycloalkyl group. In some embodiments, ring Ai is a piperazine group, a piperidine group, a pyrrolidine group, an azabicycloalkane or an azaspiroalkane group. In some embodiments, ring Ai is a piperazine group. In some embodiments, ring Ai is a piperidine group. In other embodiments, ring Ai is a

[0280] - 33 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0281] pyrrolidine group. In other embodiments, ring Ai is an azabicycloalkane. In yet other embodiments, ring Ai is an azaspiroalkane group.

[0282]

[0123] In some embodiments, ring Ai is a 3-7 membered cycloalkyl group. In some embodiments, ring Ai is a cyclobutyl group or a cyclohexyl group. In some embodiments, ring Ai is a cyclobutyl group. In some embodiments, ring Ai is a cyclohexyl group.

[0283] According to the disclosure, ring A2 is absent, is a 3-15 membered cycloalkyl group, a 4-15 membered heterocycloalkyl group, an aryl group, or a heteroaryl group. In some embodiments, ring A2 is abent. In some embodiments, ring A2 is a 3-15 membered cycloalkyl group. In some embodiments, ring A2 is a 4-15 membered heterocycloalkyl group. In other embodiments, ring A2 is an aryl group. In other embodiments, ring A2 is a heteroaryl group. In some embodiments, ring A2 is optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

[0284] In some embodiments, ring A2 is absent, or is a 4-15-membered heterocycloalkyl group. In some embodiments, ring A2 is absent. In some embodiments, ring A2 is a piperazine group. In some embodiments, ring A2 is a piperidine group. In other embodiments, ring A2 is a pyrrolidine group. In other embodiments, ring A2 is a diazaspiroalkyl group. In other embodiments, ring A2 is an azabicycloalkyl group. In yet other embodiments, ring A2 is absent. In some embodiments, ring A2 is optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

[0285]

[0124] In some embodiments, Y in Formula I is

[0286]

[0287] wherein

[0288] * is a point of attachment to the ULM;

[0289] is a point of attachment to the oxygen atom of PTM;

[0290] L2is a bond, CRlaRlb, O, S, SO, SO2, NRlc, SO2NRlc, SONRlc, SO(=NRlc),

[0291]

[0292] ring Ai and ring A2 are each independently a 3-15 membered cycloalkyl, optionally substituted with 1-6 Rlaor Rlbgroups, a 3-15 membered heterocycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups, an aryl optionally substituted with 1-6 Rlaor Rlbgroups, or a heteroaryl optionally substituted with 1-6 Rlaor Rlbgroups,

[0293] wherein Rla, Rlb, Rlc, and Rldare each independently, -H, -halo, -Ci-Csalkyl, -O-Ci-Csalkyl, -Ci-Cehaloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-Csalkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocycloalkyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered

[0294] - 34 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0295] cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, -SO2-aryl, -SO2-heteroaryl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -C(O)OCi-C8alkyl, -CO2H, -CN, -CF3, -CHF2, -CH2F, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-C8alkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2.

[0296]

[0125] In some embodiments, Y in Formula I is

[0297]

[0298] wherein

[0299] ** is a point of attachment to the ULM;

[0300] * is a point of attachment to the oxygen atom of PTM;

[0301] L2is a bond, (C(Rl0)2)P, CO or C(O)O;

[0302] p is 1, 2, 3 or 4;

[0303] each R10is independently H or C1-C4 alkyl; and

[0304] ring Ai and ring A2are each independently a 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, a 6-10-membered aryl group, or a 5-10-membered heteroaryl group. In some embodiments, ring Ai and ring A2are each optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

[0305]

[0126] According to the disclosure, L2 is a bond, (C(R10)2)P, CO or C(O)O. In some embodiments, L2 is a bond. In some embodiments, L2 is (C(R10)2)P. In other embodiments, L2 is CO. In other embodiments, L2 is C(O)O.

[0306]

[0127] According to the disclosure, each p is independently 1, 2, 3, or 4. In some embodiments, each p is 1. In some embodiments, at least one p is 1. In some embodiments, each p is 2. In some embodiments, at least one p is 2. In other embodiments, each p is 3. In other embodiments, at least one p is 3. In other embodiments, each p is 4. In other embodiments, at least one p is 4.

[0307]

[0128] According to the disclosure, each R10is independently H, D, or C1-C4 alkyl. In some embodiments, each R10is H. In some embodiments, at least one R10is H. In some embodiments, each R10is D. In some embodiments, at least one R10is D. In other embodiments, each R10is C1-C4 alkyl. In other embodiments, at least one R10is C1-C4 alkyl. In other embodiments, each R10is methyl or ethyl. In other embodiments, at least one R10is methyl or ethyl.

[0308] - 35 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0309] According to the disclosure, ring Ai is a 3-15 membered cycloalkyl group, a 4-15 membered heterocycloalkyl group, an aryl group, or a heteroaryl group. In some embodiments, ring Ai is a 3-15 membered cycloalkyl group. In some embodiments, ring Ai is a 4-15 membered heterocycloalkyl group. In other embodiments, ring Ai is an aryl group. In other embodiments, ring Ai is a heteroaryl group. In other embodiments, ring Ai is a pyridyl group. In some embodiments, ring Ai is optionally substituted with 1-6 Rlaor Rlbgroups as defined herein. In other embodiments, ring Ai is a methyl-substituted pyridyl group. In other embodiments, ring Ai is a dimethyl-substituted pyridyl group.

[0310] In some embodiments, ring Ai is a 4-10-membered heterocycloalkyl group. In some embodiments, ring Ai is a piperazine group, a piperidine group, a pyrrolidine group, an azabicycloalkane or an azaspiroalkane group. In some embodiments, ring Ai is a piperazine group. In some embodiments, ring Ai is a piperidine group. In other embodiments, ring Ai is a pyrrolidine group. In other embodiments, ring Ai is an azabicycloalkane. In yet other embodiments, ring Ai is an azaspiroalkane group. In some embodiments, ring Ai is optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

[0311] According to the disclosure, ring A2 is a 3-15 membered cycloalkyl group, a 4-15 membered heterocycloalkyl group, an aryl group, or a heteroaryl group. In some embodiments, ring A2 is a 3-15 membered cycloalkyl group. In some embodiments, ring A2 is a 4-15 membered heterocycloalkyl group. In other embodiments, ring A2 is an aryl group. In other embodiments, ring A2 is a heteroaryl group. In some embodiments, ring Ai is optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

[0312]

[0129] In some embodiments, ring A2 is a 4-15-membered heterocycloalkyl group. In some embodiments, ring A2 is a piperazine group. In some embodiments, ring A2 is a piperidine group. In other embodiments, ring A2 is a pyrrolidine group. In other embodiments, ring A2 is a diazaspiroalkyl group. In other embodiments, ring A2 is an azabicycloalkyl group. In some embodiments, ring A2 is optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

[0313]

[0130] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-1, Formula IA-2, Formula IA-3, Formula IA-4, Formula IA-5, Formula IA-6, Formula IA-7 or Formula IA-8:

[0314] - 36 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0315]

[0316] - 37 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0317]

[0318] wherein Rhis Ci-6 alkyl;

[0319] Rdlis H, D, halo, cyano or Ci-6 alkyl;

[0320] Li is a bond, or C(R10)2;

[0321] L2 is a bond, C(R10)2, or CO;

[0322] ring Ai is a 4-10-membered heterocycloalkyl group or a 5-10-membered heteroaryl group;

[0323] ring A2 is a 4-10-membered heterocycloalkyl group or a 5-10-membered heteroaryl group; and

[0324] at least two X2 are CR15. In some embodiments, ring Ai and ring A2 are each optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

[0325]

[0131] In some embodiments, Rhin Formula (I) is C1-6 alkyl. In some embodiments, Rhin Formula (I) is methyl or ethyl. In some embodiments, Rhin Formula (I) is methyl. In some embodiments, Rhin Formula (I) is ethyl.

[0326]

[0132] In some embodiments, Rdlin Formula (I) is H, D, halo, cyano or C1-6 alkyl. In some embodiments, Rdlin Formula (I) is H. In some embodiments, Rdlin Formula (I) is D. In other embodiments, Rdlin Formula (I) is halo. In other embodiments, Rdlin Formula (I) is cyano. In other embodiments, Rdlin Formula (I) is C1-6 alkyl. In yet other embodiments, Rdlin Formula (I) is methyl. In yet other embodiments, Rdlin Formula (I) is ethyl.

[0327]

[0133] According to the disclosure, Li is a bond, or (C(R10)2)P. In some embodiments, Li is a bond. In other embodiments, Li is (C(R10)2)P.

[0328]

[0134] According to the disclosure, L2 is a bond, (C(R10)2)P, or CO. In some embodiments, L2 is a bond. In some embodiments, L2 is (C(R10)2)P. In other embodiments, L2 is CO.

[0329] According to the disclosure, ring Ai is a 4-10 membered heterocycloalkyl group or a 5-10 membered heteroaryl group. In some embodiments, ring Ai is a 4-10 membered

[0330] - 38 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0331] heterocycloalkyl group. In some embodiments, ring Ai is a 5-10 membered heteroaryl group. In other embodiments, ring Ai is a pyridyl group. In some embodiments, ring Ai is optionally substituted with 1-6 Rlaor Rlbgroups as defined herein. In some embodiments, ring Ai is a methyl-substituted pyridyl group. In some embodiments, ring Ai is a dimethyl-substituted pyridyl group.

[0332]

[0135] In some embodiments, ring Ai is a 4-10-membered heterocycloalkyl group. In some embodiments, ring Ai is a piperazine group, a piperidine group, a pyrrolidine group, an azabicycloalkane or an azaspiroalkane group. In some embodiments, ring Ai is a piperazine group. In some embodiments, ring Ai is a piperidine group. In other embodiments, ring Ai is a pyrrolidine group. In other embodiments, ring Ai is an azabicycloalkane. In yet other embodiments, ring Ai is an azaspiroalkane group. In some embodiments, ring Ai is optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

[0333]

[0136] According to the disclosure, ring A2 is a 3-15 membered cycloalkyl group, a 4-15 membered heterocycloalkyl group, an aryl group, or a heteroaryl group. In some embodiments, ring A2 is a 3-15 membered cycloalkyl group. In some embodiments, ring A2 is a 4-15 membered heterocycloalkyl group. In other embodiments, ring A2 is an aryl group. In other embodiments, ring A2 is a heteroaryl group. In some embodiments, ring A2 is optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

[0334]

[0137] In some embodiments, ring A2 is a 4-15-membered heterocycloalkyl group. In some embodiments, ring A2 is a piperazine group. In some embodiments, ring A2 is a piperidine group. In other embodiments, ring A2 is a pyrrolidine group. In other embodiments, ring A2 is a diazaspiroalkyl group. In other embodiments, ring A2 is an azabicycloalkyl group. In some embodiments, ring A2 is optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

[0335]

[0138] In some embodiments, each X2 is CR15. In some embodiments, at least one X2 is CR15. In some embodiments, at least two X2 are CR15. In some embodiments, at least three X2 are CR15. In some embodiments, each X2 is N. In some embodiments, at least one X2 is N. In some embodiments, at least two X2 are n. In some embodiments, at least three X2 are N.

[0336]

[0139] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-1:

[0337]

[0338] - 39 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0339]

[0140] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-2:

[0340]

[0341]

[0141] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-3:

[0342]

[0343]

[0142] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-4:

[0344]

[0345]

[0143] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-5:

[0346]

[0347]

[0144] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-6:

[0348] - 40 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0349]

[0350]

[0145] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-7:

[0351]

[0352]

[0146] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-8:

[0353]

[0354]

[0147] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-9, Formula IA-10, Formula IA-11, Formula IA-12, Formula IA-13, Formula IA-14, Formula IA-15 or Formula IA-16:

[0355]

[0356] - 41 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0357]

[0358] wherein Rhis methyl, ethyl or CH2F;

[0359] Rdlis H, D, halo, cyano or C1-6 alkyl;

[0360] Li is a bond, or C(R10)2;

[0361] - 42 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0362] L2 is a bond, C(R10)2, or CO;

[0363] ring Ai is a 4-10-membered heterocycloalkyl group or a 5-10-membered heteroaryl group; and

[0364] ring A2 is a 4-10-membered heterocycloalkyl group or a 5-10-membered heteroaryl group. In some embodiments, ring Ai and ring A2 are each optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

[0365]

[0148] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-9:

[0366]

[0367]

[0149] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-10:

[0368]

[0369]

[0150] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-11:

[0370]

[0371]

[0151] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-12:

[0372]

[0373] - 43 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0374]

[0152] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-13:

[0375]

[0376]

[0153] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-14:

[0377]

[0378]

[0154] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-15:

[0379]

[0380]

[0155] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-16:

[0381]

[0382]

[0156] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-17, Formula IA-18, Formula IA-19, Formula IA-20, Formula IA-21, Formula IA-22, Formula IA-23 or Formula IA-24:

[0383] - 44 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0384]

[0385] - 45 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0386]

[0387] wherein Rhis methyl, ethyl or CH2F;

[0388] L2 is a bond, C(R10)2, or CO;

[0389] ring Ai is a 4-10-membered heterocycloalkyl group or a 5-10-membered heteroaryl group; and

[0390] ring A2 is a 4-10-membered heterocycloalkyl group or a 5-10-membered heteroaryl group. In some embodiments, ring Ai and ring A2 are each optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

[0391]

[0157] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-17:

[0392]

[0393]

[0158] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-18:

[0394]

[0395]

[0159] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-19:

[0396] - 46 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0397]

[0398]

[0160] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-20:

[0399]

[0400]

[0161] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-21:

[0401]

[0402]

[0162] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-22:

[0403]

[0404]

[0163] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-23:

[0405]

[0406] - 47 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0407]

[0164] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-24:

[0408]

[0409]

[0165] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-25, Formula IA-26, Formula IA-27, Formula IA-28, Formula IA-29, Formula IA- 30, Formula IA-31 or Formula IA-32:

[0410]

[0411] - 48 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0412]

[0413] wherein ring Ai is a 5-10-membered heteroaryl group; and ring A2 is a 4-10-membered heterocycloalkyl group. In some embodiments, ring Ai and ring A2 are each optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

[0414]

[0166] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-25:

[0415]

[0416]

[0167] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-26:

[0417] - 49 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0418]

[0419]

[0168] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-27:

[0420]

[0421]

[0169] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-28:

[0422]

[0423]

[0170] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-29:

[0424]

[0425]

[0171] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-30:

[0426]

[0427] - 50 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0428]

[0172] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-31:

[0429]

[0430]

[0173] In one aspect, the disclosure is directed to compounds of Formula (I) that is a compound of Formula IA-32:

[0431]

[0432] In some embodiments, ring Ai is a pyridyl group. In some embodiments, ring A2 is a piperidine group. In some embodiments, ring Ai and ring A2 are each optionally substituted with 1-6 Rlaor Rlbgroups as defined herein. In some embodiments, ring Ai is a methyl-substituted pyridyl group. In some embodiments, ring Ai is a dimethyl-substituted pyridyl group.

[0433]

[0174] In another aspect, the disclosure is directed to a compound of Formula (I) that is:

[0434] l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)-piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0435] l-(6-(l-((5-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyrazin-2-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0436] l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridazin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0437] l-(6-(l-((5-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-6-methylpyrazin-2-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0438] l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-4-methoxypyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0439] - 51 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0440] l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-methoxypyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0441] l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-fluoropyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0442] l-(6-(l-((2-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0443] 3-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione;

[0444] l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0445] l-(6-(l-((2-(((6aS,8R)-6a-Ethyl-2-(3-fluoro-2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0446] l-(6-(l-((2-(((6aS,8R)-6a-Ethyl-2-(5-fluoro-2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0447] 1 -(6-( 1 -((2-(((6aS, 8R)-2-(3, 5 -Difluoro-2-hy droxyphenyl)-6a-ethyl -5, 6, 6a, 7, 8,9-hexa-hydropyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0448] l-(6-(l-((6-(((6aS,8R)-2-(2-Hydroxyphenyl)-6a-methyl-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0449] l-(6-(l-((6-(((6aS,8R)-6a-(Fluoromethyl)-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0450] l-(6-(4-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)piperazin-l-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0451] - 52 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0452] l-(6-(((S)-l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)pyrrolidin-3-yl)amino)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0453] l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-pyrazolo[3,4-b]pyridin-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0454] 3-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-pyrazolo[3,4-b]pyri din-3 -yl)piperidine-2, 6-dione;

[0455] l-(6-(l-((2-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)piperidin-4-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0456] 1 -(6-( 1 -((2-(((6aS, 8R)-2-(2-hy droxyphenyl)-6a-methyl -5, 6,6a, 7, 8, 9-hexahy dropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)piperidin-4-yl)-l-methyl-lH-pyrazolo[3,4-b]pyridin-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0457] l-(l-Benzyl-6-(l-((6-(((6aS,8R)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0458] l-[l-ethyl-6-[l-[[6-[[(4R,6S)-6-ethyl-12-(2-hydroxyphenyl)-2,8,10,ll-tetrazatricyclo [7.4.0.02,6]trideca-l(13),9,ll-trien-4-yl]oxy]-3-pyridinyl]methyl]piperidin-4-yl]indazol-3-yl]- 1.3-diazinane-2, 4-dione;

[0459] l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)piperidin-4-yl)-5-fluoro-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0460] 3-(5-(4-((6-(((6aS,8R)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperazin-l-yl)-3-methyl -2-oxo- 2.3-dihydro-lH-benzo[d]imidazol-l-yl)piperidine-2, 6-dione;

[0461] l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l,5-dimethyl-1 H-indazol -3 -yl)dihy dropyrimidine-2,4( 1 H, 3H)-dione;

[0462] l-(5-Ethyl-6-(l-((6-(((6aS,8R)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0463] - 53 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0464] l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-(2-methoxy ethyl)-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;

[0465] 3-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-4,5-dimethylpyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione;

[0466] 3-(6-(l-((5-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-3,4-dimethylpyridin-2-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione;

[0467] 3-(4-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)piperidin-4-yl) phenyl)piperidine-2, 6-dione;

[0468] 3-(6-(4-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-7-methyl-3,4-dihydroisoquinolin-2(lH)-yl) methyl)piperidin-l-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione;

[0469] or a pharmaceutically acceptable salt thereof.

[0470]

[0175] In another aspect, the disclosure is directed to a compound of Formula (I) that is:

[0471] l-(6-(l-((6-(((6a5,8A)-6a-Ethyl-2-(5-fluoro-2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-IT / -indazol-3-yl)dihydropyrimidine-2,4(l7 / ,37 / )-dione;

[0472] l-(6-(l-((6-(((6a5,8A)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo-[T,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)piperidin-4-yl)-l7 / -indazol-3-yl)dihydropyrimidine-2, 4(1H,3H)-dione;

[0473] or a pharmaceutically acceptable salt thereof.

[0474]

[0176] In yet another aspect, the disclosure is directed to a compound of Formula (I) that is in the form of a pharmaceutically acceptable salt.

[0475]

[0177] In yet another aspect, the disclosure is directed to a compound of Formula (I) that is in the form of a pharmaceutically acceptable solvate.

[0476]

[0178] In yet another aspect, the disclosure is directed to a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

[0477]

[0179] It will be apparent that the compounds of Formula (I), including all subgenera described herein, may have multiple stereogenic centers. As a result, there exist multiple stereoisomers (enantiomers and diastereomers) of the compounds of Formula (I) (and subgenera described herein). The present disclosure contemplates and encompasses each stereoisomer of any

[0478] - 54 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0479] compound of Formula (I) (and subgenera described herein), as well as mixtures of said stereoisomers.

[0480]

[0180] Pharmaceutically acceptable salts and solvates of the compounds of Formula (I) (including all subgenera described herein) are also within the scope of the disclosure.

[0481]

[0181] Isotopic variants of the compounds of Formula (I) (including all subgenera described herein) are also contemplated by the present disclosure.

[0482] Pharmaceutical Compositions and Methods of Administration

[0483]

[0182] The subject pharmaceutical compositions are typically formulated to provide a therapeutically effective amount of a compound of the present disclosure as the active ingredient, or a pharmaceutically acceptable salt, or solvate (including hydrate) thereof. Where desired, the pharmaceutical compositions contain pharmaceutically acceptable salt and / or coordination complex thereof, and one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.

[0484]

[0183] The subject pharmaceutical compositions can be administered alone or in combination with one or more other agents, which are also typically administered in the form of pharmaceutical compositions. Where desired, the one or more compounds of the invention and other agent(s) may be mixed into a preparation or both components may be formulated into separate preparations to use them in combination separately or at the same time.

[0485]

[0184] In some embodiments, the concentration of one or more compounds provided in the pharmaceutical compositions of the present invention is less than 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% (or a number in the range defined by and including any two numbers above) w / w, w / v or v / v.

[0486]

[0185] In some embodiments, the concentration of one or more compounds of the invention is greater than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25%, 19%, 18.75%, 18.50%, 18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%, 16.50%, 16.25%, 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%, 14.50%, 14.25% 14%, 13.75%, 13.50%, 13.25%, 13%, 12.75%, 12.50%, 12.25%, 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25%, 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25%, 7%, 6.75%, 6.50%, 6.25%, 6%, 5.75%, 5.50%, 5.25%, 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%, 3.25%, 3%,

[0487] - 55 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0488] 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50%, 1.25%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% (or a number in the range defined by and including any two numbers above) w / w, w / v, or v / v.

[0489]

[0186] In some embodiments, the concentration of one or more compounds of the invention is in the range from approximately 0.0001% to approximately 50%, approximately 0.001% to approximately 40%, approximately 0.01% to approximately 30%, approximately 0.02% to approximately 29%, approximately 0.03% to approximately 28%, approximately 0.04% to approximately 27%, approximately 0.05% to approximately 26%, approximately 0.06% to approximately 25%, approximately 0.07% to approximately 24%, approximately 0.08% to approximately 23%, approximately 0.09% to approximately 22%, approximately 0.1% to approximately 21%, approximately 0.2% to approximately 20%, approximately 0.3% to approximately 19%, approximately 0.4% to approximately 18%, approximately 0.5% to approximately 17%, approximately 0.6% to approximately 16%, approximately 0.7% to approximately 15%, approximately 0.8% to approximately 14%, approximately 0.9% to approximately 12%, approximately 1% to approximately 10% w / w, w / v or v / v.

[0490]

[0187] In some embodiments, the concentration of one or more compounds of the invention is in the range from approximately 0.001% to approximately 10%, approximately 0.01% to approximately 5%, approximately 0.02% to approximately 4.5%, approximately 0.03% to approximately 4%, approximately 0.04% to approximately 3.5%, approximately 0.05% to approximately 3%, approximately 0.06% to approximately 2.5%, approximately 0.07% to approximately 2%, approximately 0.08% to approximately 1.5%, approximately 0.09% to approximately 1%, approximately 0.1% to approximately 0.9% w / w, w / v or v / v.

[0491]

[0188] In some embodiments, the amount of one or more compounds of the invention is equal to or less than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009 g, 0.008 g, 0.007 g, 0.006 g, 0.005 g, 0.004 g, 0.003 g, 0.002 g, 0.001 g, 0.0009 g, 0.0008 g, 0.0007 g, 0.0006 g, 0.0005 g, 0.0004 g, 0.0003 g, 0.0002 g, or 0.0001 g (or a number in the range defined by and including any two numbers above).

[0492]

[0189] In some embodiments, the amount of one or more compounds of the invention is more than 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065 g, 0.007 g, 0.0075 g, 0.008 g, 0.0085 g, 0.009 g, 0.0095 g, 0.01 g, 0.015 g, 0.02

[0493] - 56 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0494] g, 0.025 g, 0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05 g, 0.055 g, 0.06 g, 0.065 g, 0.07 g, 0.075 g, 0.08 g, 0.085 g, 0.09 g, 0.095 g, 0.1 g,, 0.15 g, 0.2 g,, 0.25 g, 0.3 g,, 0.35 g, 0.4 g,, 0.45 g, 0.5 g, 0.55 g, 0.6 g,, 0.65 g, 0.7 g, 0.75 g, 0.8 g, 0.85 g, 0.9 g, 0.95 g, 1 g, 1.5 g, 2 g, 2.5, 3 g, 3.5, 4 g, 4.5 g, 5 g, 5.5 g, 6 g, 6.5g, 7 g, 7.5g, 8 g, 8.5 g, 9 g, 9.5 g, or 10 g (or a number in the range defined by and including any two numbers above).

[0495]

[0190] In some embodiments, the amount of one or more compounds of the invention is in the range of 0.0001-10 g, 0.0005-9 g, 0.001-8 g, 0.005-7 g, 0.01-6 g, 0.05-5 g, 0.1-4 g, 0.5-4 g, or 1-3 g-

[0191] The compounds according to the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from 0.01 to 1000 mg, from 0.5 to 100 mg, from 1 to 50 mg per day, and from 5 to 40 mg per day are examples of dosages that may be used. An exemplary dosage is 10 to 30 mg per day. The exact dosage will depend upon the route of administration, the form in which the compound is administered, the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician.

[0496]

[0192] A pharmaceutical composition of the invention typically contains an active ingredient (e.g., a compound of the disclosure) of the present invention or a pharmaceutically acceptable salt and / or coordination complex thereof, and one or more pharmaceutically acceptable excipients, carriers, including but not limited to inert solid diluents and fillers, diluents, sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.

[0497]

[0193] Described below are non- limiting exemplary pharmaceutical compositions and methods for preparing the same.

[0498] Pharmaceutical Compositions for Oral Administration

[0499]

[0194] In some embodiments, the invention provides a pharmaceutical composition for oral administration containing a compound of the invention, and a pharmaceutical excipient suitable for oral administration.

[0500]

[0195] In some embodiments, the invention provides a solid pharmaceutical composition for oral administration containing: (i) an effective amount of a compound of the invention; optionally (ii) an effective amount of a second agent; and (iii) a pharmaceutical excipient suitable for oral administration. In some embodiments, the composition further contains: (iv) an effective amount of a third agent.

[0501]

[0196] In some embodiments, the pharmaceutical composition may be a liquid pharmaceutical composition suitable for oral consumption. Pharmaceutical compositions of the invention suitable for oral administration can be presented as discrete dosage forms, such as capsules, - 57 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0502] cachets, or tablets, or liquids or aerosol sprays each containing a predetermined amount of an active ingredient as a powder or in granules, a solution, or a suspension in an aqueous or nonaqueous liquid, an oil-in- water emulsion, or a water-in-oil liquid emulsion. Such dosage forms can be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier, which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet can be prepared by compression or molding, optionally with one or more accessory ingredients.

[0503] Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free- flowing form such as powder or granules, optionally mixed with an excipient such as, but not limited to, a binder, a lubricant, an inert diluent, and / or a surface active or dispersing agent. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

[0504]

[0197] This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising an active ingredient, since water can facilitate the degradation of some compounds. For example, water may be added (e.g., 5%) in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf- life or the stability of formulations over time. Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms of the invention which contain lactose can be made anhydrous if substantial contact with moisture and / or humidity during manufacturing, packaging, and / or storage is expected. An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions may be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastic or the like, unit dose containers, blister packs, and strip packs.

[0505]

[0198] An active ingredient can be combined in an intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms depending on the form of preparation desired for administration. In preparing the compositions for an oral dosage form, any of the usual pharmaceutical media can be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions, and elixirs) or aerosols; or carriers such as starches, sugars, micro- - 58 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0506] crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents can be used in the case of oral solid preparations, in some embodiments without employing the use of lactose. For example, suitable carriers include powders, capsules, and tablets, with the solid oral preparations. If desired, tablets can be coated by standard aqueous or nonaqueous techniques.

[0507]

[0199] Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pregelatinized starch, hydroxypropyl methyl cellulose, microcrystalline cellulose, and mixtures thereof.

[0508]

[0200] Examples of suitable fillers for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.

[0509]

[0201] Disintegrants may be used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Too much of a disintegrant may produce tablets which may disintegrate in the bottle. Too little may be insufficient for disintegration to occur and may thus alter the rate and extent of release of the active ingredient(s) from the dosage form. Thus, a sufficient amount of disintegrant that is neither too little nor too much to detrimentally alter the release of the active ingredient(s) may be used to form the dosage forms of the compounds disclosed herein. The amount of disintegrant used may vary based upon the type of formulation and mode of administration, and may be readily discernible to those of ordinary skill in the art. About 0.5 to about 15 weight percent of disintegrant, or about 1 to about 5 weight percent of disintegrant, may be used in the pharmaceutical composition. Disintegrants that can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums or mixtures thereof.

[0510]

[0202] Lubricants which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower - 59 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0511] oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, or mixtures thereof. Additional lubricants include, for example, a syloid silica gel, a coagulated aerosol of synthetic silica, or mixtures thereof. A lubricant can optionally be added, in an amount of less than about 1 weight percent of the pharmaceutical composition.

[0512]

[0203] When aqueous suspensions and / or elixirs are desired for oral administration, the active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and / or suspending agents, together with such diluents as water, ethanol, propylene glycol, glycerin and various combinations thereof.

[0513]

[0204] The tablets can be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.

[0514]

[0205] Surfactant which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. That is, a mixture of hydrophilic surfactants may be employed, a mixture of lipophilic surfactants may be employed, or a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant may be employed.

[0515]

[0206] A suitable hydrophilic surfactant may generally have an HLB value of at least 10, while suitable lipophilic surfactants may generally have an HLB value of or less than about 10. An empirical parameter used to characterize the relative hydrophilicity and hydrophobicity of nonionic amphiphilic compounds is the hydrophilic-lipophilic balance (" HLB" value). Surfactants with lower HLB values are more lipophilic or hydrophobic, and have greater solubility in oils, while surfactants with higher HLB values are more hydrophilic, and have greater solubility in aqueous solutions.

[0516]

[0207] Hydrophilic surfactants are generally considered to be those compounds having an HLB value greater than about 10, as well as anionic, cationic, or zwitterionic compounds for which the HLB scale is not generally applicable. Similarly, lipophilic (e.g., hydrophobic) surfactants are compounds having an HLB value equal to or less than about 10. However, HLB value of a surfactant is merely a rough guide generally used to enable formulation of industrial, pharmaceutical and cosmetic emulsions.

[0517]

[0208] Hydrophilic surfactants may be either ionic or non-ionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts; fusidic acid salts; fatty acid derivatives of - 60 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0518] amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; lecithins and hydrogenated lecithins; lysolecithins and hydrogenated lysolecithins; phospholipids and derivatives thereof; lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkyl sulfates; fatty acid salts; sodium docusate; acyl lactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.

[0519]

[0209] Within the aforementioned group, ionic surfactants include, by way of example: lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkyl sulfates; fatty acid salts; sodium docusate; acylactylates; mono- and diacetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.

[0520]

[0210] Ionic surfactants may be the ionized forms of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP -phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl -2 -lactyl ate, stearoyl lactylate, succinylated monoglycerides, mono / diacetylated tartaric acid esters of mono / diglycerides, citric acid esters of mono / diglycerides, cholyl sarcosine, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, stearate, lauryl sulfate, teracecyl sulfate, docusate, lauroyl carnitines, palmitoyl carnitines, myristoyl carnitines, and salts and mixtures thereof.

[0521]

[0211] Hydrophilic non-ionic surfactants may include, but are not limited to, alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyalkylene alkyl ethers such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols such as polyethylene glycol alkyl phenols; polyoxyalkylene alkyl phenol fatty acid esters such as polyethylene glycol fatty acids monoesters and polyethylene glycol fatty acids diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters such as polyethylene glycol sorbitan fatty acid esters; hydrophilic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylene sterols, derivatives, and analogues thereof; polyoxyethylated vitamins and derivatives thereof; polyoxyethylene-polyoxypropylene block copolymers; and mixtures thereof; polyethylene glycol sorbitan fatty acid esters and hydrophilic transesterification products of a polyol with at least one member of the group consisting of triglycerides, vegetable oils, and hydrogenated vegetable oils. The polyol may be - 61 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0522] glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, or a saccharide.

[0523]

[0212] Other hydrophilic-non-ionic surfactants include, without limitation, PEG- 10 laurate, PEG- 12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG- 12 oleate, PEG- 15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG- 100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate / caprylate glycerides, PEG-8 caprate / capryl ate glycerides, polyglyceryl- 10 laurate, PEG-30 cholesterol, PEG-25 phyto sterol, PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE -23 lauryl ether, POE- 10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopheryl PEG- 100 succinate, PEG-24 cholesterol, polyglyceryl-lOoleate, Tween 40, Tween 60, sucrose monostearate, sucrose mono laurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series, PEG 15-100 octyl phenol series, and poloxamers.

[0524]

[0213] Suitable lipophilic surfactants include, by way of example only: fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters; propylene glycol fatty acid esters; sorbitan fatty acid esters; polyethylene glycol sorbitan fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives; polyethylene glycol alkyl ethers; sugar esters; sugar ethers; lactic acid derivatives of mono- and di-glycerides; hydrophobic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids and sterols; oilsoluble vitamins / vitamin derivatives; and mixtures thereof. Within this group, preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters, and mixtures thereof, or are hydrophobic transesterification products of a polyol with at least one member of the group consisting of vegetable oils, hydrogenated vegetable oils, and triglycerides.

[0525]

[0214] In one embodiment, the composition may include a solubilizer to ensure good solubilization and / or dissolution of the compound of the present invention and to minimize precipitation of the compound of the present invention. This can be especially important for compositions for non-oral use, e.g., compositions for injection. A solubilizer may also be added to increase the solubility of the hydrophilic drug and / or other components, such as surfactants, or to maintain the composition as a stable or homogeneous solution or dispersion.

[0526] - 62 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0527]

[0215] Examples of suitable solubilizers include, but are not limited to, the following: alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000, such as tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methoxy PEG; amides and other nitrogen-containing compounds such as 2-pyrrolidone, 2-piperidone, s-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide and polyvinylpyrrolidone; esters such as ethyl propionate, tributyl citrate, acetyl tri ethyl citrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, a -caprolactone and isomers thereof, 6-valerolactone and isomers thereof, P-butyrolactone and isomers thereof; and other solubilizers known in the art, such as dimethyl acetamide, dimethyl isosorbide, N-methyl pyrrolidones, monooctanoin, diethylene glycol monoethyl ether, and water.

[0528]

[0216] Mixtures of solubilizers may also be used. Examples include, but not limited to, triacetin, tri ethyl citrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-100, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide. Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol and propylene glycol.

[0529]

[0217] The amount of solubilizer that can be included is not particularly limited. The amount of a given solubilizer may be limited to a bioacceptable amount, which may be readily determined by one of skill in the art. In some circumstances, it may be advantageous to include amounts of solubilizers far in excess of bioacceptable amounts, for example to maximize the concentration of the drug, with excess solubilizer removed prior to providing the composition to a subject using conventional techniques, such as distillation or evaporation. Thus, if present, the solubilizer can be in a weight ratio of 10%, 25%o, 50%), 100%o, or up to about 200%> by weight, based on the combined weight of the drug, and other excipients. If desired, very small amounts of solubilizer may also be used, such as 5%>, 2%>, 1%) or even less. Typically, the solubilizer may be present in an amount of about 1%> to about 100%, more typically about 5%> to about 25%> by weight.

[0530]

[0218] The composition can further include one or more pharmaceutically acceptable additives and excipients. Such additives and excipients include, without limitation, detackifiers, anti-foaming agents, buffering agents, polymers, antioxidants, preservatives, chelating agents,

[0531] - 63 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0532] viscomodulators, tonicifiers, flavorants, colorants, odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.

[0533]

[0219] In addition, an acid or a base may be incorporated into the composition to facilitate processing, to enhance stability, or for other reasons. Examples of pharmaceutically acceptable bases include amino acids, amino acid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic hydrocalcite, magnesium aluminum hydroxide, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, triethylamine, triisopropanolamine, trimethylamine, tri s(hydroxymethyl)aminom ethane (TRIS) and the like. Also suitable are bases that are salts of a pharmaceutically acceptable acid, such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, and the like. Salts of polyprotic acids, such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate can also be used. When the base is a salt, the cation can be any convenient and pharmaceutically acceptable cation, such as ammonium, alkali metals, alkaline earth metals, and the like. Example may include, but not limited to, sodium, potassium, lithium, magnesium, calcium and ammonium.

[0534]

[0220] Suitable acids are pharmaceutically acceptable organic or inorganic acids. Examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, boric acid, phosphoric acid, and the like. Examples of suitable organic acids include acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acids, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid and the like.

[0535] Pharmaceutical compositions for injection

[0536]

[0221] In some embodiments, the invention provides a pharmaceutical composition for injection containing a compound of the present invention and a pharmaceutical excipient suitable for injection. Components and amounts of agents in the compositions are as described herein.

[0537] - 64 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0538]

[0222] The forms in which the novel compositions of the present invention may be incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles.

[0539]

[0223] Aqueous solutions in saline are also conventionally used for injection. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, for the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.

[0540]

[0224] Sterile injectable solutions are prepared by incorporating the compound of the present invention in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, certain desirable methods of preparation are vacuum-drying and freeze- drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0541] Pharmaceutical Compositions for Topical (e.g.. Transdermal) Delivery

[0542]

[0225] In some embodiments, the invention provides a pharmaceutical composition for transdermal delivery containing a compound of the present invention and a pharmaceutical excipient suitable for transdermal delivery.

[0543]

[0226] Compositions of the present invention can be formulated into preparations in solid, semisolid, or liquid forms suitable for local or topical administration, such as gels, water soluble jellies, creams, lotions, suspensions, foams, powders, slurries, ointments, solutions, oils, pastes, suppositories, sprays, emulsions, saline solutions, dimethylsulfoxide (DMSO)-based solutions. In general, carriers with higher densities are capable of providing an area with a prolonged exposure to the active ingredients. In contrast, a solution formulation may provide more immediate exposure of the active ingredient to the chosen area.

[0544]

[0227] The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients, which are compounds that allow increased penetration of, or assist in the delivery of, therapeutic molecules across the stratum corneum permeability barrier of the skin. There are - 65 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0545] many of these penetration- enhancing molecules known to those trained in the art of topical formulation.

[0546]

[0228] Examples of such carriers and excipients include, but are not limited to, humectants (e.g., urea), glycols (e.g., propylene glycol), alcohols (e.g., ethanol), fatty acids (e.g., oleic acid), surfactants (e.g., isopropyl myristate and sodium lauryl sulfate), pyrrolidones, glycerol monolaurate, sulfoxides, terpenes (e.g., menthol), amines, amides, alkanes, alkanols, water, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

[0547]

[0229] Another exemplary formulation for use in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of a compound of the present invention in controlled amounts, either with or without another agent.

[0548]

[0230] The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U. S. Pat. Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

[0549] Pharmaceutical Compositions for Inhalation

[0550]

[0231] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.

[0551] Other Pharmaceutical Compositions

[0552]

[0232] Pharmaceutical compositions may also be prepared from compositions described herein and one or more pharmaceutically acceptable excipients suitable for sublingual, buccal, rectal, intraosseous, intraocular, intranasal, epidural, or intraspinal administration. Preparations for such pharmaceutical compositions are well-known in the art. See, e.g., Anderson, Philip O.; Knoben, James E.; Troutman, William G, eds., Handbook of Clinical Drug Data, Tenth Edition, McGraw- - 66 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0553] Hill, 2002; Pratt and Taylor, eds., Principles of Drug Action, Third Edition, Churchill Livingston, New York, 1990; Katzung, ed., Basic and Clinical Pharmacology, Ninth Edition, McGraw Hill, 2003; Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, Tenth Edition, McGraw Hill, 2001; Remingtons Pharmaceutical Sciences, 20th Ed., Lippincott Williams & Wilkins., 2000; Martindale, The Extra Pharmacopoeia, Thirty-Second Edition (The Pharmaceutical Press, London, 1999); all of which are incorporated by reference herein in their entirety.

[0554]

[0233] Administration of the compounds or pharmaceutical composition of the present invention can be affected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, intraarterial, subcutaneous, intramuscular, intravascular, intraperitoneal or infusion), topical (e.g., transdermal application), rectal administration, via local delivery by catheter or stent or through inhalation. Compounds can also be administered intraadiposally or intrathecally.

[0555]

[0234] In some embodiments, the compounds or pharmaceutical composition of the present invention are administered by intravenous injection.

[0556]

[0235] The amount of the compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician. However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg / kg / day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to 7 g / day, preferably about 0.05 to about 2.5 g / day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, e.g., by dividing such larger doses into several small doses for administration throughout the day.

[0557]

[0236] In some embodiments, a compound of the invention is administered in a single dose.

[0558]

[0237] Typically, such administration will be by injection, e.g., intravenous injection, in order to introduce the agent quickly. However, other routes may be used as appropriate. A single dose of a compound of the invention may also be used for treatment of an acute condition.

[0559]

[0238] In some embodiments, a compound of the invention is administered in multiple doses. Dosing may be about once, twice, three times, four times, five times, six times, or more than six times per day. Dosing may be about once a month, once every two weeks, once a week, or once every other day. In another embodiment a compound of the invention and another agent are administered together about once per day to about 6 times per day. In another embodiment the administration of a compound of the invention and an agent continues for less than about 7 days. In yet another embodiment the administration continues for more than about 6, 10, 14, 28 days,

[0560] - 67 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0561] two months, six months, or one year. In some cases, continuous dosing is achieved and maintained as long as necessary.

[0562]

[0239] Administration of the compounds of the invention may continue as long as necessary. In some embodiments, a compound of the invention is administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or 28 days. In some embodiments, a compound of the invention is administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In some embodiments, a compound of the invention is administered chronically on an ongoing basis, e.g., for the treatment of chronic effects.

[0563]

[0240] An effective amount of a compound of the invention may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.

[0564]

[0241] The compositions of the invention may also be delivered via an impregnated or coated device such as a stent, for example, or an artery -inserted cylindrical polymer. Such a method of administration may, for example, aid in the prevention or amelioration of restenosis following procedures such as balloon angioplasty. Without being bound by theory, compounds of the invention may slow or inhibit the migration and proliferation of smooth muscle cells in the arterial wall which contribute to restenosis. A compound of the invention may be administered, for example, by local delivery from the struts of a stent, from a stent graft, from grafts, or from the cover or sheath of a stent. In some embodiments, a compound of the invention is admixed with a matrix. Such a matrix may be a polymeric matrix and may serve to bond the compound to the stent. Polymeric matrices suitable for such use, include, for example, lactone-based polyesters or copolyesters such as polylactide, polycaprolactonglycolide, polyorthoesters, polyanhydrides, polyaminoacids, polysaccharides, polyphosphazenes, poly (ether-ester) copolymers (e.g. PEO-PLLA); polydimethylsiloxane, poly(ethylene-vinylacetate), acrylate-based polymers or copolymers (e.g. polyhydroxyethyl methylmethacrylate, polyvinyl pyrrolidinone), fluorinated polymers such as polytetrafluoroethylene and cellulose esters. Suitable matrices may be nondegrading or may degrade with time, releasing the compound or compounds. Compounds of the invention may be applied to the surface of the stent by various methods such as dip / spin coating, spray coating, dip-coating, and / or brush-coating. The compounds may be applied in a solvent and the solvent may be allowed to evaporate, thus forming a layer of compound onto the stent.

[0565] Alternatively, the compound may be located in the body of the stent or graft, for example in microchannels or micropores. When implanted, the compound diffuses out of the body of the stent to contact the arterial wall. Such stents may be prepared by dipping a stent manufactured to contain such micropores or microchannels into a solution of the compound of the invention in a - 68 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0566] suitable solvent, followed by evaporation of the solvent. Excess drug on the surface of the stent may be removed via an additional brief solvent wash. In yet other embodiments, compounds of the invention may be covalently linked to a stent or graft. To link compounds of the invention to the stent or graft, a covalent linker may be used which degrades in vivo, leading to the release of the compound from the stent or graft. Compounds of the invention may additionally be administered intravascularly from a balloon used during angioplasty. Extravascular administration of the compounds via the pericard or via adventitial application of formulations of the invention may also be performed to decrease restenosis.

[0567]

[0242] A variety of stent devices which may be used as described are disclosed, for example, in the following references, all of which are hereby incorporated by reference: U. S. Pat. No.

[0568] 5451233; U. S. Pat. No. 5040548; U. S. Pat. No. 5061273; U. S. Pat. No. 5496346; U. S. Pat. No.

[0569] 5292331; U. S. Pat. No. 5674278; U. S. Pat. No. 3657744; U. S. Pat. No. 4739762; U. S. Pat. No.

[0570] 5195984; U. S. Pat. No. 5292331; U. S. Pat. No. 5674278; U. S. Pat. No. 5879382; U. S. Pat. No.

[0571] 6344053.

[0572]

[0243] The compounds of the invention may be administered in dosages. It is known in the art that due to intersubject variability in compound pharmacokinetics, individualization of dosing regimen is necessary for optimal therapy. Dosing for a compound of the invention may be found by routine experimentation in light of the instant disclosure.

[0573]

[0244] When a compound of the invention is administered in a composition that comprises one or more agents, and the agent has a shorter half- life than the compound of the invention unit dose forms of the agent and the compound of the invention may be adjusted accordingly.

[0574]

[0245] The subject pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.

[0575] Exemplary parenteral administration forms include solutions or suspensions of active compound in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.

[0576] Methods o f Use

[0577] - 69 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0578]

[0246] The method typically comprises administering to a subject a therapeutically effective amount of a compound of the invention. The therapeutically effective amount of the subject combination of compounds may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will induce a particular response in target cells, e.g., reduction of proliferation or downregulation of activity of a target protein. The specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.

[0579]

[0247] In certain embodiment, the present invention provides a pharmaceutical composition comprising a compound of bispecific formula, or pharmaceutically acceptable salt thereof.

[0580]

[0248] In certain embodiment, the present invention provides a pharmaceutical composition comprising a compound of bispecific formula for use in degrading a target protein in a cell.

[0581]

[0249] In certain embodiment, a method of degrading a target protein comprising administering to a cell therapeutically effective amount of a bispecific compound, or pharmaceutically acceptable salt, wherein the compound is effective for degrading the target protein.

[0582]

[0250] In some embodiments, the disclosure is directed to methods of degrading a SMARCA2 protein comprising contacting the SMARCA2 protein with a compound or pharmaceutical composition of the disclosure.

[0583]

[0251] In other embodiments, the disclosure is directed to methods of degrading a SMARCA4 protein comprising contacting the SMARCA4 protein with a compound or pharmaceutical composition of the disclosure.

[0584]

[0252] In certain embodiment, the present invention provides a pharmaceutical composition comprising a compound of bispecific formula, for use in treating or preventing of a disease or disorder in which SMARCA2 and / or SMARCA4 plays a role.

[0585]

[0253] In certain embodiment, the present invention provides a pharmaceutical composition comprising a compound of bispecific formula, for use in treating or preventing of a disease or disorder in which SWI / SNF mutations plays a role.

[0586]

[0254] In certain embodiment, target proteins are SMARCA2, SMARCA4 and / or PB1.

[0587]

[0255] In certain embodiment, target protein complex is SWI / SNF in a cell.

[0588]

[0256] In certain embodiment, diseases or disorders dependent on SMARCA2 or SMARCA4 include cancers.

[0589] - 70 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0590]

[0257] In certain embodiment, diseases or disorders dependent on SWI / SNF complex include cancers.

[0591]

[0258] Exemplary cancers which may be treated by the present compounds either alone or in combination with at least one additional anti-cancer agent include squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma, hemangiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas, ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas, medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, and Schwannomas; bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease, Wilms' tumor and teratocarcinomas.

[0592]

[0259] In some embodiments, the cancer which may be treated using compounds according to the present disclosure is non-small cell lung cancer, colorectal cancer, bladder cancer, cancer of unknown primary, glioma, breast cancer, melanoma, non-melanoma skin cancer, endometrial cancer, soft tissue sarcoma, or penile cancer.

[0593]

[0260] In certain embodiments, the cancers which may be treated using compounds according to the present disclosure include, for example, acute myeloid leukemia (AML), T-lineage Acute lymphoblastic Leukemia (T-ALL), T-lineage lymphoblastic Lymphoma (T-LL), Peripheral T-cell lymphoma, Adult T-cell Leukemia, Pre-B ALL, Pre-B Lymphomas, Large B-cell Lymphoma, Burkitts Lymphoma, B-cell ALL, Philadelphia chromosome positive ALL and Philadelphia chromosome positive CML. In certain further embodiment, the cancer is a SMARCA2 and / or SMARAC4-dependent cancer.

[0594]

[0261] In certain embodiment, the present invention provides a pharmaceutical composition comprising a compound of bispecific formula for use in the diseases or disorders dependent upon SMARCA2 and / or SMARCA4 is cancer.

[0595]

[0262] Compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered to treat any of the described diseases, alone or in combination with a medical therapy. Medical therapies include, for example, surgery and radiotherapy (e.g., gamma-

[0596] - 71 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0597] radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, systemic radioactive isotopes).

[0598]

[0263] In other aspects, compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered to treat any of the described diseases, alone or in combination with one or more other agents.

[0599]

[0264] In other methods, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with agonists of nuclear receptors agents.

[0600]

[0265] In other methods, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with antagonists of nuclear receptors agents.

[0601]

[0266] In other methods, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with an anti -proliferative agent.

[0602] Combination Therapies

[0603]

[0267] In certain aspects, one or more of the compounds described herein, are co-administered in combination with at least one additional bioactive agent, especially including an anticancer agent. In particularly preferred aspects, the co-administration of compounds results in synergistic activity and / or therapy, including anticancer activity.

[0604]

[0268] For treating cancer and other proliferative diseases, the compounds of the invention can be used in combination with chemotherapeutic agents, agonists or antagonists of nuclear receptors, or other anti-proliferative agents. The compounds of the invention can also be used in combination with a medical therapy such as surgery or radiotherapy, e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes. Examples of suitable chemotherapeutic agents include any of: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, all -trans retinoic acid, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bendamustine, bevacizumab, bexarotene, bleomycin, bortezombi, bortezomib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate,

[0605] - 72 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0606] ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab, oxaliplatin, paclitaxel, pamidronate, panobinostat, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinstat and zoledronate.

[0607]

[0269] In some embodiments, the compounds of the invention can be used in combination with a therapeutic agent that targets an epigenetic regulator. Examples of epigenetic regulators include bromodomain inhibitors, the histone lysine methyltransferase inhibitors, histone arginine methyl transferase inhibitors, histone demethylase inhibitors, histone deacetylase inhibitors, histone acetylase inhibitors, and DNA methyltransferase inhibitors. Histone deacetylase inhibitors include, e.g., vorinostat. Histone arginine methyl transferase inhibitors include inhibitors of protein arginine methyltransferases (PRMTs) such as PRMT5, PRMT1 and PRMT4. DNA methyltransferase inhibitors include inhibitors of DNMT1 and DNMT3.

[0608]

[0270] For treating cancer and other proliferative diseases, the compounds of the invention can be used in combination with targeted therapies, including JAK kinase inhibitors (e.g.

[0609] Ruxolitinib), PI3 kinase inhibitors including PI3K-delta selective and broad spectrum PI3K inhibitors, MEK inhibitors, Cyclin Dependent kinase inhibitors, including CDK4 / 6 inhibitors and CDK9 inhibitors, BRAF inhibitors, mTOR inhibitors, proteasome inhibitors (e.g. Bortezomib, Carfilzomib), HD AC inhibitors (e.g. panobinostat, vorinostat), DNA methyl transferase inhibitors, dexamethasone, bromo and extra terminal family member (BET) inhibitors, BTK inhibitors (e.g. ibrutinib, acalabrutinib), BCL2 inhibitors (e.g. venetoclax), dual BCL2 family inhibitors (e.g. BCL2 / BCLxL), PARP inhibitors, FLT3 inhibitors, or LSD1 inhibitors.

[0610]

[0271] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), or PDR001. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti-PDl antibody is pembrolizumab. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-Ll monoclonal antibody. In some embodiments, the anti-PD-Ll monoclonal antibody is atezolizumab, durvalumab, or BMS-935559. In some embodiments, the inhibitor of an immune checkpoint - 73 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0611] molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab.

[0612]

[0272] In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent. Examples of an alkylating agent include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM).

[0613]

[0273] The following Examples are provided to illustrate some of the concepts described within this disclosure. While the Examples are considered to provide an embodiment, it should not be considered to limit the more general embodiments described herein.

[0614] EXAMPLES

[0615] General Synthetic Procedures

[0616]

[0274] The compounds described herein may be prepared according to the following synthetic schemes and general synthetic procedures.

[0617] Scheme 1

[0618]

[0619]

[0275] Tricyclic intermediates 1-11 can be synthesized according to the route described in Scheme 1. Protection of the -NH and -OH groups of starting materials 1-1 with an appropriate protecting group (e.g., Boc, SEM, Bn, TBDMS, etc.), followed by esterification, affords esters 1-2. Conversion of 1-2 to 1-3 can be achieved with reducing agents (e.g., LiAlH4, DIBAL-H, etc.). Substitution of the hydroxyl group in 1-3 by conversion to a leaving group under appropriate conditions (e.g., TsCl / Et3N, MsCl / Et3N, etc.) followed by substitution (e.g., NaN3) affords azides 1-4. Alternatively, compound 1-3 can be converted to an azide 1-4 under Mitsunobu conditions ((PhO)2PON3, DEAD in THF). Deprotection of 1-4 (e.g., TFA or HC1 for Boc deprotection) gives amines 1-5. SNAR reaction between amines 1-5 and pyridazines 1-6 in the presence of a

[0620] - 74 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0621] base, such as DIPEA, affords intermediates 1-7. Reduction of the azido group in compounds 1-7 via Staudinger reduction or hydrogenation, followed by intramolecular cyclization provides compounds 1-8. Protection of the -NH group and deprotection of the -OPG then gives compounds 1-9. Coupling of halides 1-9 with phenols 1-10 (wherein M = B(OH)2, B(OR)2, or SnRs) under standard cross-coupling conditions (e.g., in the presence of a palladium catalyst such as tetrakis(triphenylphosphine)palladium(0) or [l,l'-bis(diphenylphosphino)-ferrocene] dichloropalladium (Il)and a base e.g. CsF, Na2CO3, or CS2CO3) in a suitable solvent such as dioxane or DMF, with or without water as cosolvent affords intermediates 1-11.

[0622] Scheme 2

[0623]

[0624]

[0276] The compounds of the Formula (I) can also be synthesized according to the route described in Scheme 2. Mitsunobu reaction of the alcohol in compounds 1-9 with Ai, where Z = SH, OH, or NH, yields compound 2-1. Cross-coupling of halides 2-1 with phenols 1-10, where the phenol is optionally protected, followed by deprotection, affords intermediates 2-2. Reaction of 2-2 with 2-3 where X3 is CH or N, either through reductive amination or substitution affords compounds 2-4.

[0625] Scheme 3

[0626] - 75 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0627]

[0628] 2-4

[0629]

[0277] The compounds of the Formula (I) can also be made according to the route described in Scheme 3. Mesylation of the alcohol in compounds 1-11 followed by substitution with Ai and deprotection yields compound 3-1. Subsequent reductive amination of 3-1 with 2-3 affords compounds 2-4.

[0630] Scheme 4

[0631]

[0632]

[0278] Intermediates for the synthesis of compound of Formula (I) can be prepared as described in Scheme 4. Coupling of compounds 4-1 where Xais a halogen (e.g., Br or I) or pseudohalogen (e.g., OTf or OMs) with pyridines 4-2, where P3is an appropriate protecting group (e.g., Bn or PMB) and M2is a boronic acid, boronate ester, potassium trifluorob orate, or an appropriately substituted metal, such as Sn(Bu)3, Sn(Me)3, ZnBr, Znl, or ZnCl under standard Suzuki cross-coupling conditions (e.g., in the presence of a palladium catalyst, such as SPhos Pd G2) or standard Stille conditions (e.g., in the presence of a palladium (0) catalyst, such as tetrakis(triphenylphosphine)palladium (0)) or standard Negishi conditions (e.g., in the presence of a palladium catalyst, such as tetrakis(triphenylphosphine) palladium (0) or [1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium(II)), can afford compounds 4-3. Coupling of compounds 4-3 where Xbis a halogen (e.g., F, Cl or Br) or pseudohalogen (e.g., OTf or OMs) with 4-4 where Aiais an optionally protected 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, an aryl group, or a heteroaryl group that is optionally substituted with one or more reactive groups such as, but not limited to, halogen (e.g., F, Cl, Br, I), hydroxy, aldehyde, boronic acid, boronate ester, trialkyltin, carboxylic acid, or amine under

[0633] - 76 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0634] standard Suzuki (e.g., in the presence of a palladium catalyst, such as SPhos Pd G2) or standard Buchwald-Hartwig cross-coupling (e.g., in the presence of a palladium catalyst, such

[0635] as BrettPhos Pd G4, and a base, such as sodium / c / 7-butoxide) or standard S\Ar reaction conditions (e.g., in the presence of a base, such as K2CO3, or an acid, such as p-toluenesulfonic acid) can afford compounds 4-5. Compounds 4-5 can be hydrogenated under standard conditions, such as exposure to H2 or D2 gas in the presence of a transition metal catalyst (e.g., palladium on charcoal or platinum(IV) oxide) to afford compounds 4-7.

[0636] Scheme 5

[0637]

[0638]

[0279] Intermediates for the synthesis of compounds of Formula (I) can be prepared as described in Scheme 5. Coupling of compounds 4-1 with compounds 5-1, where P4is an appropriate protecting group (e.g., Bn or PMB) under standard Ullmann cross-coupling conditions (e.g., in the presence of a copper catalyst, such as copper acetate, and a ligand, such as tetramethyl phenanthroline) can afford dihydrouracils 5-2. Coupling of 5-2 with 4-4 under standard Suzuki (e.g., in the presence of a palladium catalyst, such as SPhos Pd G2) or standard Buchwald-Hartwig cross-coupling (e.g., in the presence of a palladium catalyst, such as BrettPhos Pd G4, and a base, such as sodium / c / V-butoxide) or standard S\Ar reaction conditions (e.g., in the presence of a base, such as K2CO3 or an acid, such as / ?-toluenesulfonic acid) can afford compounds 5-3. Compounds 5-3 can be deprotected under standard conditions, such as in the presence of an acid (e.g., TFA) to afford compounds 5-4.

[0639]

[0280] Intermediates for the synthesis of compounds of Formula (I) can also be prepared as previously described (WO2023019166A1; WO2022195454A1; WO2021053555A1;

[0640] WO2024255810A1; CN120025316A; WO2017197046A1; CN115557933A;

[0641] WO2021053555A1; WO2022125790A1; CN120025333A; W02017197051A1; Norris, S., et al. J. Med. Chem. 2023, 66, 16388-16409; Teng, M. et al. J. Med. Chem. 2022, 65, 747-756; Lejava, A., et al. ACS Med. Chem. Lett. 2025, 16, 89-95; Actis, et al. J. Med Chem. 2025, 68, 3591-3611.).

[0642] Example 1. l-(6-(l-((6-(((6a5,81?)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo [1 ',2': 4,5] pyrazino[2,3-c] pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)piperidin-4-yl)-l-metliyl-l / / -iiid:izol-3-yl)dihydropyrimidine-2.4( l / / .3 / / )-dione

[0643] - 77 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0644]

[0645]

[0281] Step 1. l-(tert-Butyl) 2-methyl (4R)-4-(benzyloxy)-2-ethylpyrrolidine-l,2-dicarboxylate

[0646]

[0647]

[0282] To 1 -(tert-butyl) 2-methyl (2A,4A)-4-(benzyloxy)pyrrolidine-l,2-dicarboxylate (2.00 g, 5.96 mmol) in THF (55 mL) was added LiHMDS (12 mL, 12 mmol) slowly at -78 °C. The reaction mixture was stirred at -78 °C for 1 h, after which ethyl iodide (1.9 mL, 23.6 mmol) was added. The reaction was stirred at -78 °C for 5 min then allowed to warm to rt with stirring. After 3.5 h, the reaction was quenched with MeOH (55 mL). A solution of NaOH (1.91 g, 47.7 mmol) in water (55 mL) was added and the mixture was stirred at rt for 20 min then poured into water. The aqueous layer was extracted with EtOAc (3x). The combined organic layers were washed with brine (l x) then concentrated and purified via SiC>2 FCC (0-30% EtOAc in hexanes) to afford 1 -(tert-butyl) 2-methyl (4R)-4-(benzyloxy)-2-ethylpyrrolidine-l,2-dicarboxylate (1.11 g, 51%). LCMS calcd for C15H22NO3 [M-Boc+2H]+: m / z = 264.2; Found: 264.0.

[0648]

[0283] Step 2. (4R)-4-(Benzyloxy)-l-(tert-butoxycarbonyl)-2-ethylpyrrolidine-2-carboxylic acid

[0649]

[0650]

[0284] To 1 -(tert-butyl) 2-methyl (4 / )-4-(benzyloxy)-2-ethylpyrrolidine-l,2-di carboxyl ate (2.72 g, 7.48 mmol) in 1:1 THF / MeOH (40 mL) was added a solution of NaOH (2.99 g, 74.8 mmol) in water (20 mL). The reaction was stirred at 75 °C for 2.5 h then allowed to cool to rt. The mixture was poured into water then extracted with MTBE (3 x). The combined organic layers were washed with water (2x). The combined aqueous layers were extracted once more with MTBE

[0651] - 78 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0652] then acidified to pH < 2 with 2 N HC1 (aq.) and subsequently extracted with EtOAc (3x). The combined EtOAc layers were washed with brine, dried with MgSO4, filtered then concentrated to give crude (4R)-4-(benzyloxy)-l-(tert-butoxycarbonyl)-2-ethylpyrrolidine-2-carboxylic acid (assumed quantitative yield) as a yellow oil. LCMS calcd for C14H20NO3 [M-Boc+2H]+: m / z = 250.1; Found: 250.0.

[0653]

[0285] Step 3. tert-Butyl (2R,4R)-4-(benzyloxy)-2-((4-bromo-6-chloropyridazin-3-yl)carbamoyl)-2-ethylpyrrolidine-l -carboxylate and tert-butyl (2S,4R)-4-(benzyloxy)-2-((4-bromo-6-chloro-pyridazin-3-yl)carbamoyl)-2-ethylpyrrolidine-l-carboxylate

[0654]

[0655]

[0286] To crude 1 -(tert-butyl) 2-m ethyl (4 / ?)-4-(benzyl oxy )-2-ethyl pyrrol i di ne-l,2-di carboxyl ate (672 mg, 1.43 mmol) and N, N-diisopropylethylamine (1.21 mL, 6.92 mmol) in MeCN (10 mL) was added HATU (880 mg, 2.31 mmol). The reaction was stirred at rt for 20 min then concentrated. The residue was taken up in THF (8 mL) then 4-bromo-6-chloropyridazin-3-amine (802 mg, 3.85 mmol) was added, followed by NaH (60% dispersion in mineral oil; 385 mg, 9.62 mmol). After rinsing the sides of the flask with THF (2 mL), the reaction was stirred at rt for 50 min then cooled to 0 °C and quenched with sat. NH4CI (aq.). The mixture was poured into water then extracted with EtOAc (3 x). The combined organic layers were washed with brine (l x) then concentrated. The residue was purified via SiO2 FCC (0-100% EtOAc in hexanes) to afford “diastereomer A” tert-butyl (2R,4R)-4-(benzyloxy)-2-((4-bromo-6-chloropyridazin-3-yl) carbarn oyl)-2-ethylpyrrolidine-l -carboxylate (473 mg, 46%) and “diastereomer B” tert-butyl (2S,4R)-4-(benzyloxy)-2-((4-bromo-6-chloropyridazin-3-yl)carbamoyl)-2-ethylpyrrolidine-l- carboxylate (286 mg, 28%). LCMS calcd for C23H29BrClN4O4 [M+H]+: m / z = 539.1; Found: 539.0 (diastereomer A) and 539.0 (diastereomer B).

[0656]

[0287] Step 4. (6aR,8R)-8-(Benzyloxy)-2-chloro-6a-ethyl-6a,7,8,9-tetrahydropyrrolo[l',2':4,5] pyrazino [2, 3-c]pyridazin-6(5H)-one and (6aS,8R)-8-(benzyloxy)-2-chloro-6a-ethyl-6a, 7,8,9- tetrahydropyrrolo[ I ', 2 4, 5 ] pyrazino [ 2, 3-c ]pyridazin-6(5H)-one

[0657] - 79 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0658]

[0659]

[0288] To / c / V-butyl (2 / ?,4 / ?)-4-(benzyloxy)-2-((4-bromo-6-chloropyridazin-3-yl)carbamoyl)-2- ethylpyrrolidine-1 -carboxylate (473 mg, 0.88 mmol) in DCM (17 mL) was added TFA (17 mL, 222 mmol). The reaction was stirred at rt for 3 h then concentrated. The residue was dissolved in MeCN (15 mL). A, A-Diisopropylethylamine (0.76 mL, 4.38 mmol) was added and the reaction was stirred at 80 °C for 2 h then allowed to cool to rt overnight. The reaction was concentrated to afford crude (6a7?,8A)-8-(benzyloxy)-2-chloro-6a-ethyl-6a,7,8,9-tetrahydropyrrolo[l',2':4,5] pyrazino[2,3-c]pyridazin-6(5J7)-one which was used directly without further purification. LCMS calcd for C18H22ClN4O [M+H]+: m / z = 359.1; Found: 359.1.

[0660]

[0289] Step 5. ( 6aS, 8R)-8-(Benzyloxy)-2-chloro-6a-ethyl-5, 6, 6a, 7, 8, 9-hexahydropyrrolo- [1 2 4, 5 ]pyrazino[ 2, 3-c Jpyridazine

[0661]

[0662]

[0290] To a solution of (6a5,8A)-8-(benzyloxy)-2-chloro-6a-ethyl-6a,7,8,9-tetrahydropyrrolo- [r,2’:4,5]pyrazino[2,3-c]yridazine-6(5J7)-one (1.34 g, 3.73 mmol) in THF (30 mL) was added borane dimethyl sulfide complex (3.54 mL, 37.3 mmol) at 0 °C. The resulting mixture was stirred at 50 °C for 1 h and then was cooled to 0 °C. MeOH (3 mL) was added slowly, and the reaction mixture was stirred at rt for 10 min. The mixture was concentrated and diluted with ethanol (30 mL). Sodium cyanoborohydride (1.17 g, 18.7 mmol) and acetic acid (2.14 mL, 37.3 mmol) were added, and the reaction mixture was stirred at 80 °C for 4 h. The reaction was quenched with sat. NaHCO3 (aq.) (30 mL), and the mixture was diluted with EtOAc (30 mL). The layers were separated, and the aqueous layer was extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated to afford the title compound (1.29 g, 3.74 mmol, 99% yield) as a yellow solid. LC-MS calc, for C18H22CIN4O [M+H]+m / z= 345.2 / 347.2; Found 345.4 / 347.5.

[0663]

[0291] Step 6. (6aS,8R)-2-Chloro-6a-ethyl-5,6,6a,7,8,9-hexahydropyrrolo[l',2':4,5]-pyrazino[ 2, 3-c ]pyridazin-8-ol

[0664] - 80 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0665]

[0666]

[0292] To a solution of (6a5,87?)-8-(benzyloxy)-2-chloro-6a-ethyl-5,6,6a,7,8,9-hexahydro-pyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazine (1.45 g, 4.20 mmol) in DCM (30 mL) at -78 °C was added tri chloroborane (1 N in DCM, 12.6 mL, 12.6 mmol) dropwise. The resulting mixture was slowly warmed to rt and stirred for 30 min. sat. NaHCO3 (aq.) (50 mL) was added, and the reaction mixture was diluted with DCM (20 mL). The layers were separated, and the aqueous layer was extracted with CHCh / IPA (3:1) (50 mL x 4). The combined organic layers were dried over Na2SC>4, filtered, and concentrated. The crude product was slurried in MTBE (100 mL) and collected by filtration to afford the title compound (1.01 g, 3.93 mmol, 93.4% yield) as a white solid. 'H NMR (300 MHz, DMSO-d6) 87.01 (d, J = 4.3 Hz, 1H), 6.26 (d, J = 0.9 Hz, 1H), 5.25 (d, J = 3.4 Hz, 1H), 4.45 (q, J = 6.0, 5.1 Hz, 1H), 3.52 (ddd, J = 16.1, 11.7, 5.4 Hz, 2H), 3.28 - 3.11 (m, 1H), 2.61 (dd, J= 11.6, 1.2 Hz, 1H), 2.00 (dd, J = 13.3, 1.9 Hz, 1H), 1.86 - 1.68 (m, 1H), 1.68 - 1.57 (m, 1H), 1.55 - 1.41 (m, 1H), 0.82 (t, J = 7.4 Hz, 3H). LC-MS calc, for C11H16CIN4O [M+H]+m / z= 255.1 / 257.1; Found 255.3 / 257.3.

[0667]

[0293] Step 7. (6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo[r,2':4,5] pyrazino[ 2, 3-c ]pyridazin-8-ol

[0668]

[0669]

[0294] To a solution of (6a5,87?)-2-chloro-6a-ethyl-5,6,6a,7,8,9-hexahydropyrrolo[r,2':4,5]-pyrazino[2,3-c]pyridazin-8-ol (300 mg, 1.2 mmol) in 1,4-dioxane (5.0 mL) and water (1.0 mL) was added 2-hydroxyphenylboronic acid (406 mg, 2.94 mmol) and potassium phosphate tribasic (750 mg, 3.5 mmol), followed by the addition of XPhos Pd G2 (46 mg, 0.06 mmol). The mixture was degassed three times and stirred at 100 °C for 3 h under N2. The mixture was cooled to rt and partitioned with water (15 mL) and EtOAc (15 mL). The resulting layers were separated. The aqueous layer was extracted with EtOAc (3 x 15 mL). The combined organic phases were washed with brine, dried over Na2SO4, concentrated, and purified by silica gel chromatography (0-10% MeOH / DCM) to afford the title compound (330 mg, 1.1 mmol, 89% yield), a beige solid. LCMS calc, for C17H21N4O2 [M+H]+m / z= 313.1; found 313.1.

[0670]

[0295] Step 8. 5-(l,3-Dioxolan-2-yl)-2-fluoro-3-methylpyridine

[0671] - 81 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0672]

[0673]

[0296] To a solution of 6-fluoro-5-methylnicotinaldehyde (3.0 g, 22 mmol) and ethylene glycol (3.6 mL, 65 mmol) in toluene (50 mL) was added p-toluenesulfonic acid monohydrate (370 mg, 2.2 mmol). The mixture was heated to reflux while eliminating water using a Dean-Stark trap for 2 h. The mixture was cooled to rt, washed with sat. NaHCCh (aq.) (20 mL), and the aqueous phase was extracted with EtOAc (3 x 25 mL). The combined organic phases were washed with brine, dried over ISfeSCU, concentrated and purified by silica gel chromatography (0-40% EtOAc / heptane) to give the title compound (2.1 g, 12 mmol, 53% yield), a colorless oil. LCMS calc, for C9H11FNO2 [M+H]+m / z= 184.1; Found 184.4.

[0674]

[0297] Step 9. 2-((6aS,8R)-8-((5-(l,3-Ioxolan-2-yl)-3-methylpyridin-2-yl)oxy)-6a-ethyl- 5, 6, 6a, 7, 8, 9-hexahydropyrrolo[ 1 ', 2 4, 5 ]pyrazino[ 2, 3-c ]pyridazin-2-yl)phenol

[0675]

[0676]

[0298] To a solution of (6a5,8A)-2-chloro-6a-ethyl-5,6,6a,7,8,9-hexahydropyrrolo[l',2':4,5]-pyrazino[2,3-c]pyridazin-8-ol (200 mg, 0.64 mmol) and 5-(l,3-dioxolan-2-yl)-2-fluoro-3-methylpyridine (140 mg, 0.77 mmol) in DMF (0.5 mL) and THF (2.5 mL) was added sodium hydride (46 mg, 1.9 mmol) at 0 °C. The resulting mixture was stirred at rt overnight. The reaction was diluted with sat. NH4CI (aq.) (10 mL) and resulting mixture was extracted with EtOAc (3 x 10 mL). The combined organic phases were washed with brine, dried over Na2SO4, concentrated, and purified by silica gel chromatography (0-10% MeOH / DCM) to afford the title compound (190 mg, 0.41 mmol, 63% yield), a beige solid. LCMS calc, for C26H30N5O4 [M+H]+: m / z= 476.2; Found 476.3.

[0677]

[0299] Step 10. 6-((( 6aS, 8R)-6a-Ethy 1-2 -(2 -hydroxyphenyl) -5, 6, 6a, 7, 8, 9-hexahydropyrrolo

[0678]

[0679] - 82 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0680]

[0300] A solution of (6a5,8A)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [l',2':4,5]pyrazino[2,3-c]pyridazin-8-ol (193.0 mg, 0.41 mmol) in 1% TFA (aq.) (2.0 mL) and MeCN (2.0 mL) was stirred at rt for 2 h. The reaction mixture was concentrated to afford the TFA salt of the title compound (170 mg, 0.394 mmol, 97% yield), a beige solid. LCMS calc, for C24H26N5O3 [M+H]+: m / z= 432.2; Found 432.4.

[0681]

[0301] Step 11. tert-Butyl 4-[3-(2,4-dioxo-l,3-diazinan-l-yl)-l-methylindazol-6-yl]-3,6-dihydro-2H-pyridine-l -carboxylate

[0682]

[0683]

[0302] A mixture of l-(6-bromo-l-methyl-17 / -indazol-3-yl)dihydro-2, 4(1 / 7, 3J7)-pyrimidinedione (2.4 g, 7.38 mmol), cesium acetate (5.7 g, 29.5 mmol), Pd(dppf)C12 (270 mg, 0.369 mmol), and A-Boc-l,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester (3.4 g, 11.071 mmol) in 1,4-di oxane (25 mL) and water (5 mL) was heated at 100 °C under N2 for 4 h. The reaction was cooled to ambient temperature and diluted with EtOAc (100 mL), washed with water (50 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by flash column chromatography (0-100% EtOAc / DCM) to give the title compound (2.85 g, 6.7 mmol, 91% yield), a white solid. LCMS calc, for C22H28N5O4 [M+H]+m / z= 426.2; Found 426.3.

[0684]

[0303] Step 12. tert-Butyl 4-[3-(2,4-dioxo-l,3-diazinan-l-yl)-l-methylindazol-6-yl]piperidine-l-carboxylate

[0685]

[0686]

[0304] A mixture of tert-butyl 4-[3-(2,4-dioxo-l,3-diazinan-l-yl)-l-methylindazol-6-yl]-3,6-dihydro-2 / / -pyridine- l -carboxylate (2.18 g, 5.119 mmol) and 10% palladium on carbon (54.5 mg, 0.512 mmol) was stirred under H2 atmosphere (40 Psi) in DCM (5 mL) and methanol (5 mL) for 2 d. The solid was filtered off and the filtrate was concentrated and purified by flash column

[0687] - 83 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0688] chromatography (0-90% EtOAc / DCM) to give the title compound (2.13 g, 4.98 mmol, 97% yield), a white solid. LCMS calc, for C22H30N5O4 [M+H]+m / z= 428.2; Found 428.3.

[0689]

[0305] Step 13. l-(l-Methyl-6-piperidin-4-ylindazol-3-yl)-l,3-diazinane-2, 4-dione

[0690]

[0691]

[0306] A solution of tert-butyl 4-[3-(2,4-dioxo-l,3-diazinan-l-yl)-l-methylindazol-6-yl] piperidine- 1 -carboxylate (2.13 g, 4.978 mmol) in 4 M HC1 in 1,4-dioxane (25 mL) was stirred at rt for 4 h. The mixture was concentrated to give the title compound (1.81 g, 4.978 mmol, quantitative yield), a white solid. LCMS calc, for C17H23CIN5O2 [M+H]+m / z= 328.2; Found 328.2.

[0692]

[0307] Step 14. l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[ 1 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)piperidin-4-yl)- 1 -methyl- lH-indazol-3-yl)dihydropyrimidine-2, 4(1H, 3H) -dione

[0693]

[0308] To a solution of 6-[[(47?,65)-6-ethyl-12-(2-hydroxyphenyl)-2,8,10,l 1 -tetrazatri cyclo [7.4.0.02,6]trideca-l(13),9,ll-trien-4-yl]oxy]-5-methylpyridine-3-carbaldehyde (8.6 mg, 0.02 mmol) in DMSO (1 mL) was added 7V,7V-diisopropylethylamine (0.03 mL, 0.2 mmol), followed by the addition of l-(l-methyl-6-piperidin-4-ylindazol-3-yl)-l,3-diazinane-2, 4-dione (7.8 mg, 0.02 mmol) and sodium triacetoxyborohydride (68.7 mg, 0.32 mmol). The resulting mixture was stirred at 50 °C for 1 h. The mixture was cooled to rt and directly purified by prep-HPLC on a C18 column (5-40% MeCN / 0.05% TFA (aq.)) to afford the title compound (13.9 mg, 0.019 mmol, 94% yield), a white solid. LCMS calc, for C41H47N10O4 [M+H]+: m / z= 743.4; Found 743.4.

[0694] Examples 2-8

[0695]

[0309] Examples 2-8 are shown in Tables 1 and 2. Examples 2-8 were synthesized according to procedures analogous to Example 1. All examples in these tables were prepared as the TFA salt unless otherwise noted.

[0696] Table 1. Examples 2-8

[0697]

[0698] - 84 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0699]

[0700] Table 2. Examples 2-8

[0701]

[0702] - 85 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0703]

[0704] Example 9. 3-(6-(l-((6-(((6a5,81?)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-LH-indazol-3-yl)piperidine-2, 6-dione

[0705]

[0706]

[0310] Step 1. (6aS,8R)-6a-Ethyl-2-(2-(methoxymethoxy)phenyl)-5,6,6a,7,8,9-hexahydropyrrolo [l',2 4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-ol

[0707]

[0708]

[0311] The title compound was prepared by procedure analogous to those outlined in Example 1, Step 7 using 2-(methoxymethoxy)phenylboronic acid instead of 2-hydroxyphenylboronic acid. LCMS calc, for C19H25N4O3 [M+H]+m / z= 357.2; found 357.4.

[0709]

[0312] Step 2. 3-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-(methoxymethoxy)phenyl)-5,6,6a,7,8,9-hexa-hydropyrrolo[ 1 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione

[0710] - 86 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0711]

[0712]

[0313] The title compound was prepared by procedure analogous to those outlined in Example 1, Steps 9 - 14 using 5-(l,3-dioxolan-2-yl)-2 -fluoropyridine and 3-(l-methyl-6-(piperidin-4-yl)-17T-indazol-3-yl)piperidine-2, 6-dione instead of 5-(l,3-dioxolan-2-yl)-2-fluoro-3-methylpyridine and l-(l-methyl-6-(piperidin-4-yl)-IT / -indazol-3-yl)dihydropyrimidine-2,4(l7 / ,37 / )-dione. LCMS calc, for C43H50N9O5 [M+H]+m / z= 772.4; found 772.3.

[0713]

[0314] Step 3. 3-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[ 1 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione

[0714]

[0315] 3-(6-(l-((6-(((6a5,8A)-6a-Ethyl-2-(2-(methoxymethoxy)phenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-17 / -indazol-3-yl)piperidine-2, 6-dione (20.0 mg, 0.026 mmol) was dissolved in methanol (200 pL). The mixture was cooled to 0 °C and 12 M HC1 (aq.) (200 pL) was added slowly. The reaction mixture was stirred at rt for 5 min. The reaction mixture was diluted with water and purified by preparative HPLC on a C18 column (10-40% MeCN / EEO, containing 0.05% TFA) to afford the title compound (8.0 mg, 41% yield) as TFA salt, as white solid. LCMS calc, for C41H46N9O4 [M+H]+m / z= 728.4; found 728.3.

[0715] Example 10. l-(6-(l-((6-(((6a5,81?)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro- pyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l- iiietliyl-l / / -iiid:izol-3-yl)dihydropyriniidine-2.4( l / / .3 / / )-dione

[0716] - 87 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0717]

[0718]

[0316] The title compound was synthesized by procedures analogous to those outlined in Example 9. LCMS calc, for C40H45N10O4 [M+H]+m / z= 729.4; found 729.2.

[0719] Example 11. l-(6-(l-((2-(((6a5,81?)-6a-Ethyl-2-(3-fluoro-2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [1 ',2': 4,5]pyrazino [2,3-c] pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)-piperidiii-4-yl)-l-inetliyl-l / / -iiidazol-3-yl)dihydropyriniidine-2.4( 1 / / .3 / / )-dione

[0720]

[0721]

[0317] Step 1. (6aS,8R)-6a-Ethyl-2-(3-fluoro-2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [1 2 4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-ol

[0722]

[0723]

[0318] The title compound was prepared by procedure analogous to those outlined in Example 1, Step 7 using 3-fluoro-2-hydroxyphenylboronic acid instead of 2-hydroxyphenylboronic acid. LCMS calc, for C17H20FN4O2 [M+H]+: m / z= 331.2; Found 331.4.

[0724]

[0319] Step 2. l-(6-(l-((2-(((6aS,8R)-6a-Ethyl-2-(3-fluoro-2-hydroxyphenyl)-5,6,6a,7,8,9-hexa-hydropyrrolo[ 1 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2, 4( 1H, 3H)-dione

[0725] - 88 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0726]

[0320] The title compound was synthesized by procedures analogous to those outlined in Example 1, Steps 9 - 14 utilizing 2-chloropyrimidine-5-carbaldehyde instead of 6-fluoro-5-methylnicotinaldehyde. LCMS calc, for C39H43FN11O4 [M+H]+: m / z= 748.3; Found 748.3.

[0727] Example 12. l-(6-(l-((2-(((6a5,81?)-6a-Ethyl-2-(5-fluoro-2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [1 ',2': 4,5] pyrazino[2,3-c] pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)-piperidiii-4-yl)-l-metliyl-l / / -iiidazol-3-yl)dihydropyrimidine-2.4( 1 / / .3 / / )-dione

[0728]

[0729]

[0321] Step 1. (6aS,8R)-6a-Ethyl-2-(5-fluoro-2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [l',2 4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-ol

[0730]

[0731]

[0322] The title compound was prepared by procedure analogous to those outlined in Example 1, Step 7 using 4-fluoro-2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenol instead of 2-hydroxyphenylboronic acid. LCMS calc, for C17H20FN4O2 [M+H]+: m / z= 331.2; Found 331.5.

[0732]

[0323] Step 2. l-[6-[l-[[2-[[(4R,6S)-6-Ethyl-12-(5-fluoro-2-hydroxyphenyl)-2,8,10,ll-tetraza-tricyclo[7.4.0.02, 6 ] trideca- 1( 13), 9, ll-trien-4-yl oxy ]pyrimidin-5-yl methyl ]piperidin-4-yl -l-methylindazol-3-yl ]-l, 3-diazinane-2, 4-dione

[0733]

[0324] The title compound was synthesized by procedures analogous to those outlined in Example 1, Steps 9 - 14 utilizing 2-chloropyrimidine-5-carbaldehyde instead of 6-fluoro-5-methylnicotinaldehyde. LCMS calc, for C39H43FN11O4 [M+H]+: m / z= 748.3; Found 748.2.

[0734] Example 13. l-(6-(l-((2-(((6a5,81?)-2-(3,5-Difluoro-2-hydroxyphenyl)-6a-ethyl-5,6,6a,7,8,9-hexahydropyrrolo [1 ',2': 4,5] pyrazino[2,3-c] pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)-piperidiii-4-yl)-l-metliyl-l / / -iiidazol-3-yl)dihydropyrimidine-2.4( 1 / / .3 / / )-dione

[0735] - 89 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0736]

[0737]

[0325] Step 1. (6aS,8R)-2-(3,5-Difluoro-2-hydroxyphenyl)-6a-ethyl-5,6,6a,7,8,9-hexahydro-pyrrolo[ 1 2 4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-ol

[0738]

[0739]

[0326] The title compound was prepared by procedure analogous to those outlined in Example 1, Step 7 utilizing 3,5-difluoro-2-hydroxyphenylboronic acid instead of 2-hydroxyphenylboronic acid. LCMS calc, for C17H19F2N4O2 [M+H]+: m / z= 349.1; Found 349.6.

[0740]

[0327] Step 2. l-(6-(l-((2-(((6aS,8R)-2-(3,5-Difluoro-2-hydroxyphenyl)-6a-ethyl-5,6,6a,7,8,9-hexahydropyrrolo[ 1 2 4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl) oxy)pyrimidin-5-yl)methyl)piperidin- 4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2, 4( 1H, 3H)-dione

[0741]

[0328] The title compound was synthesized by procedures analogous to those outlined in Example 1, Steps 9 - 14 utilizing 2-chloropyrimidine-5-carbaldehyde instead of 6-fluoro-5-methylnicotinaldehyde. LCMS calc, for C39H42F2N11O4 [M+H]+: m / z= 766.3; Found 766.3.

[0742] Example 14. l-(6-(l-((6-(((6a5,81?)-2-(2-Hydroxyphenyl)-6a-methyl-5,6,6a,7,8,9-hexahydro- pyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl) piperidin-4-yl)-l- methyl-l / / -ind:izol-3-yl)dihydropyrimidine-2.4( l / / .3 / / )-dione

[0743]

[0744]

[0329] Step 1. 2-Benzyl 1 -(tert-butyl) (2S,4R)-4-hydroxypyrrolidine-l,2-dicarboxylate

[0745] - 90 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0746]

[0747]

[0330] To a mixture of (2,4 / ?)- l-( / c77-butoxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid (25.0 g, 108 mmol) and K2CO3 (44.8 g, 324 mmol) in DMF (250 mL) was added benzyl bromide (26.7 mL, 216 mmol). The reaction was stirred at rt for 2 h and then diluted with MTBE (500 mL) and filtered through a pad of Celite®. The filtrate was dried over anhydrous Na2SC>4, filtered, and concentrated under reduced pressure to give the title compound (assumed quantitative yield) which was used without further purification. LCMS calc, for C17H24NO5 [M+H]+: m / z = 322.2; Found: 322.5.

[0748]

[0331] Step 2. 2-Benzyl 1 -(tert-butyl) (2S,4R)-4-(benzyloxy)pyrrolidine-l,2-dicarboxylate

[0749]

[0750]

[0332] To crude 2-benzyl l-(terLbutyl) (25,4 / ?)-4-hydroxypyrrolidine-l,2-dicarboxylate (34.7 g, 108 mmol) in DMF (300 mL) was added benzyl bromide (19.2 mL, 162 mmol) then KOH (18.2 g, 324 mmol). The reaction was stirred at rt for 3 h and then diluted with MTBE (500 mL) and filtered through a pad of Celite®. The filtrate was washed sequentially with 1 N HC1 (aq.) (500 mL), sat. NaHCCh (aq.) (500 mL), and brine (500 mL). The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated. The crude material was purified by flash silica gel column chromatography eluting with a gradient of 0 to 40% MTBE / heptanes to give the title compound (26.0 g, 59% yield) as colorless oil. LCMS calc, for C24H30NO5 [M+H]+: m / z = 412.2; Found: 412.5.

[0751]

[0333] Step 3. 2-benzyl 1 -(tert-butyl) (4R)-4-(benzyloxy)-2-methylpyrrolidine-l,2-dicarboxylate

[0752]

[0753]

[0334] To 2-benzyl l-( / c / 7-butyl) (25,4 / ?)-4-(benzyloxy)pyrrolidine-l,2-dicarboxylate (34.7 g, 84.3 mmol) in THF (8 mL) at 0 °C was added methyl iodide (6.3 mL, 101 mmol) portion-wise. The reaction was stirred for 30 min, after which LiHMDS (16.9 g, 101 mmol) was added. The reaction was allowed to warm to rt, stirred for 12 h, and then quenched with sat. NH4CI (aq.) (200 mL) and extracted with MTBE (3 x 200 mL). The combined organic phase was dried over

[0754] - 91 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0755] anhydrous Na2SC>4, filtered, and concentrated. The crude material was purified by flash silica gel column chromatography eluting with a gradient of 0 to 20% MTBE / heptanes to give the title compound (33.2 g, 93% yield) as colorless viscous oil. LCMS calc, for C25H32NO5 [M+H]+: m / z = 426.2; Found: 426.1.

[0756]

[0335] Step 4. (4R)-4-(Benzyloxy)-l-(tert-butoxycarbonyl)-2-methylpyrrolidine-2-carboxylic acid

[0757]

[0758]

[0336] To 2-benzyl 1 -(tert-butyl) (4 / ?)-4-(benzyl oxy )-2-m ethyl pyrrol i di ne-l,2-di carboxyl ate (33.2 g, 78.0 mmol) in MeOH (150 mL) at 0 °C was added NaOH (12.5 g, 312 mmol) in water (150 mL) dropwise. The reaction was stirred at 75 °C for 12 h, after which most of MeOH was removed under reduced pressure. The resultant aqueous phase was diluted with water (150 mL), washed with 2: 1 heptanes / MTBE (3 x 150 mL), and then acidified to pH ~2 with 4 N HC1 (aq.), and extracted with MTBE (3 x 150 mL). The combined organic phase from the latter three MTBE extractions was dried over anhydrous Na2SO4, filtered, and concentrated to afford the title compound (mixture of diastereomers) (27.0 g, quantitative) which was used without further purification. LCMS calc, for C18H26NO5 [M+H]+: m / z = 336.2; Found: 336.3.

[0759]

[0337] Step 5. (6R,7aS)-6-(Benzyloxy)-7a-methyltetrahydro-lH,3H-pyrrolo[l,2-c]oxazole-l,3-dione

[0760]

[0761]

[0338] To a solution of DMF (4.5 mL, 58 mmol) in DCM (20 mL) at 0 °C was added oxalyl chloride (4.32 mL, 50.4 mmol) dropwise. The reaction mixture was stirred at 0 °C for 30 min, after which a solution of (4 / ?)-4-(benzyloxy)- l -(tert-butoxycarbonyl )-2 -methyl pyrrol idine-2-carboxylic acid (13.0 g, 38.8 mmol) and pyridine (3.12 mL, 38.8 mmol) in DCM (100 mL) was added, dropwise. After an additional 30 min of stirring at 0 °C, the reaction mixture was washed with cold water (100 mL), and then dried over anhydrous Na2SO4, filtered, and concentrated. The residue was purified by flash silica gel column chromatography eluting with a gradient of 0 to 100% EtOAc / heptanes to give “diastereomer A” and the desired “diastereomer B” (the title compound) (820 mg, 8%) as colorless viscous oils.

[0762]

[0339] Step 6. (2S,4R)-4-(Benzyloxy)-N-(4-bromo-6-chloropyridazin-3-yl)-2-methylpyrrolidine-2-carboxamide

[0763] - 92 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0764]

[0765]

[0340] To a cold solution of (6 / 7aS')-6-(benzyloxy)-7a-methyltetrahydro-l / 7,3 / 7-pyrrolo[l,2- c] oxazole- 1,3 -di one (diastereomer B) (820 mg, 3.14 mmol) and 4-bromo-6-chloropyridazin-3- amine (0.59 g, 2.8 mmol) in THF (4 mL), was added NaH (60% suspension in mineral oil; 0.19 g, 4.71 mmol) in portions at 0 °C. When HPLC analysis indicated the reaction had stalled, additional NaH (60% suspension in mineral oil; 0.093 g, 2.4 mmol) was added. HPLC analysis indicated improved conversion. The reaction was quenched with a 10% citric acid (aq.) solution (20 mL), and the mixture was extracted with 3:1 CHCh / IPA (15 mL x 5). The combined organic phase was dried over anhydrous Na2SC>4, filtered, and concentrated to afford the title compound (assumed quantitative yield) which was used in next step without further purification. LCMS calc, for Ci7Hi9BrClN4O2 [M+H]+: m / z = 425.0; found: 425.2.

[0766]

[0341] Step 7. (6aS,8R)-8-(Benzyloxy)-2-chloro-6a-methyl-6a,7,8,9-tetrahydropyrrolo[l',2':4,5] pyrazino[ 2, 3-c ]pyridazin-6(5H)-one

[0767]

[0768]

[0342] To crude (25',47?)-4-(benzyloxy)-7V-(4-bromo-6-chloropyridazin-3-yl)-2-methyl-pyrrolidine-2-carboxamide in THF (20 mL) was added A-methylmorpholine (228 mg, 2.26 mmol) slowly. The reaction mixture was stirred overnight at 120 °C and then concentrated under reduced pressure. The residue was taken up in water (10 mL) and DCM (10 mL), and the organic layer was separated. The aqueous layer was extracted with DCM (3 x 50 mL), and the combined organic phase was dried over anhydrous Na2SC>4, filtered, and concentrated. The residue was purified by flash silica gel column chromatography eluting with a gradient of 30 to 50% EtOAc / heptanes to afford the title compound (255 mg, 24% yield over two steps) as white solid. LCMS calc, for CnHisC Ch [M+H]+: m / z = 345.1; found: 345.4.

[0769]

[0343] Step 8. ( 6aS, 8R)-8-(Benzyloxy)-2-chloro-6a-methyl-5, 6, 6a, 7, 8, 9-hexahydropyrrolo [l',2 4, 5 ]pyrazino[ 2, 3-c Jpyridazine

[0770] - 93 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0771]

[0772]

[0344] To (6a£,8A)-8-(benzyloxy)-2-chloro-6a-methyl-6a,7,8,9-tetrahydropyrrolo[r,2’:4, 5] pyrazino[2,3-c]pyridazine-6(5J7)-one (260 mg, 0.74 mmol) in THF (3 mL) was added BH3 SMe2 (0.35 mL, 3.7 mmol) at 0 °C. The reaction mixture was heated to 50 °C and stirred for 90 min. The reaction mixture was cooled to 0 °C and quenched slowly with MeOH and then concentrated under reduced pressure. The crude material was then dissolved in EtOH (3 mL). NaBEECN (279 mg, 4.4 mmol) and AcOH (0.51 mL, 8.9 mmol) were added at 0 °C. The reaction mixture was slowly heated to 80 °C and refluxed overnight. Next, it was allowed to cool to rt and poured into cold sat. NaHCCh (aq.) (25 mL). The aqueous layer was extracted with DCM (20 mL x 3). The combined organic phase was dried over anhydrous Na2SC>4, filtered, and concentrated. The residue was purified by flash silica gel column chromatography eluting with a gradient of 10 to 60% EtOAc / DCM to give the title compound (210 mg, 86% yield) as colorless viscous oil. LCMS calc, for C17H20CIN4O [M+H]+: m / z = 331.1; found: 331.5.

[0773]

[0345] Step 9. (6aS,8R)-2-Chloro-6a-methyl-5,6,6a,7,8,9-hexahydropyrrolo[r,2':4,5] pyrazino[ 2, 3-c ]pyridazin-8-ol

[0774]

[0775]

[0346] Tri chloroborane (IM in DCM, 425 mg, 3.63 mmol) was added dropwise to a solution of (6a5,8A)-8-(benzyloxy)-2-chloro-6a-methyl-5,6,6a,7,8,9-hexahydropyrrolo[T,2':4,5]pyrazino [2,3-c]pyridazine (240 mg, 0.73 mmol) in DCM (3 mL) at -78 °C. The resulting mixture was stirred at -78 °C for 30 min, and the reaction was quenched with MeOH (10 mL). The volatiles were removed under reduced pressure, and the residue was basified by addition of 10% Na2COs (aq.). The mixture was then extracted with CHCI3 / IPA (3:1, 10 mL x 6). The combined organic phase was dried over anhydrous Na2SO4, filtered, and concentrated. The residue was triturated in MTBE (5 mL) for 30 min. The solid material was filtered, washed with MTBE, and dried under reduced pressure to give the title compound (150 mg, 86% yield) as a white solid. LCMS calc, for C10H14CIN4O [M+H]+: m / z = 241.1; found: 241.3.

[0776] - 94 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0777]

[0347] Step 9. l-(6-(l-((6-(((6aS,8R)-2-(2-Hydroxyphenyl)-6a-methyl-5,6,6a,7,8,9-hexahydro-pyrrolo[ 1 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2, 4( 1H, 3H)-dione

[0778]

[0348] The title compound was synthesized by procedures analogous to those outlined in Example 1, Steps 7-14. LCMS calc, for C39H43N10O4 [M+H]+m / z= 715.3; Found 715.2.

[0779] Example 15. l-(6-(l-((6-(((6a5,81?)-6a-(Fluoromethyl)-2-(2-hydroxyphenyl)-5,6,6a,7,8,9- hexahydropyrrolo [1 ',2': 4,5]pyrazino [2, 3-c] pyridazin-8-yl)oxy)pyridin-3-yl)methyl)- piperidiii-4-yl)-l-metliyl-l / / -iiidazol-3-yl)dihydropyrimidine-2.4( 1 / / .3 / / )-dione

[0780]

[0781]

[0349] The title compound was synthesized by procedures analogous to those outlined in Example 1 utilizing fluoroiodomethane instead of ethyl iodide in Step 1 and 6-fluoro-nicotinaldehyde instead of 6-fluoro-5-methylnicotinaldehyde in Step 8. LCMS calc, for C39H42FN10O4 [M+H]+m / z= 733.3; Found 733.4.

[0782] Example 16. l-(6-(4-((6-(((6a5,81?)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro- pyrrolo [1 ',2': 4,5] pyrazino[2,3-c] pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)- piperaziii-l-yl)-l-metliyl-l / / -iiidazol-3-yl)dihydropyrimidine-2.4( 1 / / .3 / / )-dione

[0783]

[0784]

[0350] Step 1. tert-Butyl 4-(3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)piperazine-l -carboxylate

[0785] - 95 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0786]

[0787]

[0351] A mixture of l-(6-bromo-l-methyl-lJ7-indazol-3-yl)dihydropyrimidine-2, 4(1 / 7, 3rt)-dione (899 mg, 2.78 mmol), tert-butyl 1 -piperazinecarboxylate (1.04 g, 5.56 mmol), Pd-PEPPSI-IHept- C1 (136 mg, 0.14 mmol), and cesium carbonate (2.72 g, 8.35 mmol) in 1,4-dioxane (10 mL) was heated at 100 °C under nitrogen for 6 h. Additional tert-butyl 1 -piperazinecarboxylate (1.04 g, 5.56 mmol), Pd-PEPPSI-IHept-Cl (136 mg, 0.14 mmol), and cesium carbonate (2.72 g, 8.35 mmol) were added and the reaction was stirred for 18 h under nitrogen at 100 °C. The reaction was cooled to ambient temperature and partitioned with water (50 mL) and EtOAc (50 mL). The organic phase was separated, and the aqueous phase was extracted with EtOAc (4 x 25 mL). The combined organic phase was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by flash column chromatography eluting with a gradient of 0 to 75% EtOAc / DCM to give the title compound (611 mg, 51% yield) as white solid. LCMS calc, for C21H29N6O4 [M+H]+: m / z= 429.2; Found 429.3.

[0788]

[0352] Step 2. l-(6-(4-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[ 1 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)piperazin-l-yl)- 1 -methyl- lH-indazol-3-yl)dihydropyrimidine-2, 4(1H, 3H) -dione

[0789]

[0790]

[0353] The title compound was synthesized by procedures analogous to those outlined in Example 1, Steps 13 - 14 utilizing tert-butyl 4-(3-(2,4-dioxotetrahydropyrimidin-l(2rt)-yl)-l-methyl-U / -indazol-6-yl)piperazine-l -carboxylate instead of tert-butyl 4-(3-(2,4-dioxotetrahydro-pyrimidin-l(2rt)-yl)-l-methyl-U / -indazol-6-yl)piperidine-l-carboxylate in Step 13. LCMS calc, for C40H46N11O4 [M+H]+: m / z= 744.4; Found 744.4.

[0791] - 96 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0792] Example 17. l-(6-(((S)-l-((6-(((6a5,81?)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexa-hydropyrrolo [1 ',2': 4,5]pyrazino [2,3-c] pyridazin-8-yl)oxy)pyridin-3-yl)methyl)pyrrolidin-3-yl):iiiiiiio)-l-iiietliyl-l / / -iiid:izol-3-yl)dihydropyriniidine-2.4( 1 / / .3 / / )-dione

[0793]

[0794]

[0354] Step 1. tert-Butyl (S)-3-((3-(2,4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-indazol-6-yl)ammo)pyrrolidme-l -carboxylate

[0795]

[0796]

[0355] A solution of l-(6-bromo-l-methyl-177-indazol-3-yl)dihydropyrimidine-2, 4(1 / 7, 377)-dione (100 mg, 0.31 mmol), tert-butyl (S)-3 -aminopyrrolidine- 1 -carboxylate (75 mg, 0.40 mmol), palladium (II) acetate (7 mg, 0.03 mmol), rac-BINAP (38.5 mg, 0.06 mmol) and sodium tert-butoxide (89.2 mg, 0.93 mmol) in toluene (2 mL) was sparged with nitrogen for 5 min. The mixture was heated to 100 °C under nitrogen for 3 h. The mixture was cooled to rt and then concentrated. The crude material was partitioned with EtOAc (5 mL) and water (5 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (3 x 5 ml). The combined organic phase was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude material was purified by flash silica gel column chromatography eluting with a gradient of 0 to 5% MeOH / DCM to give the title compound (58.5 mg, 44% yield) as beige solid. LCMS calc, for C21H29N6O4 [M+H]+m / z= 429.2; found 429.5.

[0797]

[0356] Step 2. (S)-l-(l-Methyl-6-(pyrrolidin-3-ylamino)-lH-indazol-3-yl)dihydropyrimidine-2,4(1H, 3 H) -di one

[0798]

[0799]

[0357] To a solution of tert-butyl (5)-3-((3-(2,4-dioxotetrahydropyrimidin-l(277)-yl)-l-methyl-17 / -indazol-6-yl)amino)pyrrolidine-l-carboxylate (25 mg, 0.06 mmol) in DCM (0.80 mL) was added 2,2,2-trifluoroacetic acid (0.2 mL, 2.61 mmol). The resulting mixture was stirred at rt for 2

[0800] - 97 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0801] h. The mixture was concentrated and redissolved in 20% MeCN / water and lyophilized to give the TFA salt of the title compound (14 mg, 73% yield) as white solid. LCMS calc, for CieFFiNeCh [M+H]+: m / z= 329.2; Found 329.4.

[0802]

[0358] Step 3. l-(6-(((S)-l-((6-(((6aS,8R)-6a-Ethyl-2-(2-bydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[ 1 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)pyrrolidin-3-yl)amino)- l-methyl-lH-indazol-3-yl)dihydropyrimidine-2, 4( 1H, 3H)-dione

[0803]

[0359] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 14 utilizing (S)-l-(l-methyl-6-(pyrrolidin-3-ylamino)-l / 7-indazol-3-yl)dihydro-pyrimidine-2, 4(1 / 7, 3 / 7)-dione instead of l-(l-methyl-6-(piperidin-4-yl)-l / 7-indazol-3-yl)dihydro-pyrimidine-2, 4(1 / 7, 3 / 7)-dione. LCMS calc, for C39H44N11O4 [M+H]+: m / z= 730.4; Found 730.3.

[0804] Example 18. l-(6-(l-((6-(((6a5,81?)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro- pyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l- methyl-l / 7-pyrazolo[3,4-b]pyridin-3-yl)dihydropyrimidine-2, 4(1 / 7, 3E7)-dione

[0805]

[0806]

[0360] Step 1. l-(6-Chloro-l-methyl-lH-pyrazolo[3,4-b]pyridin-3-yl)-3-(4-methoxybenzyl)-dihydropyrimidine-2, 4(1H, 3H) -dione

[0807]

[0808]

[0361] 6-Chl oro-3 -iodo- 1-m ethyl- l / 7-pyrazolo[3,4-Z>]pyri dine (400 mg, 1.36 mmol), 3-(4-methoxybenzyl)dihydropyrimidine-2, 4(1 / 7, 3 / 7)-dione (479 mg, 2.04 mmol), copper (II) acetate ( 24.8 mg, 0.14 mmol), 3,4,7,8-tetramethyl-l,10-phenanathroline (64 mg, 0.27 mmol), potassium phosphate tribasic (579 mg, 2.73 mmol) and DMSO (6.8 mL) were added to a tube. The tube was sealed, and the mixture was degassed by sparging nitrogen. The reaction mixture was heated at 80 °C for 3 h. After cooling to rt, the mixture was diluted with EtOAc (30 mL) and water (30 mL). The layers were separated, and the aqueous layer was extracted with EtOAc (2 x 30 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated - 98 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0809] under reduced pressure. The crude material was purified by flash silica gel column chromatography eluting with a gradient of 0 to 70% EtOAc / heptane to afford the title compound (380 mg, 70% yield). LCMS calc, for C19H19CIN5O3 [M+H]+m / z= 400.1; found 400.1.

[0810]

[0362] Step 2: tert-Butyl 4-(3-(3-(4-methoxybenzyl)-2, 4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-pyrazolo[ 3, 4-b ]pyridin-6-yl)-3, 6-dihydropyridine-l(2H)-carboxylate

[0811]

[0812]

[0363] l-(6-Chl oro-1 -methyl-177-pyrazolo[3,4-Z>]pyri din-3 -yl)-3-(4-methoxybenzyl)dihy dro-pyrimidine-2, 4(1 / 7, 3rt)-dione (380.0 mg, 0.95 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-3,6-dihydropyridine-l(2rt)-carboxylate (588 mg, 1.9 mmol), XPhos Pd G2 ( 75 mg, 0.10 mmol), potassium phosphate tribasic (605 mg, 2.85 mmol), 1,4-dioxane (8.5mL), and water (1 mL) were added to a tube. The tube was sealed, and the mixture was degassed by sparging nitrogen. The mixture was heated at 90 °C for 2 h. The reaction mixture was diluted with EtOAc (30 mL) and water (30 mL). The layers were separated, and the aqueous layer was extracted with EtOAc (2 x 30 mL). The combined organic layers were dried over anhydrous Na2SO4and concentrated. The crude material was purified by flash silica gel column chromatography eluting with a gradient of 0 to 70% EtOAc / heptane to afford the title compound (450 mg, 80% yield). LCMS calc, for C29H35N6O5 [M+H]+m / z= 547.3; found 547.3.

[0813]

[0364] Step 3: tert-Butyl 4-(3-(3-(4-methoxybenzyl)-2, 4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-pyrazolo[ 3, 4-b ]pyridin-6-yl)piperidine-l -carboxylate

[0814]

[0815]

[0365] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 12. LCMS calc, for C29H37N6O5 [M+H]+m / z= 549.3; found 549.4.

[0816]

[0366] Step 4: l-(l-Methyl-6-(piperidin-4-yl)-lH-pyrazolo[3,4-b]pyridin-3-yl)dihydro-pyrimidine-2, 4(1H, 3H)-dione

[0817] - 99 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0818]

[0819]

[0367] tert-Butyl 4-(3-(3-(4-methoxybenzyl)-2,4-dioxotetrahydropyrimidin-l(2J7)-yl)-l-methyl- l#-pyrazolo[3,4-Z>]pyridin-6-yl)piperidine-l -carboxylate (320 mg, 0.58 mmol) was dissolved in 10% triflic acid in TFA (3.2 mL). The reaction mixture was stirred at 65 °C for 2 h. The mixture was concentrated to dryness, redissolved in 20% MeCN (aq.) solution. Undissolved solids were filtered off and the resulting solution was purified by preparative HPLC on a Cl 8 column (5-20% MeCN / FfO, containing 0.05% TFA (aq.)) to afford the TFA salt of the title compound (150 mg, 58% yield), as white solid. LCMS calc, for CieFFiNeCh [M+H]+m / z= 329.2; found 329.1

[0820]

[0368] Step 5: 6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [l',2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)nicotinaldehyde

[0821]

[0822]

[0369] The title compound was synthesized by procedures analogous to those outlined in Example 1, Steps 7- 10 utilizing 5-(l,3-dioxolan-2-yl)-2-fluoropyridine instead of 5-(l,3- dioxolan-2-yl)-2-fluoro-3-methylpyridine. LCMS calc, for C23H24N5O3 [M+H]+m / z= 418.2; found 418.3.

[0823]

[0370] Step 6: l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[ 1 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-pyrazolo[ 3, 4-b ]pyridin-3-yl)dihydropyrimidine-2, 4(1H, 3H)-dione

[0824]

[0371] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 14 utilizing (6a5,8A)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-8-ol and l-(l-methyl-6-(piperidin-4-yl)-U7-pyrazolo- [3,4-Z>]pyridin-3-yl)dihydropyrimidine-2,4(lJ7,3J7)-dione instead of (6a5,8A)-6a-ethyl-2-(3-fluoro-2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-8-ol and l-(l-methyl-6-(piperidin-4-yl)-U7-indazol-3-yl)dihydropyrimidine-2,4(U7,3J7)-dione. LCMS calc, for C39H44N11O4 [M+H]+m / z= 730.4; found 730.3. 'H NMR (300 MHz, CD3OD) 8 8.45-8.40 (m, 1H), 8.17 (d, J= 2.0 Hz, 1H), 7.95-7.90 (m, 1H), 7.55-7.50 (m, 1H), 7.45-7.35 (m,

[0825] - 100 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0826] 1H), 7.15-7.10 (m, 1H), 7.05 - 6.95 (m, 3H), 6.81 (s, 1H), 5.90-5.80 (m, 1H), 4.45-4.40 (m, 2H), 4.26 (dd, J= 13.9, 6.6 Hz, 1H), 4.15-4.05 (m, 2H), 4.01 (s, 3H), 3.95-3.85 (m, 2H), 3.70-3.65 (m, 2H), 3.30-3.20 (m, 3H), 3.05-3.00 (m, 1H), 2.90-2.80 (m, 2H), 2.65-2.60 (m, 2H), 2.30 - 2.00 (m, 6H), 1.90 - 1.85 (m, 1H), 0.98 (t, J= 7.4 Hz, 3H).

[0827] Example 19. 3-(6-(l-((6-(((6a5,81?)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro- pyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l- methyl- lH-pyrazolo[3,4- / >]pyridin-3-yl)piperidine-2, 6-dione

[0828]

[0829]

[0372] Step 1. 3-(2, 6-bis(benzyloxy)pyridin-3-yl)-6-chloro-l-methyl-lH-pyrazolo[ 3, 4-b ]pyridine

[0830]

[0831]

[0373] 6 -Chi oro-3 -iodo- 1-m ethyl- U / -pyrazolo[3,4-Z>]pyri dine (600 mg, 2.04 mmol), 2,6-bis- (benzyloxy)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (938 mg, 2.25 mmol), sodium carbonate (455 mg, 4.29 mmol), Pd(PPh3)4 (236 mg, 0.20 mmol), l,4-dioxane(7.2 mL), and water(2.4 mL) were added to a tube and the tube was sealed. The mixture was degassed by sparging nitrogen. The mixture was stirred at 100 °C for 15 h. The mixture was diluted with water and EtOAc. The organic layer was separated, and the aqueous layer was extracted once more with EtOAc. The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated. The crude material was purified by flash silica gel column chromatography eluting with a gradient of 0 to 25% EtOAc / heptane to give the title compound (580 mg, 59% yield) as white solid. LCMS calc, for C26H22CIN4O2 [M+H]+m / z= 457.1; found 457.1.

[0832]

[0374] Step 2. tert-Butyl 4-(3-(2, 6-bis(benzyloxy)pyridin-3-yl)-l -methyl- lH-pyrazolo[ 3, 4-b] pyridin-6-yl)-3,6-dihydropyridine-l(2H)-carboxylate

[0833] - 101 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0834]

[0835]

[0375] The title compound was synthesized by procedures analogous to those outlined in Example 18, Step 2. LCMS calc, for C36H38N5O4 [M+H]+m / z= 604.3; found 604.5.

[0836]

[0376] Step 3. tert-Butyl 4-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-lH-pyrazolo[3,4-b]pyridin-6-yl)piperidine-l -carboxylate

[0837]

[0838]

[0377] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 12. LCMS calc, for C22H30N5O4 [M+H]+m / z= 428.2; found 428.4.

[0839]

[0378] Step 4. 3-(l-Methyl-6-(piperidin-4-yl)-lH-pyrazolo[3,4-b]pyridin-3-yl)piperidine-2,6-dione

[0840]

[0841]

[0379] The title compound was synthesized by procedures analogous to those outlined in Example 18, Step 4. LCMS calc, for C17H22N5O2 [M+H]+m / z = 328.2; found 328.2.

[0842]

[0380] Step 5. 3-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[ 1 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-pyrazolo[ 3, 4-b ]pyridin-3-yl)piperidine-2, 6-dione

[0843]

[0381] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 14 utilizing (6a5,87?)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-8-ol and 3-(l-methyl-6-(piperidin-4-yl)-17 / -pyrazolo- [3, 4-Z>]pyri din-3 -yl)piperidine-2, 6-dione instead of (6aA',8 / ?)-6a-ethyl-2-(3-fluoro-2-hydroxy-phenyl)-5,6,6a,7,8,9-hexahydropyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-8-ol and l-(l-methyl-

[0844] - 102 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0845] 6-(piperidin-4-yl)-17 / -indazol-3-yl)dihydropyrimidine-2, 4(1 / 7, 3Z / )-dione. LCMS calc, for C40H45N10O4 [M+H]+m / z= 729.4; found 729.5.

[0846] Example 20. l-(6-(l-((2-(((6a5,81?)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo [1 ',2': 4,5] pyrazino[2,3-c] pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)piperidin-4-yl)-1 -methyl- 17 / -pyrrolo|2.3-b|pyridiii-3-yl)dihydropyriniidine-2.4( 1 / / .3 / / )-dione

[0847]

[0848]

[0382] Step 1. 6- Chloro- 3-iodo-lH-pyrrolo[ 2,3-b ]pyridine

[0849]

[0850]

[0383] To a solution of 6-chloro-17 / -pyrrolo[2,3-Z>]pyridine (2.03 g, 13.3 mmol) in DMF (20 mL) was added N-iodosuccinimide (3.58 g, 15.9 mmol). The mixture was stirred at rt for 4 h, poured into saturated aqueous Na2S2O5 (100 mL) to give a suspension. The solid was collected by filtration, washed with water, and dried to give the title compound (3.08 g, 83% yield) as beige solid. LCMS calc, for C7H5CIIN2 [M+H]+m / z= 278.9; Found 278.9.

[0851]

[0852]

[0385] To a solution of 6-chloro-3-iodo-17 / -pyrrolo[2,3-Z>]pyridine (3.08 g, 11.06 mmol) in DMF (30 mL) was added sodium hydride (0.51 g, 12.72 mmol) at 0 °C. The mixture was stirred for 10 min. lodomethane (792 pL, 12.72 mmol) was added. The mixture was stirred at rt for 1 h, poured into water (100 mL) to give a suspension. The solid was collected by filtration, and dried to give the title compound (3.23 g, 100% yield) as off-white solid. LCMS calc, for C8H7CIIN2 [M+H]+m / z= 292.9; Found 292.7.

[0853]

[0386] Step 3. l-(6-Chloro-l-methyl-lH-pyrrolo[2,3-b]pyridin-3-yl)-3-(4-methoxybenzyl)-dihydropyrimidine-2, 4(1H, 3H) -dione

[0854] - 103 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0855]

[0856]

[0387] The title compound was synthesized by procedures analogous to those outlined in Example 18, Step 1. LCMS calc, for C20H20CIN4O3 [M+H]+m / z= 399.1; Found 399.0.

[0857]

[0388] Step 4. tert-Butyl 4-(3-(3-(4-methoxybenzyl)-2, 4-dioxotetrahydropyrimidin-l(2H)-yl)-l-methyl-lH-pyrrolo[2, 3-b]pyridin-6-yl)-3,6-dihydropyridine-l(2H)-carboxylate

[0858]

[0859]

[0389] The title compound was synthesized by procedures analogous to those outlined in Example 18, Step 2. LCMS calc, for C30H36N5O5 [M+H]+m / z= 546.2; Found 546.4.

[0860]

[0390] Step 5. tert-Butyl 4-(3-(3-(4-methoxybenzyl)-2, 4-dioxotetrahydropyrimidin-l(2H)-yl)-l-

[0861]

[0862]

[0391] The title compound was synthesized by procedures analogous to those outlined in Example 18, Step 3. LCMS calc, for C30H38N5O5 [M+H]+m / z= 548.3; Found 548.3.

[0863]

[0392] Step 6. l-( 1 -Methyl-6-(piperidin-4-yl)-lH-pyrrolo[ 2, 3-b ]pyridin-3-yl)dihydropyrimidine- 2,4(1H, 3H)-dione

[0864]

[0865] - 104 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0866]

[0393] The title compound was synthesized by procedures analogous to those outlined in Example 18, Step 4. LCMS calc, for C17H22N5O2 [M+H]+m / z= 328.2; Found 548.3.

[0867]

[0394] Step 7. 2 -Chloro-5-( 1, 3-dioxolan-2-yl)pyrimidine

[0868]

[0869]

[0395] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 8 utilizing 2-chloropyrimidine-5-carbaldehyde instead of 6-fluoro-5-methyl-nicotinaldehyde. LCMS calc, for C7H8CIN2O2 [M+H]+m / z= 187.0; Found 187.3.

[0870]

[0396] Step 8. 2-((6aS,8R)-8-((5-(l,3-Dioxolan-2-yl)pyrimidin-2-yl)oxy)-6a-ethyl-5,6,6a, 7,8,9-hexahydropyrrolo[ 1 ', 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-2-y I) phenol

[0871]

[0872]

[0397] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 9 utilizing 2-chloro-5-(l,3-dioxolan-2-yl)pyrimidine instead of 5-(l,3-dioxolan-2-yl)-2-fluoro-3-methylpyridine. LCMS calc, for C24H27N6O4 [M+H]+m / z= 463.2; Found 463.1.

[0873]

[0398] Step 9. 2-((( 6aS, 8R)-6a-Ethyl-2-(2-hydr oxyphenyl) -5, 6, 6a, 7, 8, 9-hexahydropyrrolo [l',2 4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)pyrimidine-5-carbaldehyde

[0874]

[0875]

[0399] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 10. LCMS calc, for C22H23N6O3 [M+H]+m / z= 419.2; Found 419.2.

[0876]

[0400] Step 10. l-(6-(l-((2-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[ 1 ', 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)piperidin-4-yl)-l-methyl-lH-pyrrolo[ 2, 3-b ]pyridin-3-yl)dihydropyrimidine-2, 4(1H, 3H)-dione

[0877]

[0401] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 14 utilizing 2-(((6a5',8 / ?)-6a-ethyl-2-(2-hydroxyphenyl)-5, 6, 6a, 7,8, 9-hexahydro-pyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyrimidine-5-carbaldehyde and l-(l-methyl- 6-(piperidin-4-yl)-17 / -pyrrolo[2, 3-Z>]pyridin-3-yl)dihydropyrimidine-2, 4(1 / 7, 3J7)-dione instead of

[0878] - 105 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0879] (6a5,87?)-6a-ethyl-2-(3-fluoro-2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo[l',2':4,5]-pyrazino[2,3-c]pyridazin-8-ol and l-(l-methyl-6-(piperidin-4-yl)-lH-indazol-3-yl)dihydro-pyrimidine-2,4(lH,3H)-dione. LCMS calc, for C39H44N11O4 [M+H]+m / z= 730.4; Found 730.3.

[0880] Example 21. l-(6-(l-((2-(((6a5,81?)-2-(2-hydroxyphenyl)-6a-methyl-5,6,6a,7,8,9-hexahydro-pyrrolo [1 ',2': 4,5] pyrazino[2,3-c] pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)piperidin-4-yl)-l-inetliyl-l / / -pyr:izolo|3.4- / i|pyridiii-3-yl)dihydropyriniidine-2.4( 1 / / .3 / / )-dione

[0881]

[0882]

[0402] Step 1. 2 -Chloro-5-(dimethoxymethyl)pyrimidine

[0883]

[0884]

[0403] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 8 utilizing 2-chloropyrimidine-5-carbaldehyde instead of 6-fluoro-5-methylnicotinaldehyde. LCMS calc, for C7H10CIN2O2 [M+H]+m / z= 189.0; Found 188.9.

[0885]

[0404] Step 2. 2-(((6aS,8R)-2-(2-Hydroxyphenyl)-6a-methyl-5,6,6a,7,8,9-hexahydropyrrolo-[l',2 4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)pyrimidine-5-carbaldehyde

[0886]

[0887]

[0405] To a solution of (6a5,87?)-2-(2-hydroxyphenyl)-6a-methyl-5,6,6a,7,8,9-hexahydropyrrolo-[l',2':4,5]pyrazino[2,3-c]pyridazin-8-ol (42.0 mg, 0.14 mmol, Example 14, Step 8) and 2-chloro-5-(dimethoxymethyl)pyrimidine (53.1 mg, 0.28 mmol) in DMF (1 mL) was added sodium hydride (22.5 mg, 0.56 mmol). The mixture was stirred at rt for 1.5 h and then 4 N HC1 (1.0 mL, 4 mmol) was added. The mixture was diluted with water, filtered and purified by prep-HPLC on

[0888] - 106 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0889] C18 column (10-35% MeCN in water with 0.05% TFA) to afford the title compound (43.9 mg, 77% yield) as a brown solid. LCMS calc, for C21H21N6O3 [M+H]+m / z= 405.2; Found 405.5.

[0890]

[0406] Step 3. l-(6-(l-((2-(((6aS,8R)-2-(2-Hydroxyphenyl)-6a-methyl-5,6,6a,7,8,9-hexahydro-pyrrolo[ 1 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)piperidin-4-yl)-l-methyl-lH-pyrazolo[ 3, 4-b ]pyridin-3-yl)dihydropyrimidine-2, 4(1H, 3H)-dione

[0891]

[0407] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 14 utilizing instead 2-(((6a5,8A)-2-(2-hydroxyphenyl)-6a-methyl-5,6,6a,7,8,9-hexahydropyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyrimidine-5-carbaldehyde and 3- (l-methyl-6-piperidin-4-ylpyrazolo[3,4-b]pyri din-3 -yl)piperidine-2, 6-dione instead of 4R,6S)-6- ethyl-12-(3-fluoro-2-hydroxyphenyl)-2,8,10,ll-tetrazatricyclo[7.4.0.02,6]trideca-l(13),9,ll-trien-4-ol and l-(l-methyl-6-piperidin-4-ylindazol-3-yl)-l,3-diazinane-2, 4-dione. LCMS calc, for C37H41N12O4 [M+H]+m / z= 717.3; Found 717.2.

[0892] Example 22. l-(l-Benzyl-6-(l-((6-(((6a5,81?)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9- hexahydropyrrolo [1 ',2': 4,5]pyrazino [2,3-c] pyridazin-8-yl)oxy)pyridin-3-yl)methyl)- piperidiii-4-yl)-l / / -iiid:izol-3-yl)dihydropyriniidine-2.4( 1 / / .3 / / )-dione

[0893]

[0894]

[0408] Step 1. l-Benzyl-6-bromo-3-iodo-lH-indazole

[0895]

[0896]

[0409] 6 -Bromo-3-iodo-lJT-indazole (1.0 g, 3.1 mmol) was dissolved in DMF (10.3mL).

[0897] Potassium hydroxide (261 mg, 4.64 mmol) was added at 0 °C and the mixture was stirred vigorously for 15 min. Benzyl bromide (442 pL, 3.72 mmol) was added dropwise at 0 °C and the reaction mixture was stirred at rt for 1 h. The mixture was diluted with EtOAc and water. The layers were separated, and the aqueous layer was extracted with EtOAc (x2). The combined organic layers were dried with Na2SO4, concentrated and purified by silica gel flash column

[0898] - 107 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0899] chromatography (0-5% MTBE / heptane) to give the title compound (1.0 g, 77% yield), as a white solid. LCMS calc, for Ci4HnBrIN2[M+H]+m / z= 412.9; Found 412.8.

[0900]

[0410] Step 2. l-(l-Benzyl-6-bromoindazol-3-yl)-3-[(4-methoxyphenyl)methyl]-l,3-diazinane-2, 4-dione

[0901]

[0902]

[0411] The title compound was synthesized by procedures analogous to those outlined in Example 18, Step 1. LCMS calc, for C26H24BrN4C>3 [M+H]+m / z= 519.1; Found 519.0.

[0903]

[0412] Step 3. tert-Butyl 4-[ l-benzyl-3-[ 3-[ (4-methoxyphenyl)methyl]-2, 4-dioxo-l, 3-diazinan-l-yl ]indazol-6-yl -3, 6-dihydro-2H-pyridine-l -carboxylate

[0904]

[0905]

[0413] The title compound was synthesized by procedures analogous to those outlined in Example 18, Step 2. LCMS calc, for C36H40N5O5 [M+H]+m / z= 622.3; Found 622.0.

[0906]

[0414] Step 4. l-[l-Benzyl-6-(l,2,3,6-tetrahydropyridin-4-yl)indazol-3-yl]-3-[(4-methoxy-phenyl)methyl ]-l, 3-diazinane-2, 4-dione

[0907]

[0908]

[0415] To a solution of tert-butyl 4-[l-benzyl-3-[3-[(4-methoxyphenyl)methyl]-2,4-dioxo-l,3- diazinan-l-yl]indazol-6-yl]-3,6-dihydro-2rt-pyridine-l -carboxylate (490 mg, 0.79 mmol) in DCM (2 mL) was added TFA (2 mL, 26.1 mmol). The mixture was stirred at rt for 15 min, concentrated to give the title compound (501 mg, quantitative yield), as a amber oil. LCMS calc, for C31H32N5O3 [M+H]+m / z= 522.3; Found 522.2.

[0909] - 108 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0910]

[0416] Step 5. l-(l-Benzyl-6-piperidin-4-ylindazol-3-yl)-3-[(4-methoxyphenyl)methyl]-l,3-diazinane-2, 4-dione

[0911]

[0912]

[0417] The title compound was synthesized by procedures analogous to those outlines in Example 1, Step 12. LCMS calc, for C31H34N5O3 [M+H]+m / z= 524.3; Found 524.4.

[0913]

[0418] Step 6. l-(l-Benzyl-6-piperidin-4-ylindazol-3-yl)-l,3-diazinane-2, 4-dione

[0914]

[0915]

[0419] The title compound was synthesized by procedures analogous to those outlined in Example 18, Step 4. LCMS calc, for C23H26N5O2 [M+H]+m / z= 404.2; Found 404.5.

[0916]

[0420] Step 7. l-[ l-Benzyl-6-[ l-[ [6-[[(4R,6S)-6-ethyl-12-(2-hydroxyphenyl)-2,8, 10, 11-tetraza-tricyclo[ 7.4.0.02, 6 ] trideca- 1( 13), 9, 1 l-trien-4-yl oxy ]-3-pyridinyl methyl ]piperidin-4-yl indazol-3-yl ]-l, 3-diazinane-2, 4-dione

[0917]

[0421] The title compound was synthesized by procedures analogous to those outlines in Example 1, Step M using (47?,6S)-6-ethyl-12-(3-fluoro-2-hydroxyphenyl)-2,8,10,l 1-tetraza-tricyclo[7.4.0.02,6]trideca-l(13),9,ll-trien-4-ol (Example 18, Step 5) and l-(l-benzyl-6-piperidin-4-ylindazol-3-yl)-l,3-diazinane-2, 4-dione instead of (47?,6S)-6-ethyl-12-(3-fluoro-2-hydroxyphenyl)-2,8,10,l l-tetrazatricyclo[7.4.0.02,6]trideca-l(13),9,l l-trien-4-ol and 1-(1-methyl-6-piperidin-4-ylindazol-3-yl)-l,3-diazinane-2, 4-dione. LCMS calc, for C46H49N10O4 [M+H]+m / z= 805.4; Found 805.3.

[0918] Example 23. l-[l-ethyl-6-[l-[[6-[[(4R,6S)-6-ethyl-12-(2-hydroxyphenyl)-2,8,10,ll-tetraza-tricyclo[7.4.0.02,6]trideca-l(13),9,ll-trien-4-yl]oxy]-3-pyridinyl]methyl]piperidin-4-yl] indazol-3-yl]-l,3-diazinane-2, 4-dione

[0919] - 109 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0920]

[0921]

[0422] The title compound was synthesized by procedures analogous to those outlined in Example 20, utilizing iodoethane and 6-bromo-3-iodo-lJ / -indazole instead of iodomethane and 6-chloro-3-iodo-l / Z-pyrrolo[2,3-Z>]pyridine in Step 2. LCMS calc, for C41H47N10O4 [M+H]+m / z= 743.4; found 743.4.XH NMR (300 MHz, CD3OD): 8.36 (d, J= 2.0 Hz, 1H), 7.91 (dd, J = 8.6, 2.4 Hz, 1H), 7.65-7.60 (m, 1H), 7.51 (dd, J = 8.0, 1.6 Hz, 1H), 7.45-7.35 (m, 2H), 7.10-6.95 (m, 4H), 6.81 (s, 1H), 5.85-5.80 (m, 1H), 4.45-4.35 (m, 4H), 4.26 (dd, J= 14.0, 6.6 Hz, 1H), 4.10-4.00 (m, 2H), 3.95-3.85 (m, 2H), 3.70-3.60 (m, 2H), 3.30-3.25 (m, 1H), 3.25-3.15 (m, 2H), 3.05-3.00 (m, 2H), 2.90-2.80 (m, 2H), 2.65-2.55 (m, 1H), 2.20-2.00 (m, 6H), 1.90-1.80 (m, 1H), 1.44 (t, J= 7.2 Hz, 3H), 0.97 (t, J= 7.4 Hz, 3H).

[0922] Example 24. l-(6-(l-((6-(((6a5,81?)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo [1 ',2': 4,5] pyrazino[2,3-c] pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)piperidin- 4-yl)-5-fluoro-l-methyl-LH-indazol-3-yl)dihydropyrimidine-2,4(lH,3 )-dione

[0923]

[0924]

[0423] Step 1. tert-Butyl 4-[3-(2,4-dioxo-l,3-diazinan-l-yl)-5-fluoro-l-methylindazol-6-yl]-3,6-dihydro-2H-pyridine-l -carboxylate

[0925]

[0926] - 110 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0927]

[0424] The title compound was synthesized by procedures analogous to those outlined in Example 18, Step 2 utilizing l-(6-bromo-5-fluoro-l-methylindazol-3-yl)-l,3-diazinane-2, 4-dione instead of l-(6-chloro-l-methylpyrazolo[5,4-Z>]pyridin-3-yl)-3-[(4-methoxyphenyl)methyl]-l,3- diazinane-2, 4-dione. LCMS calc, for C22H27FN5O4 [M+H]+m / z= 444.2; found 444.3.

[0928]

[0425] Step 2. l-(5-Fluoro-l-methyl-6-( 1, 2, 3, 6-tetrahydropyridin-4-yl)-lH-indazol-3-yl)dihydro-pyrimidine-2, 4(1H, 3H)-dione

[0929]

[0930]

[0426] The title compound was synthesized by procedures analogous to those outlined in Example 22, Step 4. LCMS calc, for C17H19FN5O2 [M+H]+m / z= 344.1; found 344.1.

[0931]

[0427] Step 3. l-(5-Fluoro-l-methyl-6-(piperidin-4-yl)-lH-indazol-3-yl)dihydropyrimidine-2,4(1H, 3 H) -di one

[0932]

[0933]

[0428] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 12. LCMS calc, for C17H21FN5O2 [M+H]+m / z= 346.2; found 346.1.

[0934]

[0429] Step 4. l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[ 1 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)piperidin-4-yl)-5-fluoro- 1 -methyl- lH-indazol-3-yl)dihydropyrimidine-2, 4(1H, 3H)-dione

[0935]

[0430] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 14 utilizing l-(5-fluoro-l-methyl-6-(piperidin-4-yl)-U / -indazol-3-yl)dihydro-pyrimidine-2, 4(1 / 7, 3Z / )-dione instead of l-(l-methyl-6-piperidin-4-ylindazol-3-yl)-l,3-diazinane-2, 4-dione. LCMS calc, for C41H46FN10O4 [M+H]+m / z= 761.4; found 761.4. *HNMR (300 MHz, CD3OD): 8.18 (s, 1H), 7.75 (s, 1H), 7.51 (dd, J= 8.0, 1.5 Hz, 1H), 7.45-7.35 (m, 3H), 7.05-6.95 (m, 2H), 6.80 (s, 1H), 5.90-5.85 (m, 1H), 4.35-4.30 (m, 2H), 4.25 (dd, J= 14.1, 6.4 Hz, 1H), 4.05-4.00 (m, 2H), 4.00 (s, 3H), 3.95-3.85 (m, 2H), 3.70-3.60 (m, 2H), 3.25-3.20 (m, 2H), 3.05- 3.00 (m, 1H), 2.90-2.80 (m, 2H), 2.70-2.60 (m, 3H), 2.28 (s, 3H), 2.20-2.05 (m, 6H), 1.90-1.80 (m, 1H), 1.01 (t, J= 7.4 Hz, 3H).

[0936] - Ill - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0937] Example 25. 3-(5-(4-((6-(((6a5,81?)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperazin-l-yl)-3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-l-yl)piperidine-2, 6-dione

[0938]

[0939]

[0431] Step 1. tert-Butyl 4-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lH-benzo[d]imidazol-5-yl)piperazine-l-carboxylate

[0940]

[0941]

[0432] The title compound was synthesized by procedures analogous to those outlined in Example 16, Step 1, utilizing 3-(5-bromo-3-methyl-2-oxo-2,3-dihydro-17 / -benzo[t ]imidazol-l-yl)piperidine-2, 6-dione instead of l-(6-bromo-l-methyl-17 / -indazol-3-yl)dihydro-2,4(lZ / ,3Z / )-pyrimidinedione. LCMS calc, for C22H30N5O5 [M+H]+: m / z= 444.2; Found 444.4.

[0942]

[0433] Step 2. 3-(3-Methyl-2-oxo-5-(piperazin-l-yl)-2,3-dihydro-lH-benzo[d]imidazol-l-yl)piperidine-2, 6-dione

[0943]

[0944]

[0434] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 7, utilizing tert-butyl 4-(l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-17 / -benzo[t / ]imidazol-5-yl)piperazine-l -carboxylate instead of tert-butyl 4-(3-(2,4-dioxotetrahydropyrimidin-l(2Z / )-yl)-l-methyl-l / / -indazol-6-yl)piperidine-l -carboxylate. LCMS calc, for C17H22N5O3 [M+H]+: m / z= 344.1; Found 344.5.

[0945] - 112 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0946]

[0435] Step 3. 6-((( 6aS, 8R)-6a-Ethy 1-2 -(2 -hydroxyphenyl) -5, 6, 6a, 7, 8, 9-hexahydropyrrolo-[l',2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)nicotinaldehyde

[0947]

[0948]

[0436] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 8-10, utilizing 6-fluoronicotinaldehyde instead of 6-fluoro-5-methylnicotin- aldehyde in Step 2. LCMS calc, for C23H24N5O3 [M+H]+: m / z= 418.2; Found 418.8.

[0949]

[0437] Step 4. 3-(5-(4-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[ 1 ', 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperazin-l-yl)-3-methyl-2 -oxo-2, 3-dihydro-lH-benzo[ d]imidazol-l-yl)piperidine-2, 6-dione

[0950]

[0438] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 14, utilizing 3-(3-methyl-2-oxo-5-piperazin-l-ylbenzimidazol-l-yl)piperidine-2, 6-dione instead of l-(l-methyl-6-piperidin-4-ylindazol-3-yl)-l,3-diazinane-2, 4-dione and 6- (((6a5,87?)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)nicotinaldehyde. LCMS calc, for C40H45N10O5 [M+H]+: m / z=745.4; Found 745.7.

[0951] Example 26. l-(6-(l-((6-(((6a5,81?)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro- pyrrolo [1 ',2': 4,5] pyrazino[2,3-c] pyridazin-8-yl)oxy)pyridin-3-yl)methyl)-piperidin-4-yl)- 1.5-diinetliyl-l / / -iiid:izol-3-yl)dihydropyriniidine-2.4( l / / .3 / / )-dione

[0952]

[0953]

[0439] Step 1. 6-Bromo-3-iodo-5-methyl-lH-indazole

[0954]

[0955] - 113 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0956]

[0440] To a solution 6-bromo-5-methyl-l / 7-indazole (500 mg, 2.4 mmol), iodine (1.2 g, 4.7 mmol) in DMF (2.0 mL) was added potassium hydroxide (530 mg, 9.5 mmol). The resulting mixture was stirred at rt for 3 h. The reaction was diluted with sat. NaHSCh (aq.) (150 mL) and the resulting precipitate was collected by filtration. The solid was washed with water (3 ^ 30 mL) and dried to give the title compound (800 mg, quantitative yield), a pale-yellow solid. LCMS calc, for C8H7BrIN2[M+H]+m / z= 338.9; found 338.8.

[0957]

[0441] Step 2. l-(l,5-Dimethyl-6-(piperidin-4-yl)-lH-indazol-3-yl)dihydropyrimidine-2,4(1H, 3 H) -di one

[0958]

[0959]

[0442] The title compound was synthesized by procedures analogous to those outlined in Example 20 Step 2, Example 18 Steps 1-2,4, and Example 1 Step 12, utilizing 6-bromo-3-iodo- 5-methyl-l / 7-indazole instead of 6-chloro-3-iodo-l-methyl-l / 7-pyrrolo[2,3-Z>]pyridine. LCMS calc, for C18H24N5O2[M+H]+m / z= 342.2; found 342.4.

[0960]

[0443] Step 3. l-(6-(l-((6-(((6aS,8R)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[ 1 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l, 5-dimethyl-lH-indazol-3-yl)dihydropyrimidine-2, 4( 1H, 3H)-dione

[0961]

[0444] The title compound was synthesized by procedures analogous to those outlined in Example 1, step 14, utilizing l-(l,5-dimethyl-6-(piperidin-4-yl)-l / 7-indazol-3-yl)dihydro-pyrimidine-2, 4(1 / 7, 3 / 7)-dione; instead of l-(l-methyl-6-(piperidin-4-yl)-l / 7-indazol-3-yl)dihydropyrimidine-2, 4(1 / 7, 3 / 7)-dione and 6-(((6a5,8 / ?)-6a-ethyl-2-(2-hydroxyphenyl)- 5,6,6a,7,8,9-hexahydropyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)nicotinaldehyde instead of 6-(((6a5,8 / ?)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo[l',2':4,5]-pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-methylnicotinaldehyde. LCMS calc, for C41H47N10O4 [M+H]+m / z= 743.4; found 743.5.

[0962] Example 27. l-(5-Ethyl-6-(l-((6-(((6a5,81?)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9- hexahydropyrrolo [1 ',2': 4,5]pyrazino [2, 3-c] pyridazin-8-yl)oxy)pyridin-3-yl)methyl)- piperidin-4-yl)-l-methyl-lE7-indazol-3-yl)dihydropyrimidine-2, 4(1 / 7, 3 / 7)-dione

[0963] - 114 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0964]

[0965]

[0445] Step 1. l-(5-Bromo-6-chloro-l-methyl-lH-indazol-3-yl)-3-(4-methoxybenzyl)dihydro-pyrimidine-2, 4(1H, 3H)-dione

[0966]

[0967]

[0446] The title compound was synthesized by procedures analogous to those outlined in Example 20 Step 2 and Example 18 Step 1 utilizing 5-Bromo-6-chloro-3-iodo-17 / -indazole instead of 6-Bromo-3-iodo-5-methoxy-17 / -indazole in Step 2. LCMS calc, for C2oHi9BrClN4C>3 [M+H]+m / z= 477.0; found 476.9.

[0968]

[0447] Step 2. l-(6-Chloro-l-methyl-5-vinyl-lH-indazol-3-yl)-3-(4-methoxybenzyl)dihydro-pyrimidine-2, 4(1H, 3H)-dione

[0969]

[0970]

[0448] To a solution of l-(5-bromo-6-chloro-l-methyl-17 / -indazol-3-yl)-3-(4-methoxybenzyl)- dihydropyrimidine-2, 4(1 / 7, 3J7)-dione(l 58 mg, 0.33 mmol) in l,4-dioxane(2.25 mL) and water (0.55 mL) was added 4,4,5,5-tetramethyl-2-vinyl-l,3,2-dioxaborolane (53.5 mg, 0.35 mmol), potassium carbonate (45.7 mg, 0.33 mmol), Pd(dppf)C12 (24.2 mg, 0.03 mmol). The solution was heated to 90 °C overnight under N2 atmosphere. The reaction was cooled to rt, partitioned with water (5 mL) and EtOAc (5 mL). The resulting layers were separated, and the aqueous layer was extracted with EtOAc (3 x 5 mL). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated. The crude was purified by prep-HPLC on a Cl 8 column (15-70% MeCN / 0.05% TFA (aq.)) to afford the title compound (115 mg, 82% yield) as a white solid. LCMS calc, for C22H22CIN4O3 [M+H]+m / z= 425.1; Found 425.4.

[0971] - 115 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0972]

[0449] Step 3. l-(6-Chloro-5-ethyl-l -methyl- lH-indazol-3-yl)-3-(4-methoxybenzyl)dihydro-pyrimidine-2, 4(1H, 3H)-dione

[0973]

[0974]

[0450] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 12 utilizing l-(6-chloro-5-ethenyl-l-methylindazol-3-yl)-3-[(4-methoxyphenyl)-methyl]-l,3-diazinane-2, 4-dione instead of tert-butyl 4-(3-(2,4-dioxotetrahydropyrimidin-l(2 / 7)-yl)-l-methyl-l77-indazol-6-yl)-3,6-dihydropyridine-l(277)-carboxylate. LCMS calc, for C22H24CIN4O3 [M+H]+m / z= 427.1; Found 427.2.

[0975]

[0451] Step 4. l-(5-Ethyl-l-methyl-6-(piperidin-4-yl)-lH-indazol-3-yl)dihydropyrimidine-2,4(1H, 3 H) -di one

[0976]

[0977]

[0452] The title compound was synthesized by procedures analogous to those outlined in Example 18 Steps 2,4 and Example 1 Step 12 utilizing l-(6-chloro-5-ethyl-l-methyl-l / 7-indazol- 3-yl)-3-(4-methoxybenzyl)dihydropyrimidine-2,4(l77,377)-dione instead of l-(6-bromo-5-methoxy-1 -methyl-l / 7-indazol-3-yl)-3-(4-methoxybenzyl)dihydropyrimidine-2, 4(1 / 7, 377)-di one in Step 4. LCMS calc, for C19H26N5O2 [M+H]+m / z= 356.2; found 356.3.

[0978]

[0453] Step 5. l-(5-Ethyl-6-(l-((6-(((6aS,8R)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexa-hydropyrrolo[ 1 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2, 4( 1H, 3H)-dione

[0979]

[0454] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 14, utilizing l-(5-ethyl-l-methyl-6-(piperidin-4-yl)-l / 7-indazol-3-yl)dihydro-pyrimidine-2, 4(1 / 7, 37 / )-dione instead of l-(l-methyl-6-(piperidin-4-yl)-l / 7-indazol-3-yl)dihydro-pyrimidine-2, 4(1 / 7, 3 / 7)-dione and 6-(((6a5,8 / ?)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexa-hydropyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)nicotinaldehyde instead of 6- (((6a,8 / ?)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo[r,2':4,5]-pyrazino[2,3-

[0980] - 116 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0981] c]pyridazin-8-yl)oxy)-5-methylnicotinaldehyde. LCMS calc, for C42H49N10O4 [M+H]+: m / z= 757.4; Found 757.2.

[0982] Example 28. l-(6-(l-((6-(((6a5,81?)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l- (2-methoxyethyl)-LH-indazol-3-yl)dihydropyrimidine-2,4(lH,3#)-dione

[0983]

[0984]

[0455] The title compound was synthesized by procedures analogous to those outlined in Example 20, utilizing l-iodo-2 -methoxy ethane and 6-bromo-3-iodo-lJ / -indazole instead of iodomethane and 6-chloro-3-iodo-l / Z-pyrrolo[2,3-Z>]pyridine in Step 2. LCMS calc, for C42H49N10O5 [M+H]+: m / z= 773.4; Found 773.4.

[0985] Example 29.3-(6-(l-((6-(((6a5,81?)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo [1 ',2': 4,5] pyrazino[2,3-c] pyridazin-8-yl)oxy)-4,5-dimethylpyridin-3-yl)methyl)-piperidin-4-yl)-l-methyl-l / / -ind:izol-3-yl)piperidine-2.6-dione

[0986]

[0987]

[0456] Step 1: (6aS,8R)-2-Chloro-8-((3,4-dimethyl-5-vinylpyridin-2-yl)oxy)-6a-ethyl-5, 6, 6a, 7, 8, 9-hexahydropyrrolo[ 1 2 4, 5 ]pyrazino[ 2, 3-c Jpyridazine

[0988] - 117 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0989]

[0990]

[0457] (6a5,8 / ?)-2-Chloro-6a-ethyl-5,6,6a,7,8,9-hexahydropyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-ol (70.0 mg, 0.275 mmol, Example 1 Step 6), 3,4-dimethyl-5-vinylpyridin-2-ol (65.6 mg, 0.44 mmol), and triphenylphosphine (257 mg, 0.41 mmol) were added to a 20-mL vial followed by DCM (6.5 mL) and THF (3.2 mL). The vial was sealed with a septum cap and purged with nitrogen for 3 min. Diisopropyl azodicarboxylate (81.2 pL, 0.41 mmol) was added and the mixture was stirred at 30 °C overnight. Next, the volatiles were removed under reduced pressure and the crude material was partially purified by flash silica gel column chromatography eluting with a gradient of 0-5% MeOH / DCM to afford the title compound (assumed quantitative) as yellow solid. LCMS calc, for C20H25CIN5O [M+H]+: m / z =386.2; Found: 386.2.

[0991]

[0458] Step 2: 2-((6aS,8R)-8-((3,4-Dimethyl-5-vinylpyridin-2-yl)oxy)-6a-ethyl-5,6,6a, 7,8,9-hexa-

[0992]

[0993]

[0459] (6a5,87?)-2-Chloro-8-((3,4-dimethyl-5-vinylpyridin-2-yl)oxy)-6a-ethyl-5,6,6a,7,8,9-hexahydropyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazine (106 mg, 0.275 mmol), 2-hydroxyphenyl-boronic acid (114 mg, 0.824 mmol), potassium carbonate (152 mg, 1.10 mmol), 1,4-dioxane (4 mL), and water (0.4 mL) were added to a 20 mL vial and the mixture was sparged with nitrogen for 5 min. Chloro(2-dicyclohexylphosphino-2',6'-dimethoxy-l,l'-biphenyl)[2-(2'-amino-l,l'-biphenyl)]palladium(II) (SPhos Pd G2) (19.8 mg, 0.03 mmol) was and the mixture was stirred at 95 °C for 3 h. After cooling to rt, the mixture was diluted with DCM (10 mL), dried over anhydrous magnesium sulfate, filtered, and concentrated. The crude material was purified by flash silica gel column chromatography eluting with a gradient of 0-5% MeOH / DCM to afford the title compound (assumed quantitative) as pale-yellow gum. LCMS calc, for C26H30N5O2 [M+H]+: m / z =444.2; Found: 444.1.

[0994]

[0460] Step 3: 6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo-[l',2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)-4, 5-dimethylnicotinaldehyde

[0995] - 118 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[0996]

[0997]

[0461] 2-((6a5',8. R)-8-((3,4-Dimethyl-5-vinylpyridin-2-yl)oxy)-6a-ethyl-5,6,6a,7,8,9-hexahydropyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-2-yl)phenol (121 mg, 0.27 mmol), 2,6-lutidine (63.2 pL, 0.55 mmol), 1,4-dioxane (1.5 mL), and water (0.5 mL) were added to a 20 mL vial charged followed by osmium tetroxide (173 pL, 27 pmol, 4 wt% in water) and sodium periodate (175 mg, 0.82 mmol). The mixture was stirred at rt for 2 h. The mixture was then diluted with DCM (10 mL), dried over anhydrous magnesium sulfate, filtered through a pad of silica gel (10 g) eluting with 10% MeOH / DCM (30 mL), and concentrated to afford the title compound (assumed quantitative yield) as brown solid. LCMS calc, for C25H28N5O3 [M+H]+: m / z =446.2; Found: 446.1.

[0998]

[0462] Step 4: 3-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[ 1 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)-4, 5-dimethylpyridin-3-yl)methyl)piperidin- 4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione

[0999]

[0463] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 14 utilizing 6-(((6a5,87?)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-4,5-dimethylnicotinaldehyde and 3-(l-methyl-6-(piperidin-4-yl)-17 / -indazol-3-yl)piperidine-2, 6-dione instead of 6-(((6a5,87?)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-8-yl) oxy)-5-methylnicotinaldehyde and l-(l-methyl-6-(piperidin-4-yl)-l / / -indazol-3-yl)dihydro-pyrimidine-2, 4(1 / 7, 3J7)-dione. LCMS calc, for C43H50N9O4 [M+H]+: m / z = 756.4; Found: 756.3.

[1000] Example 30. 3-(6-(l-((5-(((6a5,81?)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro- pyrrolo [1 ',2': 4,5] pyrazino[2,3-c] pyridazin-8-yl)oxy)-3,4-dimethylpyridin-2-yl)methyl)- piperidiii-4-yl)-l-inetliyl-l / / -iiidazol-3-yl)piperidine-2.6-dione

[1001] - 119 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[1002]

[1003]

[0464] Step 1. 5-((( 6aS, 8R)-6a-ethyl-2-( 2-hydroxyphenyl) -5, 6, 6a, 7, 8, 9-hexahydropyrrolo-[l',2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)-3, 4-dimethylpicolinaldehyde

[1004]

[1005]

[0465] The title compound was synthesized by procedures analogous to those described in Example 29 Steps 1-3 utilizing 4,5-dimethyl-6-vinylpyridin-3-ol instead of 3,4-dimethyl-5-vinylpyridin-2-ol. LCMS calc, for C25H28N5O3 [M+H]+: m / z = 446.2; Found: 446.1.

[1006]

[0466] Step 2. 3-(6-(l-((5-(((6aS,8R)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[ 1 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)-3, 4-dimethylpyridin-2-yl)methyl)piperidin- 4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione

[1007]

[0467] The title compound was synthesized by procedures analogous to those described in Example 1 Step 14 utilizing 5-(((6a5,87?)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-3, 4-dimethylpicolinaldehyde instead of 6- (((6a5,87?)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-methylnicotinaldehyde. LCMS calc, for C43H50N9O4 [M+H]+: m / z = 756.4; Found: 756.1.

[1008] Example 31.3-(4-(l-((6-(((6a5,81?)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro- pyrrolo [1 ',2': 4,5] pyrazino[2,3-c] pyridazin-8-yl)o y)-5-methylpyridin-3-yl)methyl)piperidin- 4-yl)phenyl)piperidine-2, 6-dione

[1009] - 120 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[1010]

[1011]

[0468] Step 1. 6-((( 6aS, 8R)-6a-ethyl-2-( 2-hydroxyphenyl) -5, 6, 6a, 7, 8, 9-hexahydropyrrolo-[l',2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)-5-methylnicotinaldehyde

[1012]

[1013]

[0469] The title compound was synthesized by procedures analogous to those described in Example 29 Steps 1-3 utilizing 3-methyl-5-vinylpyridin-2-ol instead of 3,4-dimethyl-5-vinylpyridin-2-ol. LCMS calc, for C24H26N5O3 [M+H]+: m / z =432.2; Found: 432.1.

[1014]

[0470] Step 2: 3-(4-(l-((6-(((6aS,8R)-6a-ethyl-2-(2-hydroxyphenyl)-5, 6, 6a, 7,8,9-hexahydro-pyrrolo[ 1 ', 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)piperidin-4-yl)phenyl)piperidine-2, 6-dione

[1015]

[0471] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 14 utilizing 3-(4-(piperidin-4-yl)phenyl)piperidine-2, 6-dione (synthesized according to literature procedures, W02023025091) instead of l-(l-methyl-6-(piperidin-4-yl)- 17 / -indazol-3-yl)dihydropyrimidine-2, 4(1H,3H)-dione. LCMS calc, for C40H46N7O4 [M+H]+: m / z = 688.4; Found: 688.1.

[1016] Example 32: 3-(6-(4-((6-(((6a5,81?)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro- pyrrolo [1 ',2': 4,5] pyrazino[2,3-c] pyridazin-8-yl)oxy)-7-methyl-3,4-dihydroisoquinolin-2(lE7)-yl)methyl)piperidin-l-yl)-l-methyl-l / 7-indazol-3-yl)piperidine-2, 6-dione

[1017] - 121 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[1018]

[1019]

[0472] Step 1. tert-Butyl 6-hydroxy-7-methyl-3,4-dihydroisoquinoline-2(lH)-carboxylate

[1020]

[1021]

[0473] To 7-methyl-l,2,3,4-tetrahydroisoquinolin-6-ol;hydrobromide (250 mg, 1.02 mmol), DMAP (12.5 mg, 0.1 mmol) and A A-diisopropylethylamine (0.45 mL, 2.6 mmol) were added to a solution of BOC2O (0.24 g, 1.1 mmol) in THF (4.3 mL). The resulting mixture was stirred at RT for 1 h then diluted with EtOAc and washed with brine. The organic layer was dried over Na2SC>4, filtered and concentrated. The crude residue was purified by silica gel chromatography (10-30% EtOAc in hexanes) to afford the title compound (121 mg, 45% yield) as a white solid. LCMS calc, for C11H14NO3 [M-tBu+2H]+: m / z = 208.1; Found: 208.0.

[1022]

[0474] Step 2. tert-Butyl 6-( ( f 6aS, 8R)-2-chloro-6a-ethyl-5, 6, 6a, 7, 8, 9-hexahydropyrrolo-[l',2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)-7-methyl-3, 4-dihydroisoquinoline-2( 1H)~ carboxylate

[1023]

[1024]

[0475] The title compound was synthesized by procedures analogous to that described in Example 29 Step 1 utilizing tert-butyl 6-hydroxy-7-methyl-3,4-dihydroisoquinoline-2( lrt)-carboxylate instead of 3,4-dimethyl-5-vinylpyridin-2-ol. LCMS calc, for C26H35CIN5O3 [M+H]+: m / z = 500.2; Found: 500.0.

[1025] - 122 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[1026]

[0476] Step 3. tert-Butyl 6-(((6aS,8R)-6a-ethyl-2-(2-hydroxyphenyl)-5, 6, 6a, 7,8,9-hexahydro-pyrrolo[ 1 ', 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)- 7-methyl-3, 4-dihydroisoquinoline-2( IH)-carboxylate

[1027]

[1028]

[0477] The title compound was synthesized by procedures analogous to that described in Example 29 Step 2 utilizing tert-butyl 6-(((6a5,8A)-2-chloro-6a-ethyl-5,6,6a,7,8,9-hexahydro-pyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-7-methyl-3,4-dihydroisoquinoline-2(lrt)- carboxylate instead of (6a5,8A)-2-chloro-8-((3,4-dimethyl-5-vinylpyridin-2-yl)oxy)-6a-ethyl- 5,6,6a,7,8,9-hexahydropyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazine. LCMS calc, for C32H40N5O4 [M+H]+: m / z = 558.3; Found: 558.2.

[1029]

[0478] Step 4. 6-((( 6aS, 8R)-6a-Ethyl-2 -(2 -hydroxyphenyl) -5, 6, 6a, 7, 8, 9-hexahydropyrrolo-[l',2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl) oxy) -7 -methyl- 1, 2, 3, 4-tetrahydroisoquinolin-2-ium trifluoromethanesulfonate

[1030]

[1031]

[0479] To a solution of tert-butyl 6-(((6a5,8A)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-7-methyl-3,4-dihydroiso- quinoline-2(lrt)-carboxylate (44 mg, 0.08 mmol) in DCM (1.0 mL) was added TFA (0.3 mL, 3.9 mmol) and stirred at RT for 1 h. The reaction mixture was concentrated to give afford the trifluoromethanesulfonate salt of the title compound (assumed quantitative yield) as a thick, viscous brown oil. LCMS calc, for C27H33N5O2[M+H]+: m / z = 458.3; Found: 458.1.

[1032]

[0480] Step 5. 3-(6-(4-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[ I ', 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)- 7-methyl-3, 4-dihydroisoquinolin-2( IH)-yl)methyl)piperidin-l-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione

[1033]

[0481] The title compound was synthesized by procedures analogous to those described in Example 1 Step 14 utilizing 6-(((6a5,8A)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[l',2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-7-methyl-l,2,3,4-tetrahydroisoquinolin-2-ium trifluoromethanesulfonate and l-(3-(2,6-dioxopiperidin-3-yl)-l-methyl-U / -indazol-6- - 123 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[1034] yl)piperidine-4-carbaldehyde (synthesized according to literature procedures, W0024039901) instead of 6-(((6a5,87?)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo[r,2':4,5]-pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-methylnicotinaldehyde and l-(l-methyl-6-(piperidin-4-yl)-17 / -indazol-3-yl)dihydropyrimidine-2, 4(1H,3H)-dione. LCMS calc, for C46H54N9O4 [M+H]+: m / z = 796.4; Found: 796.2.

[1035] Example 33. l-(6-(l-((6-(((6a5,81?)-6a-Ethyl-2-(5-fluoro-2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [1 ',2': 4,5]pyrazino [2,3-c] pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)piperidin-4-yl)- 1 -methyl- l / / -iiidazol-3-yl)dihydropyrimidine-2.4( l / / .3 / / )-dione

[1036]

[1037]

[0482] The title compound was synthesized by procedures analogous to those outlined in Example 1, Steps 9 - 14 utilizing (6a£,8 / ?)-6a-ethyl-2-(5-fluoro-2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [l',2':4,5]pyrazino[2,3-c]pyridazin-8-ol (Example 12, Step 1) instead of (6a5,8 / ?)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo[r,2':4,5] pyrazino[2,3-c]pyridazin-8-ol. LCMS calc, for C41H46FN10O4 [M+H]+: m / z = 761.4; Found: 761.4.

[1038] Example 34. l-(6-(l-((6-(((6a5,81?)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [1 ',2': 4,5]pyrazino [2,3-c] pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)metliyl)piperidiii-4-yl)-l / / -iiidazol-3-yl)dihydropyrimidine-2.4( 1 / / .3 / / )-dione

[1039]

[1040]

[0483] Step 1. 6-Bromo-3-iodo-l-( tetrahydro-2H-pyran-2-yl)-lH-indazole

[1041] - 124 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[1042]

[1043]

[0484] A solution of 6-bromo-3-iodo-177-indazole (2.66 g, 8.23 mmol), 3,4-dihydro-277-pyran (1.88 mL, 20.6 mmol), and pyridinium -toluenesulfonate (0.414 g, 1.65 mmol) in DCE (30 mL) was heated to 70 °C for 4 h. The reaction mixture was cooled to room temperature then washed with water (75 mL) and brine (75 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated. The crude residue was purified by silica gel chromatography (0-20% EtOAc / heptane) to afford the title compound (2.79 g, 6.85 mmol, 83.2% yield) as an off-white solid. LCMS calc, for Ci2Hi3BrIN2O [M+H]+: m / z = 406.9, 408.9; Found: 407.1, 409.1.

[1044]

[0485] Step 2. l-(6-Bromo-l-(tetrahydro-2H-pyran-2-yl)-lH-indazol-3-yl)-3-(4-methoxybenzyl)dihydropyrimidine-2, 4(1H, 3H)-dione

[1045]

[1046]

[0486] The title compound was synthesized by procedures analogous to those outlined in Example 18, Step 1 utilizing 6-bromo-3-iodo-l-(tetrahydro-277-pyran-2-yl)-177-indazole instead of 6-chl oro-3 -iodo- 1-m ethyl- 177-pyrazolo[3,4-Z>]pyri dine. LCMS calc, for C24H2oBrN404 [M+H]+: m / z = 513.1, 515.1; Found: 513.2, 515.2.

[1047]

[0487] Step 3. l-(6-Bromo-lH-indazol-3-yl)-3-(4-methoxybenzyl)dihydropyrimidine-2,4(lH,3H)-dione

[1048]

[1049]

[0488] To a solution of l-(6-bromo-l-(tetrahydro-277-pyran-2-yl)-177-indazol-3-yl)-3-(4-methoxybenzyl)dihydropyrimidine-2, 4(17 / , 37 / ) -di one (2.30 g, 4.47 mmol) in DCM (27 mL) was added TFA (6.00 mL, 78.4 mmol) and the resulting mixture was heated to 40 °C for 4 h. The reaction mixture was cooled to room temperature and concentrated. The residue was diluted with water (20 mL) and sat. NaHCO3 (aq.), adjusting the pH to ~8, then extracted with DCM (20 mL x 3). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. The crude residue was purified by silica gel chromatography (0-75% EtOAc / DCM) to afford the

[1050] - 125 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[1051] title compound (1.55 g, 3.60 mmol, 80.5% yield) as a white solid. LCMS calc, for Ci9Hi8BrN4O3 [M+H]+: m / z = 429.1; Found: 429.2.

[1052]

[0489] Step 4. tert-Butyl 4-(3-(3-(4-methoxybenzyl)-2,4-dioxotetrahydropyrimidin-l(2H)-yl)-lH-indazol-6-yl)piperidine-l -carboxylate

[1053]

[1054]

[0490] The title compound was synthesized by procedures analogous to those outlined in Example 1, Steps 11-12 utilizing l-(6-bromo-l / 7-indazol-3-yl)-3-(4-methoxybenzyl)dihydropyrimidine-2, 4(1 / 7, 3 / 7) -di one instead of 1 -(6-bromo-l -methyl- 1H-indazol-3-yl)dihydro-2, 4(1 / 7, 3 / 7)-pyrimidinedione. LCMS calc, for C29H36N5O5 [M+H]+: m / z = 534.3; Found: 534.4.

[1055]

[0491] Step 5. l-(6-(Piperidin-4-yl)-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione

[1056]

[1057]

[0492] The title compound was synthesized by procedures analogous to those outlined in Example 18, Step 4 utilizing / c / V-butyl 4-(3-(3-(4-methoxybenzyl)-2,4-dioxotetrahydropyrimidin- l(2 / / )-yl)-17 / -indazol-6-yl)piperidine-l-carboxylate instead of tert-butyl 4-(3-(3-(4- methoxybenzyl )-2, 4-di oxotetrahydropyrimidin-l (2 / 7)-yl)-l -methyl -I / 7-pyrazolo[3,4-A]pyri din-6-yl)piperidine-l -carboxylate. LCMS calc, for C16H20N5O2 [M+H]+: m / z = 314.2; Found: 314.2.

[1058]

[0493] Step 6. l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[ 1 2 ':4, 5 ]pyrazino[ 2, 3-c ]pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)piperidin-4-yl)-lH-indazol-3-yl)dihydropyrimidine-2, 4(1H, 3H)-dione

[1059]

[0494] The title compound was synthesized by procedures analogous to those outlined in Example 1, Step 14 utilizing l-(6-(piperidin-4-yl)-l / / -indazol-3-yl)dihydropyrimidine-2,4(17 / ,3 / / )-dione instead of l-(l-methyl-6-piperidin-4-ylindazol-3-yl)-l,3-diazinane-2, 4-dione. 'HNMR (300 MHz, CD3OD) 88.17 (s, 1H), 7.74 (s, 1H), 7.66 (d, J= 8.6 Hz, 1H), 7.51 (d, J = 6.8 Hz, 1H), 7.38 (dd, J= 17.5, 9.9 Hz, 2H), 7.15 - 6.96 (m, 3H), 6.80 (s, 1H), 5.90 (t, J= 6.2

[1060] - 126 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[1061] Hz, 1H), 4.39 - 4.18 (m, 3H), 4.05 (dd, J= 13.8, 7.1 Hz, 2H), 3.89 (dd, J= 13.1, 5.8 Hz, 2H), 3.63 (d, J= 12.3 Hz, 2H), 3.25 - 2.92 (m, 4H), 2.87 (t, J= 6.7 Hz, 2H), 2.65 (t, J= 7.1 Hz, 2H), 2.26 (d, J= 8.4 Hz, 3H), 2.21 - 1.93 (m, 7H), 1.87 (dd, J= 13.8, 7.4 Hz, 1H), 1.02 (t, J= 7.4 Hz, 3H). LCMS calc, for C40H45N10O4 [M+H]+: m / z = 729.4; Found: 729.4.

[1062] Example A. SMARCA2 HiBiT and SMARCA4 HiBiT Degradation Assay Preparation of SMARCA2 / 4-HiBiT knock-in cells

[1063]

[0495] HiBiT peptide knock-in of SMARCA2 in LgBiT expressing HEK293T cells was performed by CRISPR-mediated tagging system as described Promega. The homozygous HiBiT knock-in on c-terminus SMARCA2 was confirmed by sanger sequence. SMARCA2 -HiBiT knock-in Hela monoclonal cell (CS302366) and SMARCA4-HiBiT knock-in Hela monoclonal cell (CS3023226) were purchased from Promega. The heterozygous HiBiT-knock-in was confirmed by sanger sequence in both SMARCA2 -HiBiT and SMARCA4-HiBiT monoclonal cells.

[1064] SMARCA2 HiBiT and SMARCA4 HiBiT degradation assay in HeLa cells

[1065]

[0496] Dispense lOul aliquot of prepared Hela-SMARCA2 -HiBiT or Hela-SMARCA4-HiBiT cells (1:1 ratio of cells: Trypan Blue (#1450013, Bio-Rad)) onto cell counting slide (#145-0011, Bio-Rad) and obtain cell density and cell viability using cell counter (TC20, Bio-Rad). Remove appropriate volume of resuspended cells from culture flask to accommodate 2500 cells / well @ 20 mL / well. Transfer Hela-HiBiT cells to 50 mL conical (#430290, Corning). Spin down at 1000 rpm for 5 min using tabletop centrifuge (SPINCHRON 15, Beckman). Discard supernatant and resuspend cell pellet in modified EMEM (#30-2003, ATCC) cell culture media containing 10% FBS (F2422-500ML, Sigma), and IX Penicillin / Streptomycin (200g / L) (30-002-CI, Corning) to a cell density of 125,000 cells / mL. Dispense 20 mLof resuspended Hela-HiBit cells per well in 384-well TC treated plate (#12-565-343, Thermo Scientific) using standard cassette (#50950372, Thermo Scientific) on Multidrop Combi (#5840310, Thermo Scientific) inside laminar flow cabinet.

[1066]

[0497] Compounds were dissolved in DMSO to make 10 mM stock and 3 -fold series dilutions were further conducted keeping the highest concentration 10 pM. Dispense test compounds onto plates using digital liquid dispenser (D300E, Tecan). Incubate plates in humidified tissue culture incubator @37 °C for 18 hours. Add 20 mL of prepared Nano-Gio® HiBiT Lytic detection buffer (N3050, Promega) to each well of 384-well plate using small tube cassette (#24073295, Thermo Scientific) on Multidrop Combi, incubate @ RT for 30-60 min. Read plates on microplate reader (Envision 2105, PerkinElmer) using 384 well Ultra-Sensitive luminescence - 127 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[1067] mode. Raw data files and compound information reports are swept into centralized data lake and deconvoluted using automated scripts designed by TetraScience, Inc. Data analysis, curve-fitting and reporting done in Dotmatics Informatics Suite using Screening Ultra module. Results are summarized below in Table 3.

[1068] Table 3. SMARCA2 and SMARCA4 Degradation

[1069]

[1070]

[0498] In Table 3, columns DCso, an “A” denotes DCso < 0.1 nM; a “B” denotes 0.1 nM < DCso < 1 nM; a “C” denotes DCso > 1.0 nM. In Table 1, columns Dmax, an “A” denotes Dmax > 90%; a “B” denotes 50% < Dmax< 90%; a “C” denotes that a Dmax< 50%.

[1071] - 128 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application

[1072]

[0499] While we have described a number of embodiments of this invention, it is apparent that our basic examples may be altered to provide other embodiments that utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments that have been represented by way of example.

[1073] - 129 - 105807.001161\4928-3254-4676.1

Claims

105807.001161 - PCT ApplicationWhat is claimed:

1. A compound of F ormula (I):PTM ULM (i)or a pharmaceutically acceptable salt or solvate thereof,wherein PTM is a moiety of Formula IA:whereinR1is a covalent bond, or chemical moiety that links PTM and ULM;* is a point of attachment to ULM;Rhis H, D, C1-6 alkyl, C3-6 cycloalkyl, C1-3 haloalkyl, or C1-4 alkoxy;Rdlis H, D, halo, cyano, C1-6 alkyl, C3-6 cycloalkyl, C1-3 haloalkyl, or Ci-4alkoxyl; ULM iswhereineach X2 is independently N or CR15, provided that one X2 is a C atom having the attachment point to R1; and- 130 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Applicationeach R15is independently H, D, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, C1-8 alkoxy, Ce-io aryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C5-12 heteroaryl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl;wherein in R15, any alkyl group, alkenyl group, alkoxy group, aryl group, cycloalkyl group, cycloalkenyl group, heteroaryl group, heterocycloalkyl group, or heterocyclo-alkenyl group is optionally substituted by one or more Rfgroups;each Rfis independently D, oxo, halogen, Ci-Cs alkoxy, Ci-Cs alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, -OH, -CN, -NO2, -C2-C6 alkenyl, -C2-C6 alkynyl, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Rb, -C(O)ORb, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)RcRd, -P(O)(ORb)(ORb), -B(ORc)(ORd), -S(O)2Rb, -C(O)NRbORb, -S(O)2ORb, -OS(O)2ORb, or -OPO(ORb)(ORb); wherein said Ci-C8alkoxy, Ci-C8alkyl, Ci-C8alkoxy, Ci-Cs alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, -OH, -CN, -NO2, -C2-C6 alkenyl, -C2-C6 alkynyl, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, is optionally substituted by 1-6 groups selected from D, halogen, -ORa, -SRa, -NRcRd, -NRaRc, -C(O)Rb, -OC(O)Rb, -C(O)ORb, -C(O)NRcRd, -S(O)Rb, -S(O)2NRcRd, -S(O)(=NRb)Rb, -SF5, -P(O)RbRb, -P(O)RcRd, -P(O)(ORb)(ORb), -B(ORc)(ORd), -S(O)2Rb, -C(O)NRbORb, -S(O)2ORb, -OS(O)2ORb, or -OPO(ORb)(ORb);each Rais independently H, D, -C(O)Rb, -C(O)ORC, -C(O)NRcRd, -C(=NRb)NRbRc, -C(=NORb)NRbRc, -C(=NCN)NRbRc, -P(ORC)2, -P(O)RcRb, -P(O)RcRd, -P(O)ORcORb, -S(O)Rb, -S(O)NRcRd, -S(O)2Rb, -S(O)2NRcRd, SiRb3, -Ci-Cioalkyl, -C2-C10 alkenyl, -C2-C10 alkynyl, Ci-C8alkoxy, Ce-io aryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C5-12 heteroaryl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl;each Rb, is independently H, D, -Ci-Ce alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, Ci-Cs alkoxy, Ce-io aryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C5-12 heteroaryl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl;each Rcor Rdis independently H, D, -C1-C10 alkyl, -C2-C6 alkenyl, -C2-C6 alkynyl, Ci-Cs alkoxy, Ce-io aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, or C3-8 heterocycloalkenyl;or Rcand Rd, together with the atom to which they are both attached, form a monocyclic or multicyclic heterocycloalkyl, or a monocyclic or multicyclic heterocycloalkenyl group; and wherein any alkyl group, alkenyl group, alkoxy group, aryl group, cycloalkyl group, cycloalkenyl group, heteroaryl group, heterocycloalkyl group, or heterocycloalkenyl group ofRa, Rb, Rcand Rdare optionally substituted by one or more Rlegroups;- 131 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Applicationwherein each Rleis independently D, -halo, -Ci-Cs alkyl, -O-Ci-Cs alkyl, -Ci-Ce haloalkyl, -S-Ci-Cs alkyl, -NHCi-Cs alkyl, -N(Ci-Cs alkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-Csalkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -CO2H, -CN, -CF3, -CHF2, -CH2F, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-Csalkyl, -SON(Ci-C8alkyl)2, -CONHCi-C8alkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2.

2. The compound according to claim 1, wherein R1is a covalent bond.

3. The compound according to claim 1, wherein R1is a chemical moiety represented by the formula:■(A)q-,wherein:q is an integer from 1 to 14;each A is independently selected from the group consisting of a bond, CRlaRlb, O, S, SO,NRlcC(=NCN)NRldNRlcC(=NCN), NRlcC(=CNO2)NRld, 3-11 membered cycloalkyl, optionally substituted with 1-6 Rlaand / or Rlbgroups, 3-11 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups, aryl optionally substituted with 1-6 Rlaand / or Rlbgroups, or heteroaryl optionally substituted with 1-6 Rlaand / or Rlbgroups,wherein Rla, Rlb, Rlc, and Rldare each independently, -H, D, -halo, -Ci-C8alkyl, -O-Ci-C8alkyl, -Ci-Cehaloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-C8alkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-11 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-11 membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci- - 132 - 105807.001161\4928-3254-4676.1105807.001161 - PCT ApplicationCsalkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -CO2H, -CN, -CF3, -CHF2, -CH2F, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-Csalkyl, -SON(Ci-C8alkyl)2, -CONHCi-C8alkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2.

4. The compound according to claim 3, wherein q = 5 and R1is a chemical moiety represented by the formula: -AI-A2-A3-A4-AS-; wherein:each of Ai, A3and As is independently selected from the group consisting of a bond, -4NRlcS02NRld(CRlaRlb)o-4, -(CRlaRlb)o-4C(0)(CRlaRlb)o-4, -(CRlaRlb)o-4CRla=CRlb(CRlaRlb)o-4, -(CRlaRlb)o-4C=C(CRlaRlb)o-4, -(CRlaRlb)o-4SiRlaRlb(CRlaRlb)o-4, -(CRlaRlb)o-4P(0)Rla(CRlaRlb)o-4, -(CRlaRlb)o-4P(0)ORla(CRlaRlb)o-4, (CRlaRlb)i-4, optionally substituted 3-11 membered cycloalkyl, 3-11 membered heterocyclyl, aryl, and heteroaryl;each of A2and A4 is independently selected from the group consisting of is independently selected from the group consisting of a bond, (CRlaRlb)i-4, optionally substituted 3-11 memberedcycloalkyl, 3-11 membered heterocyclyl, aryl, and heteroaryl;Rlaand Rlbare each independently selected from the group consisting of -H, D, -halo, -Ci-C8alkyl, -O-Ci-C8alkyl, -Ci-C6haloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-C8alkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocyclyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-Csalkyl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-Csalkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -CO2H, -CN, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-Csalkyl, -SON(Ci-C8alkyl)2, -CONHCi-C8alkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -- 133 - 105807.001161\4928-3254-4676.1105807.001161 - PCT ApplicationNHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N-(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2; andRlcand Rldare each independently selected from the group consisting of H, D, optionally substituted C1-4 alkyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, aryl, or heteroaryl.

5. The compound according to any one of claims 1 or 3, wherein R1is a 3-11 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups, 3-11 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups, -(CRlaRlb)i-5, -(CRla=CRlb)-, -(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(CRlaRlb)i-5- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(CRla=CRlb)-(CRlaRlb)i-5-, -(CRlaRlb)i-5-( CRla=CRlb)-(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(C=C)-(CRlaRlb)i-5-, -(CRlaRlb)i-5-(C=C)-(CRlaRlb)i-5-A- wherein A is O, S, or NR1C, -(C=C)-(CRlaRlb)i-5-A-(CRlaRlb)i-5- wherein A is O, S, or NRlc, -(C=C)-(CRlaRlb)i-5, -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-, -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-, -(3-11 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-5-, -(3-11 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups) -(CRlaRlb)i-5-, -(CRlaRlb)i-5-(3-ll membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-A-, -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-A-, -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s, -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)- wherein A is O, S, orNRlc, -(CRlaRlb)i-5-(3-11 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s, -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s-A- wherein each A is independently O,- 134 - 105807.001161\4928-3254-4676.1105807.001161 - PCT ApplicationS, or NRlc, -(CRlaRlb)i-5-A-(3-ll membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s-A- wherein each A is independently O, S, or NRlc, -(CRlaRlb)i-5-A-(CRlaRlb)i-5-A- wherein A is O, S, orNRlc, -(CRlaRlb)i-5-A-(CRlaRlb)i-5-A-(CRlaRlb)i-5-A-(CRlaRlb)i-5-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(CO) wherein A is O, S, or NRlc, -(CRlaRlb)i-5-( CRla=CRlb)-(CRlaRlb)i-5-A-(CO)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(C=C)-(CRlaRlb)i-5-A-(CO)- wherein A is O, S, orNRlc, -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s-A-(CO)- wherein A is O, S, orNRlc, -(CRlaRlb)i-5-A-(CO)-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s-A-(CO)-wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(CO)-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-A-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-A-(CO)- wherein each A is independently O, S, orNRlc, -(3-11 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-CO-(CRlaRlb)i-s-A- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-l 1 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s-A-(CO)- wherein A is O, S, or NRlc, -(CRlaRlb)i-5-(3-l 1 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s-A-(CO)- wherein A is O, S, orNRlc, -(3-11 membered cycloalkyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-s-, or -(3-11 membered heterocyclyl optionally substituted with 1-6 Rlaand / or Rlbgroups)-(CRlaRlb)i-5-6. The compound according to any one of claims 1-5, wherein R1iswherein** is a point of attachment to the ULM;* is a point of attachment to the oxygen atom of PTM;Li, L2, and L3 are each independently a bond, CRlaRlb, O, S, SO, SO2, NRlc, S02NRlc,ring Ai and ring A2 are each independently absent, a 3-15 membered cycloalkyl, optionally substituted with 1-6 Rlaor Rlbgroups, a 3-15 membered heterocycloalkyl optionally- 135 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Applicationsubstituted with 1-6 Rlaor Rlbgroups, an aryl optionally substituted with 1-6 Rlaor Rlbgroups, or a heteroaryl optionally substituted with 1-6 Rlaor Rlbgroups,wherein Rla, Rlb, Rlc, and Rldare each independently, -H, -halo, -Ci-Csalkyl, -O-Ci-Csalkyl, -Ci-Cehaloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-Csalkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocycloalkyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-C8alkyl, -SO2-aryl, -SO2-heteroaryl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-Csalkyl, -C(O)OCi-C8alkyl, -CO2H, -CN, -CF3, -CHF2, -CH2F, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-C8alkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2.

7. The compound according to any one of claims 1-6, wherein R1iswherein** is a point of attachment to the ULM;* is a point of attachment to the oxygen atom of PTM;Li is a bond, (C(R10)2)P, CO or C(O)O;L2is a bond, (C(R10)2)P, CO or C(O)O;L3is a bond, (C(R10)2)P, CO or C(O)O;p is 1, 2, 3 or 4;each R10is independently H or C1-C4 alkyl;ring Ai is a 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, an aryl group, or a heteroaryl group; andring A2 is a 3-15 membered cycloalkyl group, a 4-15 membered heterocycloalkyl group, an aryl group, or a heteroaryl group, wherein ring Ai and ring A2 are each optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

8. The compound according to claim 6 or claim 7, wherein L3is a bond.- 136 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application9. The compound according to any one of claims 6-8, wherein L2 is (C(R10)2)P.

10. The compound according to any one of claims 6-9, wherein ring Ai is a 4-10-membered heterocycloalkyl group.

11. The compound according to claim 10, wherein ring Ai is a piperazine group, a piperidine group, a pyrrolidine group, an azabicycloalkane or an azaspiroalkane group.

12. The compound according to any one of claims 6-9, wherein ring Ai is a 3-7 membered cycloalkyl group.

13. The compound according to claim 12, wherein ring Ai is a cyclobutyl group or a cyclohexyl group.

14. The compound according to any one of claims 6-9, wherein ring Ai is a heteroaryl group.

15. The compound according to claim 14, wherein ring Ai is a pyridyl group.

16. The compound according to any one of claims 6-15, wherein ring A2 is a 4-15-membered heterocycloalkyl group.

17. The compound according to claim 16, wherein ring A2 is a piperazine group, a piperidine group, a pyrrolidine group, a diazaspiroalkyl group or an azabicycloalkyl group.

18. The compound according to claim 16, wherein ring A2 is a piperazine group or a piperidine group.

19. The compound according to any one of the preceding claims, wherein Li and L3 are each a bond.

20. The compound according to any one of the preceding claims, wherein R1iswherein* is a point of attachment to the ULM;is a point of attachment to the oxygen atom of PTM;- 137 - 105807.001161\4928-3254-4676.1105807.001161 - PCT ApplicationL2is a bond, CRlaRlb, O, S, SO, SO2, NRlc, SO2NRlc, SONRlc, SO(=NRlc), SO(=NRlc)NRld, CONR1C, NRlcCONRld, NRlcC(O)O, NRlcSO2NRld, CO, C(O)O, CRla=CRlb, C=C, SiRlaRlb, P(O)Rla, P(O)ORla, (CRlaRlb)i-4, -(CRlaRlb)i-4O(CRlaRlb)i-4, -(CRlaRlb)i-4S(CRlaRlb)i-4, -(CRlaRlb)i-4NRlc(CRlaRlb)i-4, NRlcC(=NCN)NRld, NRlcC(=NCN), NRlcC(=CNO2)NRld;ring Ai and ring A2are each independently a 3-15 membered cycloalkyl, optionally substituted with 1-6 Rlaor Rlbgroups, a 3-15 membered heterocycloalkyl optionally substituted with 1-6 Rlaor Rlbgroups, a 6-10-membered aryl optionally substituted with 1-6 Rlaor Rlbgroups, or a 5-10-membered heteroaryl optionally substituted with 1-6 Rlaor Rlbgroups, wherein Rla, Rlb, Rlc, and Rldare each independently, -H, -halo, -Ci-Csalkyl, -O-Ci-Csalkyl, -Ci-Cehaloalkyl, -S-Ci-C8alkyl,-NHCi-C8alkyl, -N(Ci-C8alkyl)2, 3-11 membered cycloalkyl, aryl, heteroaryl, 3-11 membered heterocycloalkyl, -O-(3-ll membered cycloalkyl), -S-(3-l 1 membered cycloalkyl), NH-(3-ll membered cycloalkyl), N(3-ll membered cycloalkyl)2, N-(3-ll membered cycloalkyl)(Ci-C8alkyl), -OH, -NH2, -SH, -SO2Ci-Csalkyl, -SO2-aryl, -SO2-heteroaryl, SO(NH)Ci-C8alkyl, P(O)(OCi-C8alkyl)(Ci-C8alkyl), -P(O)(OCi-C8alkyl)2, -C=C-Ci-C8alkyl, -C=CH, -CH=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=CH(Ci-C8alkyl), -C(Ci-C8alkyl)=C(Ci-C8alkyl)2, -Si(OH)3, -Si(Ci-C8alkyl)3, -Si(OH)(Ci-C8alkyl)2, -C(O)Ci-C8alkyl, -C(O)OCi-C8alkyl, -CO2H, -CN, -CF3, -CHF2, -CH2F, -NO2, -SF5, -SO2NHCi-C8alkyl, -SO2N(Ci-C8alkyl)2, -SO(NH)NHCi-C8alkyl, -SO(NH)N(Ci-C8alkyl)2, -SONHCi-C8alkyl, -SON(Ci-C8alkyl)2, -CONHCi-C8alkyl, -CON(Ci-C8alkyl)2, -N(Ci-C8alkyl)CONH(Ci-C8alkyl), -N(Ci-C8alkyl)CON(Ci-C8alkyl)2, -NHCONH(Ci-C8alkyl), -NHCON(Ci-C8alkyl)2, -NHCONH2, -N(Ci-C8alkyl)SO2NH(Ci-C8alkyl), -N(Ci-C8alkyl)SO2N(Ci-C8alkyl)2, -NHSO2NH(Ci-C8alkyl), -NHSO2N(Ci-C8alkyl)2, or -NHSO2NH2.

21. The compound according to any one of claims 1-20, wherein R1iswherein** is a point of attachment to the ULM;* is a point of attachment to the oxygen atom of PTM;L2is (C(R10)2)P, CO or C(O)O;p is 1, 2, 3 or 4;each R10is independently H or C1-C4 alkyl; andring Ai and ring A2are each independently a 3-7 membered cycloalkyl group, a 4-10-membered heterocycloalkyl group, a 6-10-membered aryl group, or a 5-10-membered heteroaryl- 138 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Applicationgroup, wherein ring Ai and ring A2 are each optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

22. The compound according to claim 20 or claim 21, wherein L2 is (C(R10)2)P.

23. The compound according to any one of claims 20-22, wherein ring Ai is a 5-10-membered heteroaryl group.

24. The compound according to any one of claims 20-23, wherein ring Ai is a pyridyl group.

25. The compound according to any one of claims 20-24, wherein ring A2 is a 4-10-membered heterocycloalkyl group.

26. The compound according to claim 25, wherein ring A2 is a piperazine group, a piperidine group, a pyrrolidine group, a diazaspiroalkyl group or an azabicycloalkyl group.

27. The compound according to claim 26, wherein ring A2 is a piperazine group or a piperidine group.

28. The compound according to any one of the preceding claims, wherein L2 is (C(R10)2)P.

29. The compound according to any one of the preceding claims, wherein ring Ai is a pyridyl group.

30. The compound according to any one of the preceding claims, wherein ring A2 is a piperidine group.

31. The compound according to any one of the preceding claims, wherein Rdlis H.

32. The compound according to any one of the preceding claims, wherein Rhis methyl or ethyl.

33. The compound according to any one of the preceding claims, wherein Rhis ethyl.- 139 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application34. The compound according to any one of the preceding claims, wherein ULM isprovided that one X2 is a C atom having the attachment point to R1.

35. The compound according to any one of claims 1-33, wherein ULM isd that one X2 is a C atom having the attachment point to R1. according to any one of claims 1-33, wherein ULM isprovided that one X2 is a C atom having the attachment point to R1.

37. The compound according to any one of claims 1-33, wherein ULM isprovided that one X2 is a C atom having the attachment point to R1.

38. The compound according to any one of claims 1-33, wherein ULM isprovided that one X2 is a C atom having the attachment point to R1.- 140 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application39. The compound according to any one of claims 1-33, wherein ULM isprovided that one X2 is a C atom having the attachment point to R1.

40. The compound according to any one of claims 1-33, wherein ULM isprovided that one X2 is a C atom having the attachment point to R1.

41. The compound according to any one of claims 1-33, wherein ULM isprovided that one X2 is a C atom having the attachment point to R1.

42. The compound according to any one of the preceding claims, wherein each X2 is CH, provided that one X2 is a C atom having the attachment point to R1.

43. The compound according to any one of the preceding claims, wherein the compound of Formula I is a compound of Formula IA-1, Formula IA-2, Formula IA-3, Formula IA-4, Formula IA-5, Formula IA-6, Formula IA-7 or Formula IA-8:- 141 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application- 142 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Applicationwherein Rhis Ci-6 alkyl or C1-3 haloalkyl;Rdlis H, D, halo, cyano or C1-6 alkyl;Li is a bond or C(R10)2;L2 is a bond, C(R10)2, or CO;ring Ai is a 4-10-membered heterocycloalkyl group or a 5-10-membered heteroaryl group;ring A2 is a 4-10-membered heterocycloalkyl group or a 5-10-membered heteroaryl group, wherein ring Ai and ring A2 are each optionally substituted with 1-6 Rlaor Rlbgroups as defined herein; andat least two X2 are CR15.

44. The compound according to any one of the preceding claims, wherein the compound of Formula I is a compound of Formula IA-9, Formula IA-10, Formula IA-11, Formula IA-12, Formula IA-13, Formula IA-14, Formula IA-15 or Formula IA-16:- 143 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Applicationwherein Rhis methyl, ethyl or CH2F;Rdlis H, D, halo, cyano or Ci-6 alkyl;Li is a bond or C(R10)2;L2is a bond, C(R10)2, or CO;ring Ai is a 4-10-membered heterocycloalkyl group or a 5-10-membered heteroaryl group; and- 144 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Applicationring A2 is a 4-10-membered heterocycloalkyl group or a 5-10-membered heteroaryl group, wherein ring Ai and ring A2 are each optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

45. The compound according to any one of the preceding claims, wherein the compound of Formula I is a compound of Formula IA-17, Formula IA-18, Formula IA-19, Formula IA-20, Formula IA-21, Formula IA-22, Formula IA-23 or Formula IA-24:- 145 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Applicationwherein Rhis methyl, ethyl or CH2F;L2 is a bond, C(R10)2, or CO;ring Ai is a 4-10-membered heterocycloalkyl group or a 5-10-membered heteroaryl group; andring A2 is a 4-10-membered heterocycloalkyl group or a 5-10-membered heteroaryl group, wherein ring Ai and ring A2 are each optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

46. The compound according to any one of the preceding claims, wherein the compound of Formula I is a compound of Formula IA-25, Formula IA-26, Formula IA-27, Formula IA-28, Formula IA-29, Formula IA-30, Formula IA-31 or Formula IA-32:- 146 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Application- 147 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Applicationwherein ring Ai is a 5-10-membered heteroaryl group; and ring A2 is a 4-10-membered heterocycloalkyl group, wherein ring Ai and ring A2 are each optionally substituted with 1-6 Rlaor Rlbgroups as defined herein.

47. The compound according to any one of claims 43-46, wherein ring Ai is a pyridyl group.

48. The compound according to any one of claims 43-47, wherein ring A2 is a piperidine group.

49. The compound according to any one of claims 43-48, wherein R15is a methyl group.

50. The compound according to any one of claims 1 or 3-49, wherein the compound is selected from:l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)-piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;l-(6-(l-((5-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [l',2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyrazin-2-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [l',2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridazin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;l-(6-(l-((5-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [l',2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-6-methylpyrazin-2-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [l',2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-4-methoxypyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;- 148 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Applicationl-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-methoxypyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-fluoropyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;l-(6-(l-((2-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;3-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione;l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;l-(6-(l-((2-(((6aS,8R)-6a-Ethyl-2-(3-fluoro-2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;l-(6-(l-((2-(((6aS,8R)-6a-Ethyl-2-(5-fluoro-2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;1 -(6-( 1 -((2-(((6aS, 8R)-2-(3, 5 -Difluoro-2-hy droxyphenyl)-6a-ethyl -5, 6, 6a, 7, 8,9-hexa-hydropyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;l-(6-(l-((6-(((6aS,8R)-2-(2-Hydroxyphenyl)-6a-methyl-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;l-(6-(l-((6-(((6aS,8R)-6a-(Fluoromethyl)-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;l-(6-(4-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)piperazin-l-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;- 149 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Applicationl-(6-(((S)-l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)pyrrolidin-3-yl)amino)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-pyrazolo[3,4-b]pyridin-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;3-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-pyrazolo[3,4-b]pyri din-3 -yl)piperidine-2, 6-dione;l-(6-(l-((2-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)piperidin-4-yl)-l-methyl-lH-pyrrolo[2,3-b]pyridin-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;1 -(6-( 1 -((2-(((6aS, 8R)-2-(2-hy droxyphenyl)-6a-methyl -5, 6,6a, 7, 8, 9-hexahy dropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyrimidin-5-yl)methyl)piperidin-4-yl)-l-methyl-lH-pyrazolo[3,4-b]pyridin-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;l-(l-Benzyl-6-(l-((6-(((6aS,8R)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;l-[l-ethyl-6-[l-[[6-[[(4R,6S)-6-ethyl-12-(2-hydroxyphenyl)-2,8,10,ll-tetrazatricyclo [7.4.0.02,6]trideca-l(13),9,ll-trien-4-yl]oxy]-3-pyridinyl]methyl]piperidin-4-yl]indazol-3-yl]- 1.3-diazinane-2, 4-dione;l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)piperidin-4-yl)-5-fluoro-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;3-(5-(4-((6-(((6aS,8R)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperazin-l-yl)-3-methyl -2-oxo- 2.3-dihydro-lH-benzo[d]imidazol-l-yl)piperidine-2, 6-dione;l-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l,5-dimethyl-1 H-indazol -3 -yl)dihy dropyrimidine-2,4( 1 H, 3H)-dione;l-(5-Ethyl-6-(l-((6-(((6aS,8R)-6a-ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;- 150 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Applicationl-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)pyridin-3-yl)methyl)piperidin-4-yl)-l-(2-methoxy ethyl)-lH-indazol-3-yl)dihydropyrimidine-2,4(lH,3H)-dione;3-(6-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-4,5-dimethylpyridin-3-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione;3-(6-(l-((5-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [T,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-3,4-dimethylpyridin-2-yl)methyl)piperidin-4-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione;3-(4-(l-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)piperidin-4-yl) phenyl)piperidine-2, 6-dione;3-(6-(4-((6-(((6aS,8R)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo [r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-7-methyl-3,4-dihydroisoquinolin-2(lH)-yl) methyl)piperidin-l-yl)-l-methyl-lH-indazol-3-yl)piperidine-2, 6-dione;or a pharmaceutically acceptable salt thereof.

51. The compound according to any one of claims 1 or 3-49, wherein the compound is selected from:l-(6-(l-((6-(((6a5,8A)-6a-Ethyl-2-(5-fluoro-2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydro-pyrrolo[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)-piperidin-4-yl)-l-methyl-l / / -indazol-3-yl)dihydropyrimidine-2,4(lJH,3Z / )-dione;l-(6-(l-((6-(((6a5,8A)-6a-Ethyl-2-(2-hydroxyphenyl)-5,6,6a,7,8,9-hexahydropyrrolo-[r,2':4,5]pyrazino[2,3-c]pyridazin-8-yl)oxy)-5-methylpyridin-3-yl)methyl)piperidin-4-yl)-17 / -indazol-3-yl)dihydropyrimidine-2, 4(1H,3H)-dione;or a pharmaceutically acceptable salt thereof.

52. A pharmaceutical composition comprising a compound according to any one of claims 1 to 51 and a pharmaceutically acceptable excipient.

53. A method of treating cancer in a subject in need thereof comprising administering to the subject a compound of any one of claims 1 to 51 or a pharmaceutical composition of claim 52.

54. The method of claim 53, wherein the cancer is squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the - 151 - 105807.001161\4928-3254-4676.1105807.001161 - PCT Applicationbladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma, hemangio-sarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas, ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas, medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, and Schwannomas; bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease, Wilms' tumor and teratocarcinomas.

55. The method of claim 53, wherein the cancer is T-lineage Acute lymphoblastic Leukemia (T-ALL), T-lineage lymphoblastic Lymphoma (T-LL), Peripheral T-cell lymphoma, Adult T-cell Leukemia, Pre-B ALL, Pre-B Lymphomas, Large B-cell Lymphoma, Burkitts Lymphoma, B-cell ALL, Philadelphia chromosome positive ALL and Philadelphia chromosome positive CML.

56. The method of claim 54 wherein the lung cancer is SMARCA4 deficient non-small cell lung cancer.

57. A method of degrading a SMARCA2 protein comprising contacting the SMARCA2 protein with a compound of any one of claims 1-51 or a pharmaceutical composition of claim 52.

58. A method of degrading a SMARCA4 protein comprising contacting the SMARCA4 protein with a compound of any one of claims 1-51 or a pharmaceutical composition of claim 52.

59. A method of degrading a SMARCA2 protein and a SMARCA4 protein comprising contacting the SMARCA2 protein and a SMARCA4 protein with a compound of any one of claims 1-51 or a pharmaceutical composition of claim 52.- 152 - 105807.001161\4928-3254-4676.1